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Neuropsychiatric symptoms and the basal ganglia 
Neuropsychiatric symptoms include a broad range of psychiatric symptoms that are 
believed to be mediated by alterations in brain functions and responsive to specific 
pharmacotherapeutic and psychotherapeutic interventions1-3. Common 
neuropsychiatric symptoms include depressive mood, euphoria, agitation and 
aggression, irritability or lability, anxiety, delusions and hallucinations, changes in 
eating behaviour, sleep disturbance and night-time behavioural disturbances, 
disinhibition, and stereotyped behaviours1. Neuropsychiatric symptoms frequently 
occur in neurological and neurodegenerative diseases, such as Parkinson’s disease 
(PD), cerebrovascular disease, Alzheimer’s disease and other dementias1. Moreover, 
certain conditions that were once considered to be manifestations of psychodynamic 
conflict or a strictly environmental disease, are now considered neuropsychiatric 
disorders, such as obsessive-compulsive disorder (OCD)2 and schizophrenia4.  
 
Although neuropsychiatric symptoms and neuropsychiatric disorders are assumed to 
reflect changes in brain function, their exact underlying biological mechanisms remain 
largely unknown. Characterising obvious neuropathology in relation to 
neuropsychiatric symptoms is complicated by the large overlap of neuropsychiatric 
symptoms across disorders and diseases with different underlying pathologies1. It has 
been suggested that, regardless of the underlying pathology, neuropsychiatric 
symptoms are associated with disruption of cortical-basal ganglia-thalamocortical brain 
circuits that lead to similar symptoms across different diseases1, 5.  
 
The basal ganglia (BG) are a group of interconnected sub-cortical nuclei located at the 
diencephalic-mesencephalic areas. The BG consists of the caudate nucleus, putamen, 
pallidal complex, nucleus accumbens, substantia nigra (pars compacta and reticulate) 
and the subthalamc nucleus (STN)6. While in the past the basal ganglia were believed 
to play a role in motor functioning only, it has been recognised that these structures 
also play an important role in emotional, behavioural and cognitive functions7. The 
cortico-basal ganglia-thalamocortical circuits (or loops) originate from specific cortical 
areas, project to the striatum (caudate nucleus, putamen and ventral striatum), connect 
to the globus pallidus and substantia nigra, then to the thalamus, and finally back to 
the frontal cortex. While the anatomical structures are the same for all loops, they are 
believed to be partially segregated and integrated8: the dorsolateral frontal cortex 
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projects to the dorsolateral part of the caudate nucleus, the anterior cingulate cortex 
(ACC) projects to the medial striatal/nucleus accumbens area, and the orbitofrontal 
cortex (OFC) projects to the ventral striatal areas6, 7, 9. In addition, there are projections 
to and from other cortical and subcortical structures related to each circuit, resulting in 
a direct, indirect and hyperdirect pathway within each circuit10-12. Two disorders that 
are related to pathology of the frontal-basal ganglia circuitry are PD and OCD13. 
 
Parkinson’s disease 
Parkinson’s disease (PD) is a common movement disorder and the second most 
prevalent neurodegenerative disorder after Alzheimer’s disease. The estimated 
prevalence of PD is 1-2% of the population of 65 years and older and increases with 
age14, 15. According to the Queens Square Brain Bank criteria, PD is defined by the 
presence of bradykinesia, together with at least one of the following motor symptoms: 
rigidity, resting tremor, or postural instability, and the absence of atypical features such 
as early severe autonomic disturbances, cerebellar or pyramidal features or lack of 
response to dopaminergic treatment16, 17. Recently, new clinical criteria for PD 
diagnosis have been published on behalf of the International PD and Movement 
Disorders Society (the MDS-PD criteria)18. In the MDS-PD criteria, bradykinesia must 
occur in combination with resting tremor, rigidity or both. However, postural changes 
are left out. In addition, the MDS-PD criteria define supportive criteria, absolute 
exclusion criteria and red flags. At least two supportive criteria, the absence of absolute 
exclusion criteria, and no red flags are required for a diagnosis of “clinically established 
PD” (see Table 1). 
 
The clinical motor symptoms of PD are caused by progressive loss of neurons in the 
substantia nigra pars compacta (SNpc), accompanied by the formation of Lewy 
neurites and intraneuronal Lewy bodies19. According to the staging procedure of PD 
pathology as proposed by Braak and colleagues (2004), a premotor period in which 
typical pathological changes, Lewy neuritis and Lewy bodies spread from the olfactory 
bulb and vagus nerve to lower brainstem regions (stages 1 and 2), is followed by a 
symptomatic period in which pathological changes involve the midbrain including the 
substantia nigra (stage 3), the mesocortex (stage 4) and eventually the neocortex 
(stage 5 and 6)20.  
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Table 1. MDS clinical diagnostic criteria for Parkinson’s disease18 
Supportive criteria Absolute exclusion 
criteria 
Red flags 
- Beneficial response to 
dopaminergic therapy 
- Presence of levodopa-
induced dyskinesia 
- Asymmetric rest tremor 
- Positive tests on cardiac 
sympathetic denervation 
or olfactory loss 
- Cerebellar abnormalities 
- Frontotemporal 
cognitive changes or 
primary progressive 
aphasia 
- Supra nuclear gaze 
palsy 
- Parkinsonian features 
restricted to the lower 
limbs for more than 3 
years 
- Use of anti-
dopaminergic therapy 
- Absence of levodopa 
response 
- Cortical findings (e.g. 
apraxia) 
- Rapid progression of gait 
impairment  
- Complete absence of 
progression of motor 
symptoms or signs over 5 
or more years 
- Early bulbar dysfunction 
- Severe autonomic failure 
in the first 5 years of the 
disease 
- Recurrent falls because 
of impaired balance 
within 3 years of onset 
- Absence of any of the 
common non-motor 
features of disease 
despite 5 years disease 
duration 
- Otherwise unexplained 
pyramidal tract signs 
- Bilateral symmetric 
parkinsonism 
  
PD is incurable and therapy is aimed at controlling symptoms by replacing the depleted 
dopamine or by enhancing dopaminergic functioning with antiparkinsonian medication. 
Most patients respond well to Levodopa21, and is therefore considered the gold 
standard pharmacotherapy for PD patients. However, as the disease progresses, 
motor fluctuations and disabling dyskinesia develop in approximately 50% of patients, 
usually starting with ‘end-of dose wearing-off’, but eventually leading to unpredictable 
and disabling fluctuations between on and off state22. Although the concomitant use of 
other neurochemical agents such as monoamine oxidase B inhibitors, dopaminergic 
agonists, anticholinergic agents, and amantadine may offset the diminished efficacy of 
levodopa, these agents eventually lose their efficacy and are associated with 
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significant side-effects23.  For patients who are affected by long-term complications of 
Levodopa therapy, deep brain stimulation (DBS) is increasingly accepted as an adjunct 
therapy24. DBS, which will be discussed in more detail later, is a surgical intervention 
that is aimed at restoring the balance of cortical-basal ganglia-thalamocortical brain 
circuits that are disrupted in PD25.  
 
Neuropsychiatric symptoms in Parkinson’s disease 
Apart from motor symptoms, PD is characterised by a variety of non-motor symptoms 
that contribute significantly to disability, reduced quality of life as well as caregiver 
distress26-30. Common non-motor symptoms in PD include olfactory loss, sleep 
disorders, autonomic dysfunction, cognitive alterations, and neuropsychiatric 
symptoms, including depression, anxiety, apathy and hallucinations30, 31. This thesis 
will mainly focus on cognitive and emotional disturbances in PD. Cognitive deficits in 
PD increase with age, disease-duration, and severity of PD, and commonly present as 
a dysexecutive syndrome with difficulties in abstract thinking, cognitive flexibility, 
decision-making and planning32. There is substantial heterogeneity in the clinical 
presentation and progression of cognitive impairments in PD, which likely reflects the 
diversity of brain damage caused by the disease32.  
 
The most prevalent mood symptoms in PD are depression (20-40%) and anxiety (35-
55%)33, 34. Anxiety can have a negative impact on the motor symptoms of PD, including 
freezing, gait, dyskinesias and on-off fluctuations35, and depression has been found to, 
if untreated, result in greater functional disability and faster physical and cognitive 
deterioration36. Due to the high overlap of symptoms of anxiety and depression on one 
hand, and other core symptoms of PD, such as sleep disturbances and fatigue, 
attentional and concentration changes, loss of appetite or weight changes on the other 
hand, mood symptoms in PD are often underdiagnosed and undertreated37. Moreover, 
recognising symptoms of anxiety and depression is further complicated by the fact that 
these symptoms, similar to motor symptoms, can be off-period related and fluctuate 
over the course of the day38, 39, which makes it difficult to capture them with routine 
cross-sectional assessments that are usually retrospective in nature. Recently, it has 
been suggested that the experience sampling method (ESM), a digital diary tool that 
captures moment-to-moment changes in physical and mental states, as well as 
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contextual factors, could be used to elucidate relationships between motor and mood 
states in PD patients40.  
 
Mood symptoms often occur before the onset of motor symptoms in PD and can be 
responsive to antiparkinsonian medication in some patients. Therefore, it has been 
suggested that these symptoms reflect underlying disease-pathology38. While there is 
considerable evidence that PD is the result of abnormal activity in the frontal basal-
ganglia ‘motor’ circuit due to loss of dopamine5, the frontal basal-ganglia ‘limbic’ circuit, 
which is involved in the regulation of emotional behaviour and includes the amygdala, 
ventral striatum, ventral ACC and OFC, is also highly dependent on dopaminergic 
neurotransmission41. However, symptoms do not always improve following 
dopaminergic replacement therapy, and studies have suggested that the 
noradrenergic and serotonergic neurotransmitter systems are also involved42-45. On 
the other hand, it has been suggested that fears and social implications associated 
with suffering from a neurodegenerative disorder or from the motor symptoms of PD 
can provoke or exacerbate mood symptoms in PD46. Indeed, common anxiety 
symptoms in PD include worry and insecurity of having PD, worry relating to motor 
symptoms, such as fear of falling, fear of further physical deterioration, but also worry 
relating to social embarrassment and social withdrawal due to motor symptoms and 
off-periods47. In addition, major life-events seem to play an important role for the onset 
of mood symptoms in PD, which seems to be modulated by social support and coping 
capacities48. Given the complex interaction between physiological and psychological 
factors, the diversity of the disease, as well as the fact that a number of mood 
symptoms relate to PD symptomatology, interventions should be tailored to the specific 
needs and circumstances of PD patients. 
   
To date there are few evidence-based treatments for depression in PD. There have 
been mixed reviews on the efficacy of antidepressants for depression in patients with 
PD. There is increasing evidence that treatment with selective serotonin reuptake 
inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) are 
beneficial in alleviating the symptoms of depression in PD49. However, several meta-
analyses have reported that tricyclic antidepressants are more effective compared to 
SSRIs or SNRIs50. Recently, cognitive behavioural therapy (CBT) has been proven to 
be effective for depression in PD51, 52. CBT is a psychotherapeutic intervention that 
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aims to change maladaptive patterns of thinking or behaviour. Evidence from 
neuroimaging studies suggest that CBT is able to alter activity and connectivity in 
several brain regions believed to be involved in mood symptoms53, 54.  
For anxiety in PD, no evidence-based treatment is available at present and it has been 
reported that up to 57% of PD patients with anxiety are untreated55. While 
pharmacological treatment, such as antidepressants or benzodiazepines are the most 
applied treatment by practitioners, one study reported that of the PD patients who 
received pharmacotherapy, 83% still experienced a current anxiety disorder55. 
Moreover, antidepressants often involve undesired side-effects, and benzodiazepines 
are associated with increased risk of falling35, 56. These findings suggests that anxiety 
in PD is difficult to treat and there is an urgent need for the development of evidence-
based treatment approaches tailored to address PD-specific anxiety symptomatology.   
 
Obsessive-compulsive disorder 
OCD is a neuropsychiatric disorder characterised by chronic intrusive and distressing 
thoughts or impulses (obsessions) and repetitive and ritualistic thoughts or mental acts 
(compulsions). OCD has a significant negative impact on multiple domains of quality 
of life57. The estimated lifetime prevalence of OCD is 1-3%57-59. Previously, OCD was 
grouped with “anxiety disorders” in the fourth edition of the Diagnostic and Statistical 
Manual for Mental Disorders (DSM-IV). However, findings from phenotypic, 
neuroimaging, genetic and treatment studies suggested that OCD is both 
phenomenologically and behaviourally distinct from other anxiety disorders, and was 
therefore placed in a new category called “obsessive-compulsive and related 
disorders’ in the DSM-557, 60, 61. In this new classification, four clusters have been 
identified: symmetry/ordering, hoarding, contamination/cleaning, and obsessions/ 
checking. These heterogeneous symptoms have in common that they all feature 
repetitive thought and action, expressed in relation to external and internal stimuli58.  
 
Recent evidence from neuroimaging studies suggest that OCD and OC-spectrum 
disorders are related to abnormalities in frontal-basal ganglia circuitry58. Especially the 
‘limbic’ circuit seems to be implicated in the development of OCD. Functional magnetic 
resonance (fMRI) studies found altered activities in ACC, OFC and striatum during 
resting-state and during symptom expression62, 63. Moreover, altered functional 
connectivity between the striatum and PFC areas have been reported in OCD 
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patients64-66. More evidence for the involvement of the frontal-basal ganglia circuits in 
OCD came from studies showing elevated rates of OC symptoms in PD67-69. First line 
treatments for OCD involve psychotherapeutic and/or pharmacological interventions. 
CBT is the most effective evidence-based psychotherapeutic intervention for OCD70,71, 
while SSRIs are the first choice medication for treating OCD72. These are often used 
together in clinical practice73. About 60-80% of patients respond to first-line treatments, 
and approximately 90% to treatment including antipsychotics74. The remaining 10% of 
patients remain unresponsive to all therapies and suffer from treatment-refractory 
OCD. In recent years, DBS has become a potential treatment modality for treatment-
refractory OCD. 
 
Deep brain stimulation in Parkinson’s disease and obsessive-compulsive 
disorder 
DBS is a neuromodulation procedure that involves stereotactic implantation of 
electrodes in deep targets in the brain, which are connected to a pacemaker delivering 
chronic and high frequency electrical stimulation and thereby modulate neural tissue 
at the target structure as well as surrounding and connected regions24. Although DBS 
is an invasive neurosurgical procedure, it has the advantage of being reversible. 
Furthermore, because of its adjustable stimulation parameters, it can be tailored for 
individual patients. 
 
One of the most common targets for DBS in PD is the STN. The STN is a small 
lenticular shaped nucleus located in the diencephalon-mesencephalic junction, rostral 
to the substantia nigra. It distinguishes itself from all other inhibitory basal ganglia 
structures since it is the only glutamatergic, excitatory, nucleus11. The STN has three 
functional subdivisions: the dorsolateral sensorimotor region, the ventromedial 
associative region, and the medial tip/rostral limbic region11, 75. STN-DBS has been 
proven effective in improving motor symptoms of PD such as tremor, rigidity and 
akinesia. In addition, it allows substantial reduction of dopaminergic medications and, 
thereby, reduces disabling dyskinesia and on-off fluctuations76. However, there have 
been conflicting reports on the occurrence of neuropsychiatric, behavioural and 
cognitive changes following STN-DBS, ranging from new onset or worsening of pre-
existing mood and cognitive symptoms to improvement of cognitive and 
neuropsychiatric symptoms. In addition, neuropsychiatric symptoms reported after 
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STN-DBS range from mania and impulse control disorders to apathy and 
depression77,78. Changes in mood, behaviour and cognition may potentially counteract 
the beneficial effects of STN-DBS on the motor symptoms.  
 
Several patient inherent risk factors have been identified that may partially explain 
cognitive decline following DBS, including older age, axial symptoms and prolonged 
levodopa dosage79, 80. Furthermore, it has been suggested that stimulation and 
surgical factors, such as the volume of tissue activated within and outside the STN, the 
location of the electrode, or cortical or subcortical lesions due to the lead trajectory, 
are associated with changes in cognitive functioning81. However, research on the 
factors contributing to cognitive changes following STN-DBS have led to inconsistent 
findings. Similarly, the occurrence of mood symptoms following DBS, such as 
depression, has been associated with a number of causes including current spreading 
to the limbic region of the STN, post-operative withdrawal of dopaminergic medication, 
pre-existing depressive symptoms, and mal-adaptation to the new physical and 
psychosocial situation following DBS surgery77, 82, 83. Moreover, experimental studies 
showed that STN stimulation inhibited dorsal raphe nucleus neuronal firing and a 
reduced release of serotonin in the rat, which suggests that alteration in the 
serotonergic (5-HT) neurotransmitter might be involved in the neuropsychiatric side-
effects following STN-DBS84-86.  
 
Interestingly, following the observations that STN-DBS resulted in an improvement in 
motor symptoms as well as obsessive and compulsive symptoms in PD patients with 
advanced PD and comorbid OCD, DBS gained attention as treatment option for 
treatment-refractory OCD patients87, 88.  In recent years, several clinical trials and case 
reports have published promising results regarding the effect of STN-DBS in OCD 
patients89. In addition, several other DBS targets that are part of the frontal-basal 
ganglia ‘limbic’ circuit have been studied, such as the ventral capsule/ventral striatum, 
the anterior limb of the internal capsule, the nucleus accumbens and the inferior 
thalamic peduncle89. Recent systematic reviews and meta-analyses found similar 
percentages of improvement in these different target areas with a reduction of 45-48% 
in obsessive and compulsive symptoms following DBS. Moreover, the global 
percentage of responders –a minimum reduction of 35% on the Yale-Brown 
Obsessive-Compulsive Scale– has been estimated at 58-67%89, 90. In light of these 
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findings, many questions remain regarding the underlying mechanisms of DBS on 
frontal-basal ganglia circuits and condition-specific neurobiology.  
 
Aims of this thesis 
This thesis has several aims divided into two parts:  
 
Part 1: DBS studies in OCD and PD 
The first aim was to explore the role of the STN in OCD circuitry and its 
pathophysiological mechanisms based on observations from DBS studies (Chapter 2 
and 3). The second aim was to study underlying mechanisms of emotional and 
cognitive side-effects of STN-DBS in PD patients (Chapter 4 and 5).  
 
Part 2: Mood symptoms in PD 
The third aim of this thesis was to explore the usability of ESM in PD at the individual 
and population level by exploring associations between motor and mood symptoms in 
patients who suffer from motor fluctuations (Chapter 6 and 7). And finally, we aimed 
to develop a treatment programme for anxiety in PD, which is supported by the 
knowledge of the underlying aetiology and correlations of anxiety in PD (Chapter 8 
and 9).  
 
Outline of this thesis  
Part 1 
DBS in OCD Chapter 2 provides a narrative review of the functional role of the STN 
in the pathophysiology of OCD, in which we aimed to integrate 
neuroanatomical and pathophysiological findings from DBS studies. 
Chapter 3 describes a patient who received anteromedial STN-DBS 
for treatment-resistant OCD, but developed motor side-effects that 
interfered with DBS programming. 
  
DBS in PD In Chapter 4 we aimed to investigate the role of 5-HT on mood and 
behaviour in PD patients with STN-DBS by temporarily reducing the 
level of available 5-HT in the brain by means of tryptophan depletion. 
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In Chapter 5 we aimed to study whether cognitive decline following 
STN-DBS in PD was associated with surgical characteristics.     
 
Part 2 
ESM in PD In Chapter 6 we aimed to study longitudinal associations between 
motor symptoms and mood symptoms in a PD patient by using ESM 
data. In Chapter 7 we explored the usability and sensitivity of 
routinely collected ESM data in PD patients on a group and individual 
level.  
 
CBT for PD Chapter 8 describes the rationale and methodology of a randomised 
controlled trial that aims to study the clinical effectiveness, alterations 
in brain circuitry, and cost-effectiveness of a specialised CBT 
programme for anxiety in PD. Chapter 9 presents the development, 
specific structure and content of the specialised treatment programme 
we developed for anxiety in PD, which is based on CBT principles.  
  
Summary Chapter 10 provides a general discussion, including a summary of 
the main findings of the various chapters, and implications and 
recommendations for future research and clinical practice.  
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ABSTRACT 
Obsessive-compulsive disorder (OCD) is among the most disabling chronic psychiatric 
disorders and has a significant negative impact on multiple domains of quality of life. 
For patients suffering from severe refractory OCD, deep brain stimulation (DBS) of the 
subthalamic nucleus (STN) has been applied. Reviewing the literature of the last years 
we believe that through its central position within the cortico-basal ganglia-
thalamocortical circuits, the STN has a coordinating role in decision-making and action-
selection mechanisms. Dysfunctional information-processing at the level of the STN is 
responsible for some of the core symptoms of OCD. Research confirms an 
electrophysiological dysfunction in the associative and limbic (non-motor) parts of the 
STN. Compared to Parkinson’s disease patients, STN neurons in OCD exhibit a lower 
firing rate, less frequent but longer bursts, increased burst activity in the anterior 
ventromedial area, an asymmetrical left-sided burst distribution, and a predominant 
oscillatory activity in the δ-band. Moreover, there is direct evidence for the involvement 
of the STN in both checking behaviour and OCD symptoms, which are both related to 
changes in electrophysiological activity in the non-motor STN. Through a combination 
of mechanisms, DBS of the STN seems to interrupt the disturbed information-
processing, leading to a normalisation of connectivity within the cortico-basal ganglia-
thalamocortical circuits and consequently to a reduction in symptoms. In conclusion, 
based on the STN’s strategic position within cortico-basal ganglia-thalamocortical 
circuits and its involvement in action-selection mechanisms that are responsible for 
some of the core symptoms of OCD, the STN is a mechanism-based target for DBS in 
OCD.  
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INTRODUCTION 
In the last decades the interest in neuromodulation therapies for psychiatric disorders, 
such as obsessive-compulsive disorder (OCD), has increased due to the advances in 
the field of deep brain stimulation (DBS). OCD is among the most disabling chronic 
psychiatric disorders and has a significant negative impact on multiple domains of 
quality of life1-3. Even after state-of-the-art psychotherapeutic and pharmacological 
treatments, approximately 10-20% of patients do not respond sufficiently to 
treatment4,5. For the most treatment-resistant OCD patients, DBS has resulted in a 
substantial relief of key symptoms6-8.  The rationale for the current use of DBS for OCD 
is based on findings from both clinical and experimental studies, suggesting an 
involvement of abnormal functioning of cortico-basal ganglia-thalamocortical 
circuits1,5,9. The main target areas for DBS for OCD are the ventral capsule/ventral 
striatum (VC/VS), the nucleus accumbens (NAc) with the involvement of the bed 
nucleus of the stria terminalis, the anterior limb of the internal capsule (ALIC), and the 
subthalamic nucleus (STN)1, 8, 10, 11. In this review we will focus on the latter target. The 
STN as a surgical target for OCD has recently been introduced and the therapeutic 
effects are promising3, 12. The STN is a key structure in the basal ganglia in which 
motor, cognitive and limbic projections come together13-15. It is like a crossroad in which 
different modalities of behaviour are being processed16. The present review aims the 
shed light on the functional role of the STN in the pathophysiology of OCD, by 
integrating neuroanatomical and pathophysiological findings.  
 
Obsessive-compulsive disorder 
OCD is characterised by the repeated occurrence of obsessions and/or compulsions 
that are recognised as excessive, inappropriate or unreasonable, causing marked 
distress, and significantly interfere with daily functioning1. Obsessions are defined as 
intrusive, repetitive and distressing thoughts, images, or impulses that can cause 
anxiety or distress. Compulsions can take the form of repetitive, stereotyped, or 
ritualised overt behaviours or covert mental acts, both of which perform a neutralisation 
function in order to reduce distress, to weaken an obsession, or to prevent some feared 
outcome3, 17. According to epidemiological studies, the prevalence of OCD in the 
general population and across countries has been estimated at approximately 1-3%18.  
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The treatment of OCD is based on assessment of the severity of OCD, age, and the 
presence of comorbid disorders17,18. Conventional treatments include psycho-
education, reduction of psychosocial stress, cognitive behavioural therapy (CBT) 
and/or pharmacotherapy3, 17, 18. Selective serotonin reuptake inhibitors (SSRIs) are the 
first choice of medication in OCD17, 19. However, the response to treatment can take 
months and high dosages are often required for good efficacy20, 21. Moreover, up to 
60% of OCD patients do not respond to treatment with SSRIs19, 20, 22.  
 
Deep brain stimulation 
In DBS, electrical current is delivered to specific locations in the brain through 
permanently implanted electrodes9. Because of its adjustable stimulation parameters, 
DBS therapy can be tailored for individual patients7. DBS is a treatment option only for 
OCD patients who have failed to respond to: (1) three treatment attempts with SSRIs, 
including clomipramine for at least 10-12 weeks at the maximum doses; (2) 
augmentation with a neuroleptic; and, (3) a minimum of 16-20 sessions of CBT1, 3. 
 
To date more than 100 patients with refractory-OCD have received DBS in one of the 
following targets: the VC/VS; the inferior thalamic peduncle; the NAc; the ALIC; the 
medial forebrain bundle23; and, the STN (see1, 8, 10, 24). The STN is a well-known target 
for DBS in patients with early and advanced Parkinson’s disease (PD)25, 26. The interest 
for the STN as a potential target for DBS in OCD came from case observations. In two 
patients with advanced PD and comorbid OCD, STN-DBS resulted in an improvement 
of the Parkinsonian symptoms and a substantial reduction of obsessive and 
compulsive symptoms27. A similar observation was published two years later28. Based 
on these findings and the long-term effects of stimulation of the STN in PD patients, a 
larger double-blind cross-over study of STN-DBS was performed in patients with 
refractory OCD in order to assess the efficacy and safety3. After three months of 
stimulation, 70% of patients with active stimulation showed a reduction of 35% or more 
of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and 62% of patients 
achieved satisfactory global functioning (as measured with the Global Assessment of 
Functioning scale (GAF)), compared to 12% of patients with sham stimulation. This led 
to the conclusion that STN-DBS can be an effective therapy for patients with refractory 
OCD. Complications included one intracerebral haemorrhage, two infections and three 
cases of transient, stimulation-induced hypomania3, 29. Infections are not uncommon in 
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OCD patients who have received DBS1. According to our clinical experience this is 
related to an increased tendency of OCD patients, compared to other patient groups, 
to touch their wounds. Table 1 summarises the main findings of studies with STN-DBS 
in OCD. 
Intrinsic organisation and connectivity of the STN 
The STN is a small, densely populated and highly vascularised lenticular nucleus15, 30. 
It is located in the diencephalo-mesencephalic area rostral to the substantia nigra31, 
between the zona incerta medially/superiorly and the substantia nigra inferiorly. It is 
medially and laterally encapsulated by major fiber bundles, such as the medial 
forebrain bundle and the internal capsule, respectively. STN neurons are tightly placed 
next to each other, without any intervening glial membranes. Dendrites extend to a 
relatively small part of the STN32. It is believed that most STN neurons are long-axoned 
projection neurons that emerge directly from the cell soma15. It is the only glutamatergic 
nucleus in the basal ganglia.  
The STN participates in cortico-basal ganglia-thalamocortical circuits that mediate 
motor, cognitive and emotional functioning14, 15. The current idea is that these circuits 
are partially segregated and integrated33. In line with this, the STN can be divided into 
three functional divisions: a dorsolateral motor region, a ventromedial associative 
region, and the medial tip/rostral (limbic) region (see Fig. 1)15, 32, 34, 35.  
Figure 1. Three views of the limbic tip (red) of the right STN in one healthy subject, based on the 
STN’s connectivity to limbic cortical areas as determined with diffusion weighted ultrahigh field MRI 
(7T, courtesy of Y. Temel). A = anterior, M = medial, S = superior. 
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Table 1. Reports of subthalamic nucleus-deep brain stimulation for obsessive-compulsive 
disorder  
Author Patients Effects Side-effects/comment 
Mallet et al., 2002  2  Positive case 
report 
Treatment not intended for OCD. 
Beneficial effect of STN-DBS in patients 
with Parkinson disease with comorbid 
OCD 
Fontaine et al., 2004  1 Positive case 
report 
Beneficial effect of STN-DBS in a patient 
with Parkinson disease with comorbid 
OCD 
Mallet et al., 2008  17 Y-BOCS 
reduced by 41% 
1 intracerebral haemorrhage with 
permanent finger palsy, 2 infections, and 
other reversible side-effects, including 
hypomania 
Le Jeune et al., 2010  10 patients 
included in 
Mallet et al., 
2008 
 Analysis of prefrontal metabolism after 
STN-DBS in OCD in sham- and active 
stimulation  
Piallat et al., 2011  9, of which 3 
were included 
in Mallet et al., 
2008  
 No clinical data. Analysis of neuronal 
firing 
Welter et al., 2011  12 patients 
included in 
Mallet et al., 
2008  
 Analysis of subthalamic neuronal activity 
in relation to obsessions and 
compulsions severity 
Chabardès et al., 
2012 
4, of which 2 
were included 
in Mallet et al., 
2008  
Benefit that can 
reach 50-75% 
on the Y-BOCS 
Weight-gain, voltage-dependent side-
effects, including hypomania and anxiety 
Barcia et al., 2014  2 Pre- and 
postoperative 
Y-BOCS scores 
were 33 and 16 
respectively, 
and 33 and 3, 
respectively 
Screening for the best target between 
the right and left STN and NAc. In both 
patients, the combination of electrodes, 
which best relieved the OCD symptoms 
was both the left STN and left NAc  
Bastin et al., 2014  7, of which 
some were 
included in 
Mallet et al., 
2008 and 
Chabardès et 
al., 2013  
 Analyses of electrophysiological 
recordings of the STN during acute 
symptoms of OCD 
Burbaud et al., 2014  10 patients 
included in 
Mallet et al., 
2008  
 Analyses of subthalamic neuronal 
activity while patients performed a 
cognitive task 
This table summarised the studies reporting on the effects of DBS of the STN in patients with OCD. 
The number of patients, the main effects and the side-effects are described. Some patients have been 
included in more than 1 publication. In these cases, data are only presented once. DBS = deep brain 
stimulation, STN = subthalamic nucleus, OCD = obsessive-compulsive disorder, NAc = nucleus 
accumbens.  
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A dysfunction in the cortico-basal ganglia-thalamocortical limbic circuit, which 
processes motivational and affective processes, has especially been implicated in the 
pathophysiology of OCD24, 36, 37. The limbic circuit consists of the hippocampal 
formation, the amygdala, the medial orbito-frontal cortex (OFC), the ventromedial 
prefrontal cortex (vmPFC), the anterior cingulate cortex (ACC), the VS, ventral 
pallidum and the dorsomedial nucleus of the thalamus (DM)13, 15. The medial tip of the 
STN is reciprocally connected with the ventral pallidum, also known as a major limbic 
output region15, 38. The ventral pallidum, in turn, receives projections from the VS, which 
consists of the ventromedial portions of the caudate, the NAc, and the medium-celled 
portion of the olfactory tubercle. This indirectly connects the STN with the NAc. The 
VS receives excitatory projections from the hippocampal formation, the amygdala and 
the limbic and paralimbic cortices13, 15, 38. The STN also receives direct cortical input, 
also known as the hyperdirect pathway39. Via the ventral pallidum, the limbic circuit is 
closed by a thalamo-cortical glutamateric pathway15.   
 
The behavioural role of the STN  
The STN has a pivotal place in a complex neuronal network in which indirect and 
hyperdirect pathways come together. The success and widespread use of the STN as 
a target for PD has provided the opportunity to record its electrical activity. This has 
contributed to a better understanding of the functional roles of the STN in the context 
of PD40.  
 
According to current computational models the STN acts by converging a variety of 
information from several cortical regions, and by establishing a decisional threshold in 
order to assess the amount of information needed for behavioural expression during 
situations involving conflict41. Multiple lines of evidence have consistently shown 
impaired response inhibition during conflict situations as assessed by different 
paradigms that require the withholding or inhibition of a prepotent motor response42-46. 
Moreover, electrophysiological and imaging studies suggest that the STN is involved 
in both reactive and proactive inhibition47, which are associated with changes in beta 
band activity (13-35Hz)48, 49. In addition, correlates of conflict in theta (4-8Hz) and delta 
(2-4Hz) bands of neuronal activity within the STN provided further evidence for the role 
of the STN in inhibitory processes50, 51.  
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Non-motor side-effects observed after STN-DBS in PD patients, such as impulse 
control disorders, (hypo)mania, and acute depression15, 52, 53, but also improvement in 
neuropsychiatric symptoms following STN-DBS54, indicated that the STN is not purely 
a motor structure, but is also involved in cognitive and emotional functioning. Indeed, 
deficits in non-motor inhibition have been demonstrated following DBS of the STN in 
PD, including increased errors on the Stroop interference task, which requires the 
suppression of habitual responses55. Another study showed changes in beta-band 
activity prior to response during incongruent trials in the Stroop task56.  
 
Together with structures such as the right inferior frontal gyrus (rIFG) and 
presupplementary motor area (preSMA)49, 57, the STN seems to be essential in 
decision-making and action-selection processes, by its ability to stop or inhibit 
automatic and unwanted response outputs58, 59. Interestingly, a recent study found 
synchronised activity in populations of STN neurons which reflected the subjective 
value of reward and the subjective cost of effort that could predict decision-making in 
an effort-based decision-making test 60. Thus, instead of signaling conflict, STN LFP 
responses varied in proportion to subjective value, which led the authors to suggest 
that this STN signal may be understood in the context of task-engagement and 
resource allocation, thereby implying a role for the STN in motivational and reward-
related processes60.  
 
Findings from other studies that have used DBS to explore the role of the STN in 
emotional processing suggest that the STN is not just involved in specific categories 
or sub-processes of (different) emotions, but rather plays a more general coordinating 
role46. Similar to the computational models proposed for action and cognition as 
described previously, it is believed that the STN is involved in producing temporally 
organised neuronal co-activation patterns at the cortical and subcortical levels that are 
crucial for the regulation of thoughts and emotions46. Taken together, it appears that, 
through its central position in which motor, associative, and limbic circuits come 
together, the STN gathers different types of information on the environment to 
determine the required amount of information for any behavioural program to be 
expressed29.  
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Electrophysiological recordings in the STN in patients with OCD  
Similar to studies in PD patients, single-neuron and local field potential (LFP) 
recordings in patients with OCD are beginning to provide insight into the 
pathophysiology of OCD. Based on studies that found an electrophysiological 
signature in the dorsolateral (motor) region of the STN in patients with PD, including 
increased neuronal activity, and occurrence of bursts and oscillations61-63, some 
argued that in OCD an electrophysiological signature should be found in the 
ventromedial parts of the STN64, 65. In one study, recordings of 9 OCD patients and 11 
PD patients were analysed65 and in another study 12 patients with OCD and 12 
patients with PD64. Both studies reported a lower mean STN firing rate in patients with 
OCD when compared to STN neurons of PD patients (20.5 ± 11.0Hz vs 30.8 ± 15.6Hz, 
respectively; and 22.4 ± 13.7Hz vs 31.6 ± 13.5Hz, respectively), and a significantly 
higher intraburst frequency in PD than in OCD (83.4 ± 131.2Hz vs 50.9 ± 27.8Hz, 
respectively; and 74.4 ± 34.7 vs 53.7 ± 52.6, respectively)64, 65. The mean interspike 
interval was also found to be significantly higher in OCD (71.8 ± 63.5ms), compared to 
PD (40.1 ± 26.3ms)64.   
 
Interestingly, although the proportion of burst neurons did not differ significantly 
between OCD and PD patients, in 69%-67%64 and in 75%-73%65, respectively, a 
significant difference in the proportion of bursty firing neurons within the non-motor 
STN and motor STN in OCD was found, being 83% and 50%, respectively65. In 
contrast, in PD patients an opposite pattern was observed, with a burst proportion of 
55% in the non-motor STN and a burst proportion of 81% in the motor STN65. In 
addition, in OCD patients the mean interspike interval of the STN neurons located in 
the motor part was found to be significantly higher compared to the mean interspike 
interval of the STN neurons located in the associative and limbic parts in OCD patients, 
and compared to all STN regions in PD patients64.  
 
The observed mean burst duration of STN neurons in both studies was significantly 
higher in OCD patients compared to PD patients (307.0 ± 177.0s vs 243.0 ± 131.0ms, 
respectively; and 823.5 ± 665.0ms vs 340.3 ± 246.1ms, respectively)64,65. Furthermore, 
in OCD the proportion of burst neurons was asymmetrically distributed (83% left side 
and 59% right side), whereas no asymmetry was found in PD65.   
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Additionally, oscillatory activity in the STN was analysed, as well as the relationship 
between STN burst characteristics and OCD symptom severity and the clinical 
response to DBS64. Briefly, compared to the STN of PD patients, the proportion of 
neurons displaying oscillatory activity was lower in the STN of OCD patients (46% in 
OCD vs 68% in PD), as well as the mean frequency in the β-low band (12-20 Hz) in 
STN neurons in OCD (14.4 ± 2.8Hz in OCD vs 15.8 ± 2.5Hz)64. Except for the presence 
of more θ-band (4-8Hz) activity in the STN of OCD patients and more β-low band 
activity in the STN of PD patients, the distribution of oscillatory activity was similar 
between OCD and PD patients64. Over the entire frequency range, more oscillatory 
activity was observed in the non-motor part of the STN in OCD, whereas in the STN of 
PD oscillatory activity was greater in the motor part64. Further, a relationship was found 
between STN neuronal activity and symptom severity and between STN neuronal 
activity and clinical improvements with DBS in OCD patients64. Specifically, the lower 
the burst duration and interburst interval, and the higher the mean discharge and 
intraburst frequencies, peak and power in the δ-band (1-4 Hz), the more severe 
obsessions were. Moreover, the greater the intraburst frequency and the proportion of 
oscillatory activity in the α-band (8-12 Hz), the more severe the compulsions were. 
Finally, patients with higher intraburst frequency, but with lower interburst interval had 
the best clinical outcome64.  
 
Altogether, five main characteristics were identified that distinguished STN neurons in 
OCD from those in PD: (1) a lower firing rate, (2) a bursty pattern with less frequent 
but longer bursts, and lower intraburst frequency, (3) increased burst activity in the 
anterior ventromedial area, (4) an asymmetrical left-sided burst distribution, and (5) a 
predominant oscillatory activity in the δ-band64, 65. Moreover, some burst 
characteristics were found to be related to OCD severity, and clinical improvement as 
a result of DBS seems to be dependent on STN neuronal activity, with a higher 
response for patients with higher intraburst frequency, but lower interburst interval64.  
 
Although these findings strongly point into the direction of involvement of the non-motor 
part of the STN in OCD, one should be cautious in interpreting these characteristics as 
an electrophysiological signature of OCD. Firstly, in the absence of control data, it can 
be questioned whether the observed characteristics are unique to and specifically 
reflect OCD pathology. Secondly, while burst activity and oscillatory activity in the 
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motor region of the STN in PD are related to a disturbed dopamine system61, 66, we do 
not know how these two are related in OCD. Lastly, it should be taken into account that 
neurons within different sub-regions of the STN were recorded in OCD and PD patients 
respectively. Although the authors argued that it is unlikely that the observed 
differences between STN neurons in OCD and PD are due to morphological and 
physiological differences between these sub-regions64, the existence of neural clusters 
within the STN with different types of electrical properties has been proposed15, 52. 
 
Nonetheless, additional evidence for the involvement of the STN in OCD pathology 
came from studies that performed electrophysiological recordings of the STN in OCD 
during cognitive tasks and during obsessions. One study recorded STN activity in two 
patients during acute OCD symptoms that occurred during a stop-signal task, a few 
days after the implantation of the DBS leads in the non-motor part of the STN67. In 
comparison to five patients who did not show any acute OCD symptoms, significant 
increases of STN oscillations on the majority of STN contacts within the δ-α (1–12Hz) 
frequency range were observed67. The authors suggested that this modified activity 
reflects a mixture of both pathological activity corresponding to repetitive unsuccessful 
action selection and compensatory mechanisms that reflect the maintenance of an 
over stable motor/cognitive/emotional set67. Another single-neuron recording study of 
STN activity during a decision-making task in which OCD subjects had the possibility 
of unrestricted repetitive checking, revealed that checking behaviour favoured by doubt 
was associated with a higher STN firing rate in the non-motor part68, which confirms 
its role in repetitive doubt-related thinking, one of the main clinical characteristics of 
OCD69.  
 
STN and OCD 
The involvement of the basal ganglia in the pathophysiology of OCD has been 
confirmed by multiple lines of research, including neuroimaging, neuropsychological, 
and electrophysiological studies90. However, there is still a lot of uncertainty with regard 
to the relationship between certain brain abnormalities and clinical OCD symptoms. 
Moreover, whereas the conventional view on OCD considers compulsions as a coping 
mechanism in order to neutralise distress and weaken obsessions3, 17, it has been 
proposed that obsessions and obsession-related anxiety precede or follow, rather than 
cause compulsive behaviour70, 71. Recent findings have shown that increased checking 
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behaviour in OCD was unrelated to stimulus-evoked anxiety72. Accordingly, it has been 
suggested that compulsions represent the core feature of OCD, and result from a 
disruption of balance between goal-directed action and automatic habits70, 73. As was 
pointed out before, the STN has a coordinating role in decision-making and action-
selection mechanisms, by integrating multiple streams of information from the 
environment to determine the required amount of information necessary for 
behavioural expression41. At this point the question arises how neuronal activity within 
the non-motor part of the STN is related to OCD phenomenology.  
 
Based on the electrophysiological data, there seems to be a disruption of the 
information-processing system of the associative and limbic circuits, at the level of the 
STN, in OCD65, 68. As already proposed by others, a dysfunction in this system could 
contribute to OCD symptomatology, such as increased checking behaviour or the 
incapacity to make a decision because of permanent doubt, since there is no smooth 
progression from a cognitive framework that is responsible for establishing priorities 
for potential behaviours to behavioural selection37. These anxiety-independent 
processes subsequently lead to unsuccessful action selection and freezing of 
thoughts65, 67. 
 
The disruption of information-processing could be the result of an imbalance between 
direct and indirect pathways, according to some similar to the dysfunction seen in 
movement disorders, such as PD74. While the direct pathway is thought to facilitate 
movement and the indirect pathway is thought to suppress unwanted movement, OCD 
can be conceptualised as the over-activation of the direct pathway with limited 
inhibition by the indirect pathway, only now focusing on cognitive and limbic 
functions29,74. It has been hypothesised that as a result of this imbalance, which is 
reflected by the hyperactivity of the non-motor part of the STN in OCD, the STN is 
incapable of inhibiting unwanted behavioural programs29, 68. This is consistent with 
findings of impaired performance of patients with OCD on response inhibition, 
switching and interference tasks (see75, 76). Consequently, no proper feedback signals 
are being sent out to the cortex, resulting in a state of permanent doubt, as well as in 
the perpetuation of pathological repetitive behaviours. How and whether the 
hyperdirect pathway is involved in these processes needs further investigation.  
 
 
39 
 
Alternatively, checking compulsions could be seen as an attempt to gather more 
information to reach the threshold, whereas obsessional content would be created by 
the patients in order to rationalise the compulsions29, or explain their bad habits70, 73. It 
is also possible that the STN’s decisional threshold would not be reset after the 
expression of certain behaviour due to NAc dysfunction, which is, like the STN68, 
associated with impaired goal-directed motivated behaviour in OCD77. This dysfunction 
would in turn lead to repetitive behaviour observed in OCD patients through excessive 
fronto-striatal connectivity. The pathological doubt that occurs in OCD could finally be 
caused by cortical dysfunctions that modify the decisional threshold29.  
 
Based on the electrophysiological evidence and the proposed role of the STN in OCD, 
we believe that STN-DBS interrupts the disturbed information-processing that seems 
to be responsible for the pathological repetitive behaviours characteristic for OCD by 
interfering with the pathological activity of the STN. As a consequence, other 
compensatory connective pathways can take over and normalise the feedback signals 
towards the cortex, resulting in a decrease in symptoms. In other words, local 
stimulation of the STN seems to restore the imbalance between the direct and indirect 
pathway, resulting in normalisation of the pathological connectivity within the cortico-
basal ganglia-thalamocortical circuit.   
 
This mechanism, known as the disruption hypothesis78, is consistent with findings of 
decreased OFC and medial PFC metabolism, as well as ACC activity in OCD patients 
following STN-DBS79, confirming the distal effects of DBS. Likewise, it is consistent 
with the symptom-related changes observed in the STN in OCD, which suggest that 
DBS might directly act on pathological STN activity64. Moreover, the idea that DBS acts 
on neural connectivity can account for findings of similar percentages of improvement 
of DBS in the different target areas in patients with OCD, which are all part of the 
proposed dysfunctional circuit10, 80. It has been suggested that underlying mechanisms 
of DBS are largely independent of the target81, and that DBS resets the network 
dynamics within a circuit by functionally overriding disruptive neuronal activity between 
different brain network nodes82 that are assumed to be involved in the disorder. For 
OCD, examples include the involvement of the NAc in goal-directed motivated 
behaviour77, and the role of the caudate nucleus in error-detection83.   
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In fact, there is currently no consensus with regard to the optimal anatomical target for 
OCD10, 80. It can be argued that other commonly used targets, including the ALIC, 
VC/VS and NAc, are more or less part of one and the same larger region. That is, DBS 
at the ALIC, which is part of the internal capsule, was found to be most successful 
when more ventral regions are targeted, which resulted in the exploration of the VC/VS 
as target for OCD84, 85. For VC/VS stimulation, the most ventral contact is usually 
placed in the NAc area, whereas the middle contacts are placed to stimulate the ventral 
portion of the ALIC86. For stimulation of the NAc, which is located just beneath the ALIC 
at the head of the caudate and the anterior portion of the putamen, dorsal contacts at 
the ventral border of the internal capsule seem to be involved in more favourable 
improvements86-89. The use of larger electrodes (model 3387, Medtronic, Minneapolis, 
MN) for these regions can benefit the search for the target with the greatest benefit for 
each patient. However, research has also shown that there is a high variability of 
contact placement89, which makes it difficult to compare the efficacy of the different 
structures in the search for the best target area for DBS in OCD. On the contrary, the 
STN is a relative small nucleus. Based on its central position within the cortico-basal 
ganglia-thalamocortical circuits, its coordinating role in emotional and cognitive 
functioning, its established involvement in processes related to OCD, and its familiarity 
as a target for PD, we propose that the STN can be considered a favourable and 
mechanism-based target for DBS in OCD (Fig. 2).  
 
CONCLUSION 
Although literature on the specific role of the STN in OCD circuitry and its 
pathophysiological mechanisms is limited, research findings are indicative of an 
electrophysiological dysfunction in the non-motor part of the STN, which correlates with 
symptom severity and the response to STN-DBS. Moreover, there is direct evidence 
for the involvement on the non-motor STN in both checking behaviour and OCD 
symptoms, which are both related to changes in electrophysiological activity in this 
region. These findings are in line with proposed models of decision-making, suggesting 
a key role of the STN in the integration of various types of information which is 
necessary for establishing priorities for potential behaviour and action-planning, as well 
as for the coordination of action, stream of thoughts and motivation29, 37. We believe 
that STN dysfunction leads to a disruption of information-processing of associative and 
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limbic processes, hence leading to obsessions and compulsions. Through a 
combination of mechanisms DBS of the STN interrupts this disturbed information-
processing by interfering with pathological activity of the STN and by facilitating 
compensatory connective pathways to normalise the feedback signals that are sent 
towards the cortex, eventually leading to symptom reduction.  
 
 
 
Figure 2. Schematic illustration of the subthalamic nucleus (STN) within the primate limbic circuit in 
obsessive-compulsive disorder (OCD).  
Projections from the limbic and paralimbic cortices, the amygdala (A) and hippocampus (B) are 
concentrated at the level of the ventral striatum. From the ventral striatum, the circuit is directed to the 
ventral pallidum. The medial tip of the STN (C) is reciprocally connected with the ventral pallidum, also 
known as the major limbic output area. Via the ventral pallidum, the limbic circuit is closed by a thalamo-
cortical glutamateric pathway. The STN also receives direct cortical input. Compared to Parkinson’s 
disease, neurons in the associative and limbic part of the STN (D) exhibit a lower firing rate, less frequent 
but longer bursts, and an increased burst activity in OCD.   
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ABSTRACT 
Background: patients with treatment-resistant obsessive-compulsive disorder (OCD) 
are potential candidates for deep brain stimulation (DBS). The anteromedial 
subthalamic nucleus (STN) is amongst the most commonly used targets for DBS in 
OCD. 
 
Case description: we present a patient with a 30-year history of treatment-resistant 
OCD who underwent anteromedial STN-DBS. Despite a clear mood-enhancing effect, 
stimulation caused motor side-effects including bilateral hyperkinesia, dyskinesias and 
sudden large amplitude choreatic movements of arms and legs when stimulating at 
voltages above circa 1.5V. DBS at lower amplitudes and at other contact points failed 
to result in a significant reduction of obsessions and compulsions without inducing 
motor side-effects. Due to this limitation in programming options, we decided to re-
operate and target the ventral capsule/ventral striatum (VC/VS), which resulted in a 
substantial reduction in key obsessive and compulsive symptoms without serious side-
effects.  
 
Conclusion: choreatic movements and hemiballismus have previously been linked to 
STN dysfunction and have been incidentally reported as side-effect of DBS of the 
dorsolateral STN in Parkinson’s disease (PD). However, in PD, these side-effects were 
usually transient and rarely interfered with DBS programming. In our case, the motor 
side-effects were persistent and made optimal DBS programming impossible. To our 
knowledge such severe and persistent motor side-effects have not yet been described 
for anteromedial STN-DBS.  
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BACKGROUND 
Obsessive-compulsive disorder (OCD) is characterised by the repeated occurrence of 
upsetting obsessions and/or compulsions which are related to substantial dysfunction 
in multiple domains of life1. Despite intensive psychotherapeutic and pharmacological 
treatments, a significant proportion of patients fail to respond to therapy2. Patients with 
treatment-resistant OCD are potential candidates for deep brain stimulation (DBS)3. 
The ventral capsule/ventral striatum (VC/VS), the nucleus accumbens (NAc) and the 
anteromedial limbic portion of the subthalamic nucleus (STN) are amongst the most 
common DBS targets for OCD1. The aim of DBS is to tailor the treatment on a patient-
specific basis in order to deliver optimal therapeutic effects while avoiding stimulation-
associated side-effects. At present, minor complications have been reported of which 
the majority were time-limited and reversed by adjusting the stimulation settings1, 4, 5. 
We present significant stimulation-associated side-effects following DBS of the 
anteromedial STN not previously described and requiring a reimplantation to an 
alternative target, the VC/VS.  
 
CASE  PRESENTATION 
A 47-year old woman with refractory OCD was referred to our hospital for DBS. The 
patient had been suffering from OCD since the age of 15, which was clinically 
characterised by intrusive thoughts about dirt, accompanied with excessive cleaning, 
washing and checking compulsions that occupied the entire day. Additionally, the 
patient suffered from a lowered mood, anhedonia, and occasional panic attacks, 
though failing to meet the criteria for major depressive disorder or any specific anxiety 
disorder. The patient also showed signs of borderline personality disorder. She had 
received several psychological and pharmacological treatments without any long-
lasting relief on symptoms (Table 1). The patient was informed of the risks and benefits 
of DBS and underwent extensive multidisciplinary evaluation prior to surgery to ensure 
her suitability and compatibility for the treatment. The presurgery score on the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS)6 was 34. 
 
In September 2012, at age 49, DBS electrodes (Model 3389 DBS lead; Medtronic, MN, 
USA) were implanted bilaterally in the anteromedial portion of the STN using a CT/MRI 
fusion based stereotactic approach combined with intraoperative electrophysiological 
recordings (MER) with four electrodes (anterior, medial, central and lateral). MER 
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showed approximately 5 mm of typical STN activity along the central trajectory for both 
left and right side, which was characterised by increased background activity, high-
amplitude discharges, and bursty firing neurons. Postoperative imaging validated 
appropriate placement of the electrodes (Figure 1). For final target coordinates see 
Table 1. Stimulation parameters were as follows: monopolar stimulation (left 1-, right 
9-, case+), a pulse width of 90 milliseconds, a frequency of 130Hz and an amplitude 
of 1.5V which had been slowly increased.   
 
After activating the DBS therapy, the patient exhibited an immediate mood-enhancing 
effect and relief in obsessions and compulsions. However, the patient developed 
unexpected compulsive behaviour towards the operation wounds (scratching and 
itching), which has likely contributed to the development of a hardware infection. The 
infection was treated with removing the infected hardware (implanted pulse generator 
and cables) and antibiotic therapy. Two months later new hardware was implanted and 
DBS therapy reactivated. After this period, the mood-enhancing effect decreased and 
the programming was limited by the fact that STN-DBS caused motor side-effects at 
stimulation above circa 1.5V. The motor side-effects consisted of bilateral hyperkinesia 
and dyskinesias, as well as sudden large amplitude choreatic movements of the arms 
and legs.  
 
Following multiple DBS programming sessions (Table 1), including lowering the 
amplitude and using other contact points, no significant reduction of obsessions and 
compulsions could be achieved without inducing motor side-effects. The patient 
additionally suffered from mood swings. Despite continuation of pharmacotherapy and 
additional psychotherapeutic interventions, including intensive day treatment and 
behavioural therapy, the patient’s quality of life remained very poor, and the patient 
required further hospital admissions due to increased suicidal thoughts and an 
impulsively attempted suicide by auto-intoxication. 
 
Due to the programming limitations and the fact that any therapeutic benefit was 
accompanied by intolerable motor side-effects, we decided to re-operate and target 
the VC/VS region. In April 2014, at age 51, the patient underwent stereotactic 
reimplantation of the electrodes with the deepest electrode contact point in the area of 
the NAc (Model 3387 DBS lead; Medtronic, MN, USA). For final target coordinates see 
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Table 1. Postoperative imaging showed adequate placement of the electrodes at the 
planned target (Figure 1). After programming and additional psychotherapeutic 
therapy, therapeutic effect was achieved without inducing serious side-effects. For 
stimulation parameters see Table 1. One year postoperatively, the patient’s Y-BOCS 
score was 29, and two years postoperatively 17, a reduction of 50% compared to 
baseline. At present, the patient reports a stabilisation of daily life routines and 
improved quality of life.  
 
 Table 1.  Patient characteristics and stimulation settings 
Medication used before surgery*   
 Clomipramine 
Sertraline 
Citalopram 
Mirtazapine 
Paroxetine 
Haloperidol 
Oxazepam 
Fluoxetine 
Venlafaxine 
Aripiprazol 
Target coordinates†  STN VC/VS 
X 
Y  
Z 
10  
0 
-4 
7 
12.8(L) / 12.7(R) 
-3 
Stimulator settings Left  Right  
Tested STN-DBS‡ settings 1- C+, 90 µs, 130 Hz 9- C+, 90 µs, 130 Hz 
 2- C+, 90 µs, 130 Hz 10- C+, 90 µs, 130 Hz  
 3- C+, 90 µs, 130 Hz 11- C+, 90 µs, 130 Hz 
 1- 2+, 90 µs, 130 Hz 9- 10+, 90 µs, 130 Hz 
 2- C+, 90 µs, 130 Hz 9- C+, 90 µs, 130 Hz 
 0- C+, 90 µs, 130 Hz 8- C+ 90 µs, 130 Hz 
Final VC/VS DBS settings 1- 2- 3- C+, 3.4 V, 90 µs, 
130 Hz 
9- 10- 11- C+, 3.4 V, 90 µs, 
130 Hz 
Y-BOCS    
Preoperative   34 
Postoperative VC/VS 1 year FU  29 
Postoperative VC/VS 2 year FU  17 
*Medication used before surgery refers to all the different pharmacological trials conducted since the patient 
was first treated until the first surgery. Adequate doses of these drugs were maintained for at least 12 weeks.  
† Distance from mid-anterior/posterior commissure in millimeter 
‡ Voltages were slowly increased with every setting. Dyskinesias occurred at voltages between 1.5 and 
2.1V.  
Abbreviations: STN = subthalamic nucleus, DBS = deep brain stimulation, VC/VS = ventral capsule/ventral 
striatum, Y-BOCS = Yale-Brown Obsessive Compulsive Scale, FU = follow up. 
 
CHAPTER 3 | CHOREATIC SIDE-EFFECTS OF STN-DBS IN OCD 
 
54 
 
 
Figure 1. Postoperative location of the electrodes after bilateral anteromedial STN-DBS (first surgery; 
A, B, C) and bilateral VC/VS DBS (second surgery; D, E, F). Axial preoperative MR images (A and D) 
and their enlargements (B and E). The location of the active contacts in the preoperative images was 
computed by rigidly registering the postoperative images and their coordinates of the active contacts to 
the preoperative images with FSL’s FLIRT algorithm 24. C,F). Postoperative coronal MR images showing 
the electrodes and contacts. 
Abbreviations: STN = subthalamic nucleus, DBS = deep brain stimulation, VC/VS = ventral 
capsule/ventral striatum, MR = magnetic resonance, FLIRT = FSL’s Linear Image Registration Tool. 
 
DISCUSSION 
This case illustrates that DBS of the anteromedial portion of the STN in OCD can cause 
persistent motor side-effects that resemble chorea and ballism. Choreatic movements 
and (contralateral) hemiballismus have previously been associated with STN 
dysfunction7, and have been reported following STN-DBS in Parkinson’s disease (PD), 
where typically the dorsolateral sensorimotor portion of the STN is stimulated8-11. 
Although these side-effects are usually transient in PD11 they can make DBS 
programming difficult8, 9. Moreover, dyskinetic movements as side-effect of STN-DBS 
in OCD have been reported in two patients in the STOC-study (French Stimulation 
dans le Trouble Obsessionnel Compulsif Study Group) in the first month following 
stimulation. However, these resolved spontaneously or promptly following the 
adjustment of the stimulation settings12. As far as we are aware, such severe and 
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persistent motor side-effects that interfere with DBS programming have not yet been 
described for anteromedial STN-DBS.  
 
The underlying mechanisms and pathophysiology of DBS-induced motor side-effects 
are not well understood. For the emergence of such symptoms following STN-DBS in 
PD several disease-related risk factors have been identified, including severe 
dyskinesias preoperatively and young onset PD8. Additionally, STN-DBS has been 
demonstrated to increase extracellular striatal dopamine (DA) metabolites in animal 
models of PD13. Whereas PD is characterised by a progressive degeneration of nigral 
DA neurons, one can speculate that STN-DBS may result in an increase in striatal DA 
release and subsequently in hyperdopaminergic behaviours such as dyskinesia in an 
OCD patient with an intact DA system. This is further supported by the finding that the 
increase in striatal DA metabolites following STN-DBS in naïve rats was accompanied 
with transitory involuntary movements14.  
 
Moreover, dyskinesias following STN-DBS in PD have been associated with contact 
location within the dorsolateral portion of the STN8, 10. The idea that choreiform or 
ballistic movements result from stimulation or lesions of specific subdivisions of the 
STN is supported by a study in which a Gamma-Aminobutyric Acid (GABA) A-receptor 
agonist was injected into the sensorimotor, associative, and limbic territories of the 
STN of green monkeys15. Except for behavioural changes, no abnormal movements 
were observed after microinjection in the anteromedial portion of the STN, whereas 
injection into the dorsolateral and middle portion of the STN resulted in contralateral 
violent and rhythmic involuntary movements and leg ballismus, respectively15.  
 
Despite postoperative imaging showing adequate placement of the electrodes, 
individual differences do exist with regards to volume and position of the STN16. 
Additionally, a human clinical study using diffusion-weighted tractography indicated a 
considerable degree of variation across individuals regarding the volume of structural 
subdivisions of the STN along the limbic, cognitive and motor domains17. In light of the 
individual differences that exist in structural and functional anatomy of STN 
subdivisions, it is possible that in the case of the patient discussed, although the 
anteromedial portion of the STN was targeted, this did in fact not constitute the non-
motor portion of the STN. This may have led to the development of motor side-effects, 
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either directly by stimulation of the motor portion of the STN or indirectly by current 
spreading of contact points in close proximity to the motor portion of the STN. 
Importantly, while the concept of distinct functional subdivisions within the STN is 
popular in neuroanatomy research18-20, it is still a matter of debate and others have 
suggested convergence21 or large overlap and interactions between these functional 
subdivisions22, 23.  
 
Future attempts to manage OCD with STN-DBS should focus in an individualised, 
patient-specific selection method that can determine the size and location of functional 
and structural subdivisions of the STN which may be achieved by, for example, 
preoperative diffusion weighted imaging and tractography and functional magnetic 
resonance imaging. 
 
CONCLUSION 
We presented a case of persistent bilateral motor side-effects in the lower extremities 
that limited programming possibilities in a patient who had undergone bilateral 
anteromedial STN-DBS for severe refractory OCD. Reimplantation of electrodes 
targeting the VC/VS with the deepest electrode contact point in the area of the NAc 
successfully overcame this limitation and resulted in adequate therapeutic response. 
Reimplantation to an alternative target should be considered if stimulation-associated 
side-effects interfere with adequate programming of the DBS system and this cannot 
be resolved by adjusting stimulation parameters.  
 
Patient consent 
Written informed consent was obtained from the patient for publication of this case 
report and any accompanying images.  
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ABSTRACT 
Objective: despite optimal improvement in motor functioning, both short- and long-
term studies have reported small but consistent changes in cognitive functioning 
following STN-DBS in Parkinson’s disease (PD). The aim of the present study was to 
explore whether surgical characteristics were associated with cognitive decline one 
year following STN-DBS.  
 
Methods: we retrospectively analysed 49 PD patients who underwent bilateral STN-
DBS. Cognitive change scores were related to the number of microelectrode recording 
(MER) trajectories, the STN length as measured by MER, and cortical entry points. 
Regression analyses were corrected for age at surgery, disease duration, education 
and preoperative levodopa responsiveness. Patients were then divided into a cognitive 
and non-cognitive decline group for each neuropsychological test and compared 
regarding demographic and surgical characteristics. 
 
Results: one year postoperatively, significant declines were found in verbal fluency, 
Stroop Colour-Word test and Trail Making Test B (TMT-B). Only changes in TMT-B 
were associated with the coronal entry point in the right hemisphere. The number of 
MER trajectories and STN length were not associated with cognitive change scores. 
When comparing the cognitive decline and non-cognitive decline groups, no significant 
differences were found in surgical characteristics. 
 
Conclusions: the electrode passage through the right prefrontal lobe may contribute 
to subtle changes in executive function. However, only few patients showed clinically 
relevant cognitive decline. The use of multiple MER trajectories and a longer STN 
length were not associated with cognitive decline one year following surgery. From a 
cognitive point of view, DBS may be considered a relatively safe procedure.  
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INTRODUCTION 
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective and 
widely accepted treatment for Parkinson’s disease (PD), and associated with improved 
motor functioning and quality of life1, 2. However, both short-term and long-term follow-
up studies have reported small but reliable changes in cognitive functioning, especially 
in the executive function domain3-7. Several patient inherent characteristics have been 
associated with cognitive decline following STN-DBS, such as higher age, levodopa 
dosage, impaired attention, and axial symptoms8, 9. Moreover, stimulation and surgical 
factors such as the location of the active electrode, the volume of tissue activated, and 
stimulation settings may partially explain changes in cognitive functioning10-13. It has 
also been suggested that cognitive decline following STN-DBS reflects a microlesion 
effect due to the trajectories used during surgery, such as trajectories intersecting the 
caudate nuclei4, 12, 14-18.  
 
Accurate placement of the electrode within the dorsolateral sensorimotor part of the 
STN is considered necessary for satisfactory outcome. To date, microelectrode 
recording (MER) is typically used to accurately detect the STN and to optimise lead 
implantation. A recent study showed that multiple simultaneously inserted 
microelectrodes may provide better guidance than single sequential microelectrodes19. 
Moreover, prefrontal entry points are ideally chosen in order to maximise the length of 
the DBS electrode within the STN, thereby offering more contact combinations for 
postoperative DBS programming20, 21. However, it has been hypothesised that a 
greater number of MER trajectories could result in a greater degree of local injury, 
presumably through damage to functional areas along the trajectory or at the target 
site important for cognitive functioning, thereby contributing to cognitive decline 
following surgery14, 16, 22. Moreover, maximising the STN’s length may increase the 
chance of affecting the STN’s associative area, hence leading to cognitive decline16.  
 
The goal of the present study was to investigate whether characteristics of the surgical 
trajectory, including the number of MER trajectories, the STN length as measured by 
MER, and the angles (cortical entry points) of the lead trajectories, are associated with 
cognitive decline one year following STN-DBS in PD patients. Furthermore, we tested 
associations between these characteristics and motor improvement one year following 
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surgery. The results may help in optimising the surgical procedure by balancing the 
benefits and the disadvantages to attempt for maximal STN length. 
 
METHODS 
Design and participants 
This study was conducted at Maastricht University Medical Centre and was exempted 
from ethical approval by the local ethical committee (METC azm/UM). Informed 
consent was not obtained from the patients because of the retrospective nature of the 
study. All patients (N=81) who underwent bilateral STN-DBS for Parkinson’s disease 
between 2005 and March 2017 were retrospectively identified (see Supplementary 
table 1).  Inclusion criteria for our study were: (1) pre- and postoperative neuroimaging 
sufficient for determining the surgical trajectory, (2) MER recordings, (3) available pre- 
and one year post-neuropsychological assessment, and (4) no complications or re-
implantation of electrodes. A total of 49 patients were found eligible for the study (see 
Supplementary table 2 for reasons for exclusion), of which 20 patients were also 
included in an earlier study12. 
 
Surgical details 
The surgical procedure has been described in detail previously23 and included direct 
targeting of the STN and MER guidance during surgery. Trajectory planning was 
performed on gadolinium enhanced T1 images using dedicated surgical planning 
software (Framelink, Medtronic, Minneapolis, USA). The length of the inter-
commissural line (AC-PC line), coordinates with respect to mid-commissural point 
(MCP) and both sagittal and coronal angles of the trajectory were assessed by a 
neurosurgeon. When applicable, up to five MER trajectories per side were used. In 
case of the presence of vessels, the respective trajectories were discarded. MER were 
initiated 10 mm above the target point and continued with 1.0 mm steps. From 5 mm 
above target, steps of 0.25-0.50 mm were used for MER until STN activity disappeared 
and/or until the typical substantia nigra activity appeared, as assessed by a clinical 
neurophysiologist. Trajectories with the longest STN activity were chosen for test 
stimulation. The trajectory with the least side-effects and highest effect on the key 
symptom with largest stimulation window (amplitude threshold of therapeutic and side-
effects) was chosen for the placement of the final electrode. The length of this final 
trajectory as measured by MER was recorded in mm (STN length).  
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MRI analysis 
All patients had a postoperative CT or MR scan for evaluation of postoperative 
complications and electrode localisation. Pre-and postoperative images were imported 
into the Framelink 5.1TM (Medronic BV, Minneapolis HQ, USA) software. After 
orientation of the data set had been confirmed, the preoperative MRI was automatically 
fused with the postoperative MRI or CT for analysis of the postoperative surgical 
trajectory. Subsequently, a neurosurgeon created linear vectors between the observed 
lead tip and cortical entry point in multiplanar and probe’s eye view of all 98 DBS 
electrode trajectories (both hemispheres in each patient) and determined the coronal 
and sagittal angles of the entry points. For the coronal entry point (named mid-sagittal 
plane in the software), angles closer to 0° were located to the midpoint of the AC-PC 
line, while angles close to 90° were located laterally. For the sagittal entry point (named 
axial plane in the software) angles closer to 0° were closer to the midpoint of the AC-
PC line, and angles closer to 90° were located dorsally.  
 
Neuropsychological and motor assessment 
Neuropsychological assessment was performed one month before surgery and one 
year after surgery. Preoperatively, patients were tested with medication ‘ON’, and 
postoperatively with medication and stimulation ‘ON’. The tests were part of the 
standard protocol for PD patients receiving STN-DBS. If available, alternating forms 
were used at follow-up time points to minimise practice effects. For the current study, 
we selected the Auditory Verbal Learning Test (AVLT) immediate and delayed recall24. 
The category (animals and professions) and letter fluency test were used as measures 
of semantic and phonemic verbal fluency, respectively25. The Stroop Colour-Word Test 
was used to measure mental speed and response inhibition26. The Trail Making Test 
(TMT) (part A and B) were used to assess mental speed and cognitive flexibility, 
respectively27.  
 
Motor state was assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS) 
part III. Preoperatively, patients were tested in ‘ON’ and ‘OFF’ medication state, while 
postoperatively assessments were performed with stimulation and medication ‘on’. 
Percentage improvement in motor disability was determined in respect of the 
preoperative OFF-medication condition. 
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Statistics 
Statistical analyses were performed using IBM SPSS Statistics 25.028. Possible 
differences in STN length, cortical entry points and number of MER trajectories 
between the right and left hemisphere were analysed using paired sample t-test. 
Changes in clinical and neuropsychological variables following DBS were analysed 
using parametric t-test statistics and non-parametric Wilcoxon-Rank order tests when 
appropriate (lack of normal distribution of data). A p-value <0.05 was considered to be 
statistically significant. No correction for multiple comparisons was applied in order to 
reduce the risk of type II error given the importance of detecting any adverse effects of 
surgery. Statistically significant mean differences underwent Cohen’s d calculation for 
effect size.  
 
Multiple regression analyses were performed to analyse the associations between  
surgical characteristics and both cognitive decline and motor improvement one year 
following surgery. The dependent variables were raw change scores of the 
neuropsychological tests that showed a statistically significant decline following 
surgery and the percentage of UPDRS III improvement, respectively. The predictor 
variables were the surgical characteristics, each tested in a separate model for both 
left and right hemisphere, and adjusted for age, education, disease duration and 
Levodopa equivalent daily dose (LEDD) at baseline. For the regression analyses, a 
Bonferroni adjusted p-value <0.001 was considered statistically significant.  
 
Lastly, for each neuropsychological test that showed statistically significant change 
following surgery, patients were categorised into two distinct groups based on the 
presence or absence of cognitive decline: the cognitive decline group and the non-
cognitive decline group (or stable performers). For this purpose, standardised Z-score 
were calculated at baseline and follow-up based on the mean and standard deviation 
of the total sample at baseline. Cognitive decline was defined as a raw score change 
(decline for verbal fluency and AVLT,  and increase for TMT, Stoop Colour-Word test) 
>1 Z-score from baseline. Groups (cognitive decline yes / no) were then compared 
using non-parametric Mann-Whitney tests for demographic and surgical 
characteristics. For the comparison analyses, a Bonferroni adjusted p-value <0.002 
was considered statistically significant.  
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RESULTS 
Patient and surgical characteristics 
The study population consisted of 31 males and 18 females. The average age at of PD 
onset was 49.0 years (SD = 9.6) and the average age at DBS surgery was 60.1 years 
(SD = 8.5). The average disease duration was 133.7 months (SD = 31.7). Mean 
UPDRS part III score at baseline was 37.7 (12.0) and the average LEDD was 1346.1 
mg (SD = 329.9).  
 
Surgical characteristics are provided in Table 1. In 32 patients the right hemisphere 
was operated first. The average STN length was 5.2 mm (SD = 1.5), the mean sagittal 
angle was 56.6 degrees (SD = 8.9) and the mean coronal angle was 23.3 degrees (SD 
= 5.1). There were no statistically significant differences between the right and left 
hemispheres regarding STN length, sagittal and coronal angle (coronal entry points) 
and number of MER trajectories.  
 
Table 1. Surgical characteristics 
 Right hemisphere  
(N) 
Left hemisphere 
(N) 
Total 
 
(N) 
 
MER trajectories* 
  - 1 
  - 2 
  - 3 
  - 4 
  - 5 
 
0 
3 
14 
21 
10 
 
0 
1 
17 
24 
6 
 
0 
4 
31 
45 
16 
 
Chosen trajectory** 
  - anterior 
  - medial 
  - central 
  - lateral 
  - posterior 
 
4 
6 
29 
5 
3 
 
4 
3 
34 
5 
2 
 
8 
9 
63 
10 
5 
 
First side operation 32 17   
 Right Left Total P value 
STN length  5.1 (1.5) 5.3 (1.4) 5.2 (1.5) 0.25 
Sagittal angle  56.3 (8.9) 56.9 (9.1) 56.6 (8.9) 0.45 
Coronal angle  23.3 (5.1) 23.7 (5.0) 23.5 (5.0) 0.67 
Nr of MER (median, 
range)* 
4 (2–5) 4 (2-5) 4 (2-5) 0.52 
Nr of MER: number of electrodes used for microelectrode recording registration, STN = subthalamic 
nucleus 
Results are presented as means and standard deviations, unless otherwise specified 
* Data missing for 1 patient 
** Data missing for 1 patient bilaterally and for 1 patient unilaterally  
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Neuropsychological and motor outcome following STN-DBS 
One year following surgery there were statistically significant changes in Stroop 
Colour-Word test performance (medium effect size), in TMT-B performance (small 
effect size) and in both category and letter fluency performance (large effect size) 
(Table 2). All changes reflect a decline in cognitive functioning. LEDD decreased by 
54% and UPDRS part III improved by 50.1% (table 3), all on a group level.  
 
 
Table 2. Neuropsychological test scores at baseline, 1 year following DBS surgery and test 
change scores (T1 minus T0). Means, standard deviations and Wilcoxen signed rank 
analyses or T test are shown  
 N Baseline 1 year follow 
up 
Change 
score 
P-value Cohen’s 
d 
Stroop I  49 51.0 (12.0) 55.6 (15.8) 4.6 (8.5) 0.000 0.54 
Stroop II  49 66.9 (15.1) 76.7 (25.1) 9.8 (16.4) 0.000 0.60 
Stroop III  48 113.4 (38.8) 143.4 (82.5) 29.8 (64.1) 0.000 0.46 
Stroop Int  48 50.1 (32.3 74.1 (69.9) 24.1 (59.1) 0.000 0.41 
TMT A  46 39.8 (15.0) 42.4 (18.6) 1.8 (12.4) 0.46  
TMT B  45 104.0 (69.2) 116.8 (76.7) 12.8 (41.9) 0.047 0.31 
AVLT total 48 43.5 (10.9) 43.9 (10.7) 0.4 (2.9) 0.69  
AVLT recall  48 8.7 (3.2) 8.4 (3.2) -.33 (2.9) 0.43  
Fluency category 
  - animals  
  - occupations 
49 41.3 (9.8) 
23.8 (5.2) 
18.0 (5.5) 
33.9 (11.5) 
19.5 (6.5) 
14.8 (5.6) 
-7.4 (8.4) 
-4.3 (5.0) 
-3.2 (4.2) 
0.000 
0.000 
0.000 
0.89 
0.86 
0.76 
Fluency letters  48 34.3 (11.4) 29.8 (12.3) -4.6 (8.2) 0.000 0.56 
Stroop = Stroop Colour-Word test, Int = interference score, TMT = Trail Making Test, 
AVLT = Auditory Verbal Learning test 
 
 
 
Table 3. UPDRS part III and LEDD scores at baseline and 1 year following DBS surgery and 
change scores. Means, standard deviations and T test analyses are shown 
 N Baseline 1 year follow up Change score P-value 
LEDD (mg/day) 47 1346.1 (629.9) 617.9 (476.5) -728.2(466.9) <0.001 
UPDRS III OFF  40 37.7 (12.5) 18.8 (9.8) -18.9 (14.0) <0.001 
UPDRS III ON 41 19.3 (11.5) 18.4 (9.5) -.94 (12.3) 0.63 
Patients were scored post-operatively with stimulation and medication ‘on’  
LEDD = levodopa equivalent daily dose, UPDRS = Unified Parkinson Disease Rating Scale, OFF = 
compared to baseline ‘off’ medication, ON = compared to baseline ‘on’ medication 
 
  
 
 
 
Table 4. Comparisons of demographic and surgical factors between the cognitive decline vs the non-cognitive decline group in Stroop Colour-
Word test III performance, TMT-B performance and verbal fluency. Means, standard deviations and Mann-Whitney test analyses are shown 
 Stroop III TMT-B Fluency category 
 
Fluency letters 
 
N 
Yes 
5 
No 
44 
P Yes 
5 
No 
40 
P Yes 
8 
No 
41 
P Yes 
9 
No 
39 
p 
Age at surgery 71.0 (2.4) 59.1 (8.0) 0.00
1 
69.0 (8.4) 58.6 (6.0) 0.01
1 
65.0 (8.8) 59.1 (8.2) 0.09 60.8 
(10.8) 
59.7 (8.1) 0.68 
Disease duration  100.8 
(79.9) 
138.7 
(59.7) 
0.10 117.6 
(116.8) 
132.0 
(55.9) 
0.13 123.0 
(40.4) 
135.8 
(65.5) 
0.66 154.7 
(85.8) 
127.4 
(55.4) 
0.50 
LEDD (mg/day) 711.6 
(489.6) 
1432.5 
(609.0) 
0.01
3 
687.0 
(450.8) 
1416.4 
(621.0) 
0.01
0 
1338.5 
(822.3) 
1347.6 
(596.4) 
0.79 1297.8 
(459.8) 
1352.7 
(677.0) 
0.85 
Education (range) 4.6 (3-6) 5.2 (2-7) 0.10 4.6 (3-6) 5.2 (2-7) 0.37 5.1 (3-6) 5.1 (2-7) 0.97 5.0 (4-7) 5.2 (2-7) 0.50 
Right  
MER trajectories 
(range) 
3.8 (3-5) 3.8 (2-5) 0.41 3.3 (3-4) 3.8 (2-5) 0.19 3.8 (2-5) 3.8 (2-5) 0.97 3.8 (2-5) 3.8 (2-5) 0.99 
STN length 4.1 (2.3) 5.1 (1.3) 0.41 4.0 (2.2) 5.2 (1.4) 0.33 (5.3 ) 
(1.0) 
5.0 (1.5) 0.99 4.7 (1.4) 5.2 (1.4) 0.45 
Sagittal angle 58.8 (9.7) 56.0 (9.5) 0.53 59.2 (9.3) 56.8 (8.7) 0.54 57.6 
(11.8) 
56.0 (8.2) 0.64 52.8 (4.8) 56.9 (9.4) 0.23 
Coronal angle 28.5 (4.8) 22.9 (4.9) 0.02
5 
28.8 (4.3) 22.7 (4.6) 0.00
7 
23.6 (6.3) 23.3 (5.0) 0.84 22.2 (7.2) 23.8 (4.6) 0.26 
Left  
MER trajectories 
(range) 
3.5 (3-4) 3.8 (2-5) 0.13 3.5 (3-4) 3.8 (2-5) 0.57 4.0 (3-5) 3.7 (2-5) 0.25 3.9 (3-5) 3.7 (2-5) 0.60 
STN length 4.1 (2.1) 5.4 (1.3) 0.13 4.1 (2.2) 5.5 (1.2) 0.11 5.5 (1.7) 5.2 (1.4) 0.52 4.8 (1.6) 5.4 (1.4) 0.32 
Sagittal angle 59.7 (6.5) 56.6 (9.5) 0.36 59.9 (6.5) 56.8 (9.8) 0.34 57.3 
(13.4) 
56.8 (8.3) 0.62 57.8 (4.7) 56.7 
(10.0) 
0.48 
Coronal angle 23.0 (5.0) 23.8 (5.1) 0.77 24.3 (5.2) 23.8 (4.7) 0.88 26.1 (6.9) 23.2 (4.5) 0.23 23.7 (3.6) 23.7 (5.3) 0.76 
Stroop = Stroop Colour-Word test part III, TMT = Trail Making Test, LEDD = Levodopa equivalent daily dose, MER trajectories = number of electrodes used 
for microelectrode recording registration.  
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Associations between surgical characteristics and both cognitive decline and 
motor improvement  
Multiple regression analyses were run to test the associations between surgical 
characteristics and cognitive decline (each tested in a separate model), age, 
education, disease-duration and LEDD at baseline. Changes in TMT-B performance 
were statistically significantly associated with right coronal angle: F(5,37) =5.975, p 
<0.00125, R2 =0.447, and only right coronal angle added statistically significantly to 
the model: p <0.00125. The surgical characteristics were not associated with changes 
in any of the other neuropsychological tests, nor with improvement in UPDRS III 
scores.  
 
Cognitive decline  
Patients were categorised into a cognitive decline or non-cognitive decline group for 
each neuropsychological test separately (see Table 4). Patients with cognitive decline 
in Stroop Colour-Word (card III) performance had a higher age at surgery (p =0.001), 
compared to patients without cognitive decline. For the other neuropsychological tests, 
there were no statistically significant differences between the cognitive decline and 
non-cognitive decline groups.  
 
DISCUSSION 
In this retrospective study we investigated whether characteristics of the surgical 
trajectory, including the number of MER trajectories, the STN length as measured by 
MER and angles (cortical entry points) of the surgical trajectory, were associated with 
cognitive decline and motor improvement one year following STN-DBS in PD patients. 
One year postoperatively, we found significant declines in verbal fluency, Stroop 
Colour-Word test and TMT-B. Changes in TMT-B were associated with the coronal 
entry point in the right hemisphere, independently of age, education, disease duration, 
and LEDD at baseline. When comparing patients with and without clinically relevant 
cognitive decline in TMT-B performance, no differences in any of the surgical 
characteristics could be found. Motor improvement was not associated with 
characteristics of the surgical trajectories.    
 
The declines as found in tests that measure executive function are consistent with 
other reports on cognitive (side-)effects of STN-DBS29.  Similar to previous studies10,14 
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the number of MER trajectories used for accurate lead placement was not associated 
with cognitive decline one year after surgery. Moreover, no associations were found 
between STN length as measured by MER and cognitive or motor outcome, 
respectively, which is in line with previous studies16, 30, 31. Although these results cannot 
exclude a transient microlesion effect as proposed by others22, these findings suggest 
that there is no increased risk for cognitive decline at one year following surgery when 
increasing the number of MER trajectories or with maximising the STN length.  
 
Changes in TMT-B performance, though showing a small effect size, were associated 
with the cortical entry point in the right hemisphere only, whereas we found no 
association between the left hemisphere and changes in TMT-B performance. 
Interestingly, several other studies observed hemispheric differences when studying 
the relationship between the lead trajectories and cognitive decline10, 11, 16.  La Goff 
and colleagues (2015), for example, found that patients with a decline in semantic 
verbal fluency had a left trajectory with a more anterior cortical entry point16, while the 
present study did not find any relationship between cortical entry points and decline in 
verbal fluency performance. Changes in both semantic and phonemic verbal fluency 
following surgery, with moderate to large effect sizes, are one of the most common and 
robust findings in the literature4, 22, 32-34, and there have been inconsistent findings 
regarding the associations between changes in verbal fluency performance following 
DBS and the electrode trajectories. Tröster and colleagues (2017) found differences 
between the effect of surgery and stimulation on semantic and phonemic fluency, 
respectively, suggesting that only semantic fluency is affected by the lead trajectory18. 
On the contrary, Okun and colleagues (2012) proposed that phonemic verbal fluency 
was the result of the lead placement, because a similar degree of decline was observed 
in both on-stimulation and off-stimulation states35. Another study demonstrated 
microstructural injuries along the electrode trajectories in white matter bundles that are 
implicated in verbal fluency following STN-DBS15. In general, executive function tests 
such as verbal fluency and TMT-B are difficult to interpret as they rely on a variety of 
cognitive processes. Semantic and phonemic verbal fluency depend on shared and 
distinct distributed brain regions, including the left inferior frontal gyrus, anterior 
cingulate gyrus, left frontal regions and temporal networks15. Performance on TMT-B 
involves divided and visual attention, cognitive flexibility, speed of processing, set-
shifting and working memory, which are most likely mediated by widespread activation 
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of the bilateral PFC, as well as dorsomedial and dorsolateral regions36-39. As such, the 
findings in the present study could be regarded as non-specific to these numerous 
aspects of executive functioning. Importantly, the association between the right coronal 
entry point and TMT-B is based on changes in neuropsychological test performance 
and does not necessarily translate into impairment in daily activities. Only five out of 
46 patients showed clinically relevant decline in TMT-B performance, and these five 
patients did not differ in terms of surgical characteristics compared to the non-decline 
group.  
 
The literature so far shows inconsistent results with respect to the surgical impact on 
cognition. This inconsistency is due to many methodological differences, including 
differences in follow-up period, definitions of decline and assessment, but overall the 
sample sizes are relatively small, including the present study. Besides these 
methodological issues, changes in cognitive functioning rely upon a complex interplay 
of numerous factors, including age, levodopa-response, disease-duration and disease-
progression, stimulation factors, preoperative motor symptoms, preoperative cognitive 
functioning and morphometric measures of brain atrophy8, 40 which can hardly be 
examined in one study. Further effort should be put in data sharing and multicenter 
studies to increase sample sizes and thereby overall power. Additionally, study designs 
with neuropsychological assessment in medication-ON, and both stimulation ON and 
OFF condition, may exclude (or demonstrate) a stimulation effect and, as such, relieve 
some pressure of the power.  
 
CONCLUSION 
The electrode passage through the right prefrontal lobe may contribute to subtle 
changes in executive function. However, only few patients showed clinically relevant 
cognitive decline and as such the impact is low. More importantly, while the use of 
multiple MER trajectories and a longer STN length were not associated with cognitive 
decline one year following surgery, we were also not able to observe a gain in motor 
improvement when using multiple MER trajectories and a longer STN length. To 
conclude, from a cognitive point of view, DBS may be considered a relatively safe 
procedure. Surgical teams that are ambitious of maximising the length of the DBS 
electrode within the STN do not have to be restrained by a risk of cognitive side-effects, 
but still have to prove its clinical benefits.  
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Supplementary materials 
 
Supplementary Table 1. Overview of bilateral STN-DBS surgeries 
Year surgery Nr. of patients 
operated 
Included in study Nr. of missing 
subjects 
2005 3 1 2 
2006 2 2 0 
2007 4 2 2 
2008 5 3 2 
2009 6 3 3 
2010 5 4 1 
2011 8 5 3 
2012 2 2 0 
2013 3 3 0 
2014 12 7 5 
2015 14 7 7 
2016 14 7 7 
Jan – March 2017 3 3 0 
Total 81 49 32 
 
 
Supplementary Table 2. Reasons for exclusion 
Reasons for exclusion Nr. of cases 
Pre- and postoperative neuroimaging insufficient for determining the surgical 
trajectory (bilaterally or unilaterally) 
12 
No available one year post neuropsychological evaluations* 16 
Re-implantation/removal of electrodes due to complications  4 
 32 
*In most cases, there was available neuropsychological follow-up data. However, the follow-up 
duration was >1 year 
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ABSTRACT 
Background: around 50% of Parkinson’s disease patients experience motor 
fluctuations after long-term treatment with levodopa. These fluctuations may be 
accompanied by mood fluctuations. Routine cross-sectional assessments cannot 
capture the extent of these motor and mood fluctuations and their possible 
associations. Experience sampling techniques that use frequently repeated 
measurements of symptoms over time are able to capture such fluctuations. Based on 
such data, longitudinal associations between symptoms can be studied using network 
analysis. 
 
Aim: the purpose of this study is to identify longitudinal associations between motor 
symptoms and mood states in a patient with Parkinson’s disease. 
 
Methods: a 53-year old man with Parkinson’s disease and motor fluctuations collected 
experience sampling data during 34 consecutive days. A set of dependent variables 
included tremor, rigidity, balance problems and ‘on/off’ state, and the mood variables 
anxiety, cheerful, and down. Independent variables were the same variables assessed 
at the preceding measurement. Regression coefficients were calculated and presented 
in a network graph. 
 
Results: in this patient, anxiety and cheerfulness had a central position within the 
symptom network. Higher anxiety was prospectively associated with increased rigidity 
and tremor, and with feeling down. Cheerfulness was associated with less tremor. 
Balance problems were not influenced by cheerfulness nor anxiety, but increased 
balance problems were associated with reduced cheerfulness at the next assessment. 
Feeling down did not influence self-reported motor symptom severity at the next 
assessment.  
 
Conclusion: this n=1 study shows that network analysis of experience sampling data 
may reveal longitudinal associations of self-reported motor symptoms and mood states 
that may have relevance for treatment strategies.  
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INTRODUCTION 
Up to 50% of patients with Parkinson’s disease (PD) experience motor fluctuations 
after long-term treatment with levodopa1. Such fluctuations in motor symptoms are 
often accompanied by mood fluctuations2-4. Research involving mood fluctuations, 
their underlying mechanisms and their relationship with motor fluctuations has so far 
led to inconsistent results5. Insight into the timing and associations of fluctuations in 
motor and mood symptoms may provide information that can be valuable for clinical 
management. The frequency and severity of fluctuating symptoms are, however, 
difficult to capture in routine cross-sectional assessments, as such assessments use 
rating scales where a single assessment is considered representative for symptom 
severity over a longer time frame. Diary assessments can give more clarity, but are 
usually completed retrospectively at the end of the day or may hinder people from 
continuing their everyday activities. The Experience Sampling Method (ESM) is an 
attractive alternative to diary studies and cross-sectional assessments6. ESM includes 
multiple short, repeated, within-subject assessments at random moments during the 
day. These can include motor symptoms, and mood states as well as contextual 
information and, therewith, provide a good sample of subjective experiences. The ESM 
method originated in psychiatry, but has recently been applied in a number of other 
diseases, such as migraine, stroke and COPD7-9. Broen and colleagues10 
demonstrated that ESM is also a feasible method for the assessment of mood and 
motor symptoms in PD patients. When ESM data of a single subject are collected for 
a longer period of time, network analysis can be performed to study longitudinal 
relationships between symptoms. In network models, symptoms are conceptualised 
as mutually interacting, often reciprocally reinforcing elements in a complex dynamic 
system, also referred to as symptom networks11, 12.  
 
The aim of this n=1 study was to explore whether it is possible to identify longitudinal 
associations between motor symptoms and mood states in a single patient with PD 
suffering from motor fluctuations using experience sampling data and to generate a 
symptom network of these associations. We hypothesise that there is a temporal 
relationship between mood fluctuations and motor fluctuations, with negative emotions 
(down, anxiety) being associated with increased motor symptoms at the next 
assessment and positive emotions (cheerful) being associated with less motor 
symptom severity at the next assessment.  
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METHODS 
Subject 
A 53-year old man with PD and motor fluctuations was referred to our hospital for a 
follow-up visit. The patient was diagnosed with tremor-dominant PD in 2011. Since 
then he was treated with levodopa/carbidopa. Currently, he takes a dose of 250 mg 4 
times daily. In addition, he takes entacapone 200 mg 4 times and pramipexol 1.05 mg 
once daily. He has been suffering from motor fluctuations since 2015. Initially these 
motor fluctuations, predominantly affecting tremor and rigidity, were predictable and 
involved levodopa-related ‘wearing-off’. Later, the “on/off” fluctuations became 
unpredictable. The patient did not suffer from dyskinesia. Upon the start of ESM data 
collection the patient was cognitively intact and working part-time as a teacher. 
Baseline measurements are displayed in Table 1. The patient participated in ESM as 
part of his clinical assessment and agreed to have the period of data collection 
extended to one month. Informed consent was signed for the extended data collection 
and for publication of this n=1 study. ESM data was collected from March 16th, 2017, 
to April 18th, 2017.  
 
ESM data collection 
The ESM protocol in the present study is based on the routine outcome monitoring of 
the psychiatric outpatient department of our hospital, but with 5 Parkinson-specific 
items added: tremor, rigidity, walking problems, balance problems (all scored on a 7-
point Likert scale, ranging from 1= not at all to 7= very), and “on/off” state (dichotomous 
variable). This protocol was the same that was used earlier by Broen and colleagues10. 
The patient downloaded an ESM app, the PsymateTM app [www.psymate.nl], on his 
own smartphone. Before data collection the patient received an oral briefing and a 
demonstration to ensure that the app and questionnaire were fully understood. The 
PsymateTM app was programmed to emit a signal, a so-called “beep”, 10 times daily at 
random moments in 90-minute time blocks, between 07.30 AM and 10.30 PM. After 
each beep, the patient was asked to fill out a 2-minute questionnaire that opened 
automatically after touching the phone and that consisted of 42 questions regarding 
his current mood state, the severity of his PD-related complaints, and his surroundings. 
The questions always appeared in the same order, and although it was not possible to 
skip single items before continuing to the next question, it was possible to turn back to 
previous questions and change the answer if necessary. To avoid recall bias, the 
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questionnaires were only available for 15 minutes following the beep. After this 
timeframe, the patient received a notification regarding the missed questionnaire 
without the possibility to open and answer the questionnaire. The patient collected data 
for 34 consecutive days. Two days following the start and in the second week of ESM 
data collection, the patient was contacted by telephone to inquire about any difficulties 
or concerns regarding the ESM application and the questionnaire and to answer any 
additional questions the patient might have. 
 
Table 1. Patient characteristics at baseline  
Measurement Score / range 
Hoehn & Yahr staging13 2.5 / 0 - 5 
UPDRS14 21 / 0 - 108 
Mini Mental State Examination15 28 / 0 - 30 
Parkinson Anxiety Scale16 17a / 0 - 48 
Beck Depression Inventory-II17 14 / 0 - 63 
Parkinson’s Disease Questionnaire-818 21b / 0 - 31 
UPDRS = Unified Parkinson’s Disease Rating Scale, a Slightly above the cut-off of 14 for clinically 
relevant anxiety, b Indicating a somewhat reduced quality of life 
 
Statistical analyses 
Statistical analysis and graphical representations were performed using Stata 1319 and 
R20. The network analysis performed does not identify causal relationships, but merely 
temporal relationships that may or may not be causal. All data in this analysis are from 
a single participant. Therefore, the data do not have a multilevel structure and can be 
analysed with standard linear regression techniques, as opposed to group-level 
analyses in ESM studies21. 
 
To assess variation over time, mean daily severity levels of mood and motor symptoms 
were plotted (Supplementary Figures 1A and 1B, respectively). Floor and ceiling 
effects were checked using histograms (available on request). For the present 
analysis, the affective items cheerful and down, which reflect opposite poles, were a 
priori selected as representatives for positive and negative moods, respectively. The 
affective item anxiety was added based on the presence of clinically relevant anxiety 
at baseline. Tremor, rigidity and balance problems were selected for the analysis as 
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the most disabling PD-related symptoms. The patient did not experience any gait 
problems or dyskinesia. Hence, these symptoms were not included in the analysis.  
 
Six linear regression models were analysed with cheerful, down, anxiety, tremor, 
rigidity and balance problems as dependent variables. In addition, one logistic 
regression analysis was performed with ‘on/off’ state as dependent variable. The “off” 
state was patient rated and defined as the state in which he experienced no effect of 
anti-Parkinson medication. Because regression coefficients of linear and logistic 
regression cannot be combined in one network graph, the analysis with “on/off” as 
dependent variable was repeated with linear regression as has been done in a previous 
study22. As the results, in terms of statistical significance, were very similar between 
the two analyses, the linear regression results were used to generate the network. 
Independent variables were the lag (t-1) of the same 7 variables added to the 
regression model simultaneously. In addition, a time variable was added to all 
regression models (consecutive number for beepcode to take into account time 
trends). This resulted in 49 regression coefficients. The first assessment of a new day, 
as well as assessments with a lag longer than 180 minutes from the previous 
assessment (i.e., when the participant missed 1 or more beeps) were excluded from 
the analysis. Given the exploratory nature of this study, no correction for multiple 
comparisons was performed. 
 
Using the qgraph command in R, the 49 regression coefficients were presented in a 
network graph. In this network, the nodes represent the variables and the connections 
between the nodes represent the regression coefficients. The thickness of the 
connections reflects the strength of the regression coefficient. In addition, indices of 
centrality were calculated using Excel (Microsoft, Redmond, Washington) and the 
qgraph package. In this context, “centrality” is an indicator of how central a specific 
variable is in the network. As in previous work, centrality indices are defined as follows: 
the outward strength is the sum of the connections from a specific node to all other 
nodes23, 24. The inward strength is the sum of the connections from all nodes to one 
specific node. The self-loop is the connection between a node at time point t-1 and that 
same node at time point t. In both the inward and outward strengths, the self-loop is 
included. The sum of the outward and the inward strengths represents the node 
strength. Closeness, another measure of centrality, involves the sum of the length of 
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the shortest paths between the node and all other nodes in the graph. Hence, the more 
central a node, the closer it is to all other nodes.  
 
RESULTS 
ESM data 
During the course of 34 days, the patient received a total of 340 beeps. He answered 
136 beeps, corresponding to a response rate of 40%. There were some partial missing 
data as a result of uncompleted questionnaires, resulting in 121 completed 
assessments and a response rate of 36%. The response rate declined during the 
course of ESM data collection and varied from 47% in week 1 to 29%, 46%, 36% and 
19% in weeks 2, 3, 4 and 5, respectively. In 23 of the 121 assessments (19%), the 
patient was in “off”-state. A total of 57 beep assessments were answered within 180 
minutes of a previous beep assessment and were selected for the network analysis. 
The average time between beeps was 98.9 min (SD=44.8; range 15.6 – 176.7 
minutes). Descriptive statistics are provided in Table 2. An example of fluctuations of 
included items during the course of a single day is plotted in Supplementary Figure 2.  
Except for a floor effect for anxiety, there were no strong floor effects and no ceiling 
effects. 
 
Table 2. Descriptive statistics of ESM assessment of variables included in the analysis 
 N Mean Standard 
deviation 
Minimum Maximum 
Total      
 Cheerful 121 5.0 0.49 3 6 
 Down 121 3.0 1.03 1 5 
 Anxiety 121 1.2 0.66 1 5 
 Tremor 121 1.9 0.87 1 6 
 Rigidity 121 1.7 0.90 1 6 
 Balance problems 121 1.4 0.71 1 5 
 On/off state, % 121 81% on time n.a. n.a. n.a. 
Network analysis      
 Cheerful 57 4.9 0.52 3 6 
 Down 57 3.0 1.08 1 5 
 Anxiety 57 1.1 0.54 1 5 
 Tremor 57 1.8 0.93 1 6 
 Rigidity 57 1.7 1.03 1 6 
 Balance problems 57 1.5 0.87 1 5 
 On/off state, % 57 88% on time n.a. n.a. n.a. 
Items were scored on a 7-point Likert scale (ranging from 1 = not at all to 7 = very). For ON/OFF 
state, the values 1 and 0 represent ‘ON’ state and ‘OFF’ state, respectively. 
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Network graph 
Cheerfulness and anxiety had central positions within the symptom network (Figure 1). 
A network graph displaying the significant associations only is plotted in 
Supplementary Figure 3. Anxiety was associated with higher scores for tremor 
(B=0.61, p=0.001) and rigidity (B=0.47, p=0.013) at the next assessment, as well as 
with feeling less cheerful (B=-0.40, p=0.037) and more down (B=0.52, p=0.003). 
Cheerful was associated with lower scores for tremor (B=-0.55, p=0.002) and rigidity 
(B=-0.38, p=0.037) at the next assessment. Balance problems were not predicted by 
cheerfulness (B=0.05, p=0.78) or anxiety, but instead more balance problems led to 
lower scores on cheerful at the next assessment (B=-0.50, p=0.011). In contrast, 
feeling down did not influence motor symptom severity at the next assessment, or vice 
versa. “On” and “off” states could not be predicted by motor symptoms, but anxiety was 
associated with “off” at the next assessment (B=-0.37, p=0.024). In addition to 
associations between different variables, self-loops were created that reflected the 
relationship between the severity of the same symptom at the next assessment. The 
self-loops cheerful (B=-0.66, p=0.001), anxiety (B=0.59, p=0.000), down (B=0.38, 
p=0.006) and balance problems (B=0.58, p=0.003) were statistically significant. 
 
Centrality indices are provided in Table 3.Anxiety had the highest node strength with a 
value of 4.79, followed by cheerful with a value of 4.42. “On/off” state had the lowest 
node strength, with a value of 1.77. Closeness was highest for anxiety, cheerful and 
for balance problems, indicating that those 3 nodes were closest to all other nodes in 
terms of strength. 
 
Table 3. Centrality indices 
 Closeness Inward 
strength 
Outward 
strength 
Node 
Strength 
Cheerful 0.038 1.90 2.51 4.42 
Down 0.028 1.94 1.27 3.21 
Anxiety 0.048 1.73 3.05 4.79 
Tremor 0.017 1.72 0.48 2.20 
Rigidity 0.024 1.40 0.96 2.37 
Balance problems 0.036 0.97 1.65 2.62 
On/off state 0.022 1.00 0.77 1.77 
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Figure 1. Symptom network 
Network graph displaying prospective associations between the mood states ‘cheerful’, ‘down’ and 
‘anxiety’, and Parkinsonian symptoms (tremor, rigidity, balance problems and on/off state). Negative 
regression coefficients are red, positive coefficients green. Significant coefficients are marked as tick 
lines with an asterix. The position of the variables within the graph is a measure of centrality. 
 
DISCUSSION 
Interpretation of the results 
With this n=1 study we showed that network analysis of ESM data can be used to 
prospectively reveal associations between motor and mood states in PD. In the 
symptom network of this patient, the variables of anxiety and cheerful appeared to play 
a more important role than the variable down because they had stronger associations 
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with several motor symptoms and had the highest node strength and closeness index. 
The centrality of mood variables in the symptom network indicates that affect plays an 
important role in the way motor symptoms are experienced and reported and even 
predict symptom severity prospectively. Whereas most studies in PD have focused on 
the effect of (fluctuations in) motor symptoms on mood, this finding shows that it is as 
important to understand the role of psychological factors and mood states in predicting 
self-reported symptoms in PD.  
 
“On/off” state had the lowest node strength, corresponding to the finding that “on/off” 
state could not be predicted from motor symptoms or affective states and appears to 
be relatively independent from other variables, except for anxiety. This finding is 
consistent with the notion that motor fluctuations usually start as end-of-dose 
deterioration, but tend to become random and unpredictable in the later course of the 
disease, as was the case with our patient. This unpredictability is also reflected by the 
fact that the variable “on/off” does not have a self-loop in the network graph. As a 
general comment, based on the outcome in this patient, it may be worthwhile to study 
the role of anxiety in predicting “off” states.  
 
Despite the data not being multilevel, there can be autocorrelation between 
consecutive assessments or between assessments on the same day; the shorter the 
time between 2 assessments, the higher the correlation. The regression coefficients of 
the balance problems and cheerful self-loops indicate high autocorrelation. The 
negative regression coefficient in cheerful (-0.66) is surprising and one can only 
speculate about potential explanations. It may be that the already high score on 
cheerfulness reduces the chance of scoring even higher at a next assessment. While 
the variable time was included in the analysis, it was not possible to further control for 
autocorrelation as only 1 patient was included.  
 
Data quality 
The PsymateTM app is available as an app for smartphones or other electronic devices, 
such as iPods. The patient opted for downloading the app on his own smartphone 
rather than using one of the available iPods. Previous studies have not shown any 
difference in compliance between the 2 devices10. For this patient, the response rate 
was 36%, which is above the 33% generally considered valid for analysis21, 25. Because 
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it was not possible to skip single items in the questionnaire, thereby preventing 
selective missingness, all missing values were solely the result of missed beeps and 
incidentally by not finishing a questionnaire. Missed beeps can be mostly explained 
from an inability to answer questionnaires as a result of other activities, such as being 
in traffic or working. However, it also reflects that collecting ESM data during a longer 
period of time can be burdensome, resulting in lower response rates over time as 
observed in this patient. The patient was contacted once weekly during the first 2 
weeks and at the end of data collection. As the response rate was still sufficient during 
the first 2 weeks, motivational issues were not addressed. A lack of motivation might 
have contributed to the low response rate in the final weeks of data collection. Regular 
weekly contact during ESM data collection might increase response rates, especially 
when data are being collected for a longer time frame. In future studies, it might also 
be worthwhile to evaluate the patient’s experience with ESM in order to get more 
insight into compliance10. 
 
During the last 2 weeks of data collection, the patient reported stable levels of 
cheerfulness (Likert score 5) and less fluctuations in motor symptoms. One could argue 
this created bias and that the patient only responded to beep assessments when 
feeling cheerful or refrained from answering questions during periods with severe 
motor symptoms. However, during the same period of data collection, there was a high 
degree of variation in down, which makes cheerfulness bias unlikely. Also, the higher 
response rate in the first period, during which the patient reported varying levels in 
motor symptom severity, ranging from 1 to 6, shows that experiencing more severe 
symptoms did not lead to reduced response. The present data do include various 
beeps where the patient is in the “off” state. Therefore, we expect that the network is 
representative for a large proportion of the time. 
 
Methodological issues 
To our knowledge, this is the first study to use long-term ESM data collected in a single 
patient with PD to study longitudinal associations between motor and mood symptoms. 
This exploratory study has, however, several limitations. First, the response rate of 
36% was low. Earlier ESM studies suggest that at least 33% of the assessments need 
to be completed for their data to be considered valid21, 25, 26. Preferably, prospective 
associations are studied between 2 successive beep assessments. As this would 
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result in too few usable assessments, assessments were considered valid if they were 
within 180 minutes of a previous beep, regardless of whether there was a missed beep 
in between. Although the resulting selection of 57 couples of beep assessments for the 
network analysis, of which 7 in “off” phase, does not influence the representativeness 
of the data, it does result in lower power. Because of the reduced response rate in the 
last weeks of data collection as well as the more stable scores on cheerfulness in that 
period, we performed a sensitivity analysis based on the data of the first 20 days of 
sampling, which resulted in a very similar network (see Supplementary Figure 4). 
Second, although we looked at node strength and closeness as measures of centrality, 
betweenness as measure for centrality was not determined for this study. Bak and 
colleagues23, who used network analysis in a patient with recurrent psychosis, showed 
that the importance and clinical relevance of betweenness as an indicator of network 
performance is low in this type of analysis. In their analysis, as well as in ours, all paths 
between variables are considered important and the length of various paths can be 
very similar, whereas betweenness only reflects the shortest path between variables. 
Third, when performing network analysis including lags, there is a time axis in the 
analysis. However, even with the time axis only temporal associations can be shown 
and it does not indicate causality. Finally, the patient did not collect more objective 
measures of motor functioning. 
 
Clinical implications 
The ultimate aim is to provide patients with optimal and personalised care to reduce 
their suffering and increase their well-being. ESM can be used for this purpose by 
generating treatment-relevant information specific for that patient that cannot be 
obtained by commonly used cross-sectional assessment methods and rating scales. 
Previous studies using network analysis for different diseases have demonstrated that 
ESM data can be incorporated into a personalised treatment plan and facilitate 
decision-making in a collaborative process21, 23, 27. For PD patients, ESM data can 
provide insight into the relationship between different variables and symptom severity. 
This particular network analysis focused on mood variables, but based on the specific 
situation of the patient, other relevant variables can be included in the network. 
Contextual variables, such as present company, whereabouts and activities, can 
provide information on whether symptoms worsen or improve in specific situations. 
This information can be valuable for both patients and physicians or other members of 
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the patient’s health care team, as it may give more insight into determinants of the 
patient’s symptoms and may lead to (non-pharmacological) treatment 
recommendations. For example, when affective states or contextual factors appear to 
play a central role in self-perceived motor symptom severity, it may be preferable to 
treat the mood state or to improve coping with the specific situation. Based on the 
network analysis of ESM data in the present study, our patient was offered 
individualised face-to-face feedback regarding the specific connections in his symptom 
network, and in particular regarding the possible role of positive emotions in improving 
self-perceived motor symptoms. However, the patient preferred to receive a written 
report of the results as he was limited in his time. We do not know whether a lack of 
motivation contributed to his decision of not desiring a face-to-face meeting or whether 
the patient benefited from the provided information. For future studies it would be 
interesting to use ESM data sampling to develop a treatment plan with personalised 
interventions and to use post-intervention ESM data sampling to study the 
effectiveness of the intervention. It may also be valuable to combine ESM with 
downloadable apps or wearable devices that are able to objectively quantify motor 
symptom severity, such as severity of tremor or poverty of movement. This is 
technically feasible and will provide information that, when combined with ESM, will 
allow comparison between the objectively measured severity of the tremor, and the 
subjectively experienced severity of tremor28. Integrating these measurements could 
then be useful for fine-tuning future therapies such as closed loop deep brain 
stimulation systems29.  
 
CONCLUSION AND RECOMMENDATIONS 
In this n=1 study, we showed that network analysis of ESM data can be used to sample 
moment-to-moment variability and to prospectively reveal relevant associations 
between motor and mood variables in an individual patient. These prospective 
associations may be different for different patients. When network patterns in a single 
patient can be replicated in other PD patients, this may lead to more general treatment 
recommendations. To reveal such network patterns, multiple n=1 studies with 
extensive data collection may be superior to ESM studies that include more patients 
but collect data for a briefer period of time. More research into the usefulness of ESM 
as a therapeutic tool is warranted.  
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Supplementary materials 
 
 
Supplementary Figure 1A. Mean daily severity levels per affective item per day for the total period of 
ESM data collection (note: these are mean scores and items scores may still fluctuate over the 
respective day). 
Items were scored on a 7-point likert scale (ranging from 1 = not at all to 7 = very).  
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Supplementary Figure 1B. Mean daily severity levels per motor item per day for the total period of 
ESM data collection (note: these are mean scores and items scores may still fluctuate over the 
respective day). 
Items were scored on a 7-point likert scale (ranging from 1 = not at all to 7 = very). For ON/OFF state, 
the values 1 and 0 represent ‘ON’ state and ‘OFF’ state, respectively. 
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Supplementary Figure 2. ESM scores per selected item for one day. 
Items were scored on a 7-point likert scale (ranging from 1 = not at all to 7 = very). For ON/OFF state, 
the values 1 and 0 represent ‘ON’ state and ‘OFF’ state, respectively. The patient completed 9 
questionnaires (beep assessments).  
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Supplementary Figure 3. Network graph of significant associations. 
Network graph displaying prospective significant associations between the mood states ‘cheerful’, 
‘down’ and ‘anxiety’, and Parkinsonian symptoms (tremor, rigidity, balance problems and on/off state). 
Negative regression coefficients are red, positive coefficients green. Significant coefficients are 
marked as tick lines with an asterix. The position of the variables within the graph is a measure of 
centrality. 
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Supplementary Figure 4. Sensitivity analysis network graph. 
Network graph of the sensitivity analysis of the first 20 days of ESM data collection displaying 
prospective associations between the mood states ‘cheerful’, ‘down’ and ‘anxiety’, and Parkinsonian 
symptoms (tremor, rigidity, balance problems and on/off state). Negative regression coefficients are 
red, positive regression coefficients green. Significant coefficients are marked as thick lines with an 
asterix. The position of the variables within the graph is a measure of centrality.  
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ABSTRACT 
Background: around 50% of Parkinson’s disease patients experience motor 
fluctuations, which are often accompanied by mood fluctuations. The nature of the 
relationship between motor and mood fluctuations remains unknown. It is suggested 
that the Experience Sampling Method (ESM) can reveal such associations on both a 
group and individual level. Revealing group patterns may enhance our understanding 
of symptom interactions and lead to more general treatment recommendations, while 
analyses in individual patients can be used to establish a personalised treatment plan. 
 
Objectives: to explore the usability of routinely collected ESM data over a brief period 
of time to detect associations between motor fluctuations, affective state, and 
contextual factors in Parkinson’s disease patients with motor fluctuations on a group 
level and on an individual level. 
 
Methods: eleven patients with motor fluctuations collected data at 10 semi-random 
moments over the day for five consecutive days.  
 
Results: on a group level, multilevel analyses showed significant associations 
between all motor symptoms and positive affect. Being at home was associated with 
increased balance problems and rigidity. Analyses on an individual level revealed 
much less significant associations that mostly, but not always, were in line with the 
results on a group level. 
 
Conclusion: this exploratory study showed significant associations between affective 
state, motor symptoms and contextual factors in a group of Parkinson’s disease 
patients with motor fluctuations, but less so in individual patients. Since the ultimate 
aim is to use ESM as an aid to personalise treatments, the sensitivity of the approach 
needs to be increased.  
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INTRODUCTION 
The cornerstone of treatment for Parkinson’s disease (PD) is levodopa replacement1. 
Unfortunately, fluctuations in parkinsonian symptoms due to levodopa replacement 
may occur sometimes as early as a few months after initiation of levodopa treatment2. 
These usually start with ‘end-of-dose wearing-off’, but eventually, as the disease 
progresses, lead to unpredictable fluctuations between ‘ON’ and ‘OFF’ state in 
approximately 50% of patients2, 3. The presence of motor fluctuations is associated 
with lower quality of life and accounts for significant morbidity4-6. Motor fluctuations are 
often accompanied by distressing mood fluctuations, such as fluctuations in anxiety or 
depressive symptoms7-9. Due to the fluctuating nature of motor and mood symptoms 
their frequency is difficult to capture in routine-cross sectional assessments that are 
usually retrospective in nature10-12. The Experience Sampling Method (ESM) can 
overcome these limitations13, 14. With ESM, experiences and behaviours as well as 
moment-to-moment changes in physical and mental states, and contextual factors in 
the subject’s natural environment can be sampled. Data are collected repeatedly and 
randomly during the day, for several days, thereby reducing recall bias11, 15, 16. In a 
recent N=1 study we demonstrated that ESM data collected for one month is able to 
reveal longitudinal associations between motor symptoms and mood states, and has 
the potential to be used as an aid to optimise individual treatment14, 17. However, in 
routine patient care much briefer sampling periods of 5 to7 days are commonly used, 
since longer periods of time are considered burdensome for patients14. The question 
is whether brief periods of data collection generate enough power for the identification 
of significant associations between mood and motor symptoms. Since the aim is to 
develop ESM as an aid to personalise treatment in individual patients, adequate power 
needs to be ensured.   
 
The aim of the present study was to explore the usability of ESM data routinely 
collected over a brief period of time in PD patients suffering from motor fluctuations, 
and to explore the sensitivity to detect associations between affective state, contextual 
factors, motor symptoms and motor state on both a group and individual level. For that 
purpose, we explored: (1) associations between affective state, motor symptoms and 
contextual factors in PD on a group level, as well as the role of motor (ON/OFF) state 
in these associations; and (2) whether ESM data are sensitive enough to reveal similar 
associations in individual patients. 
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METHODS 
Design and participants 
This is a cross-sectional observational study. Twelve PD patients with motor 
fluctuations were recruited from the Movement Disorder clinic of Maastricht University 
Medical Centre (MUMC+). Five of these were recruited in January and February 2015 
and participated as part of a feasibility study of ESM in PD patients11. Seven patients 
were additionally recruited between February 2017 and April 2017. Inclusion criteria 
were: a diagnosis of idiopathic PD according to the Queen Square Brain Bank 
diagnostic criteria18, the usage of a stable dose of levodopa or other antiparkinsonian 
medication for at least one month, the presence of motor fluctuations as indicated  by 
part IV of the Unified Parkinson’s Disease Rating Scale (UPDRS), and an age between 
50 and 80 years. Subjects with cognitive impairment, operationalised as a Mini-Mental 
State Examination (MMSE) <2619, were excluded in order to avoid problems with 
working with the mobile ESM application. Other exclusion criteria were: the presence 
of neurological disorders other than PD and excessive use or abuse of alcohol, drugs 
or benzodiazepines. The institution’s Medical Ethics Committee ruled that collection of 
ESM data in the context of routine clinical outcome monitoring is exempt from ethical 
approval. 
 
Assessment 
After informed consent was obtained, all patients underwent a baseline assessment 
which involved the collection of demographic and disease-related characteristics. All 
patients were tested in ON state. The following instruments and scales were 
administered: the Hoehn and Yahr staging scale20, the UPDRS part III21 to quantify 
motor symptoms, the MMSE19 to assess global cognitive function, the Parkinson 
Anxiety Scale (PAS)22 to assess anxiety symptoms, and the Beck Depression 
Inventory II (BDI-II)23 to assess depressive symptoms. Quality of life was assessed 
using the Parkinson Disease Questionnaire-824. The UPDRS-III was administered by 
a neuropsychologist holding an MDS-issued certificate of training in application of the 
UPDRS and ample experience in administering this instrument (AM). All other scales 
were administered by a trained medical student (Rv/dV). 
 
Using a mobile device with an ESM application (PsyMateTM, www.psymate.eu), 
participants were asked to answer several questions multiple times a day. During the 
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baseline assessment subjects received oral information and a demonstration to ensure 
that the ESM app was fully understood. Subjects were given the option to either install 
the ESM app on their own smartphone or to use an iPod-touch with the PsyMateTM 
app provided by MUMC for the duration of the study. The following five consecutive 
days, the PsyMateTM generated auditory reminders (beeps) at unpredictable moments 
in each of ten 90-minute time blocks between 7:30am and 10:30pm (10 beeps a day, 
during five days). After each reminder, subjects were asked to fill out a set of questions 
regarding motor, mood and general symptoms, as well as contextual factors (see ESM 
questions). Questions always appeared in the same order and were available for 15 
minutes only in order to reduce recall bias. Answering the questionnaires takes 
approximately two minutes. In addition, every morning and evening subjects were 
asked to fill out a morning and evening questionnaire, consisting of questions about 
the previous night and day, respectively.  
 
Two days following the start of data collection, participants were contacted by 
telephone to inquire about any difficulties or concerns regarding the ESM application 
and questionnaires, and to solve any problems if necessary. Five days following the 
start of data collection, the data was uploaded in an anonymous central database and 
subjects returned the Ipod-touch, if necessary. 
 
ESM questions 
The questions in the ESM protocol were based on a protocol used for routine outcome 
monitoring of the psychiatric outpatient department of our hospital. The protocol 
includes questions in several domains: context (e.g. ‘Where am I?’), events (‘the most 
important event since the last beep was’), mood (e.g. ‘I feel happy’), and somatic (e.g. 
‘I am tired’). The protocol was supplemented with 6 Parkinson-specific items (motor 
symptoms): ‘tremor’, ‘rigidity’, walking problems’, ‘balance problems’, ‘dyskinesia’ (all 
scored on a 7-point Likert scale, ranging from 1=not at all to 7=very much), and 
‘ON/OFF state’ (ON=1, OFF=0) (supplementary table 1)11. ‘ON’ and ‘OFF’ states are 
defined subjectively by each individual subject. In general, in an ‘ON’ state the subject 
perceives his antiparkinsonian medication to be working properly in alleviating 
symptoms, while in an ‘OFF’ state symptoms start to reappear. Based on standard 
ESM mood items (also scored on a 7-point Likert scale), two mood-related variables 
reflecting positive and negative affect were computed. Positive affect was defined as 
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the mean score of the items ‘cheerful’, ‘relaxed’ and ‘satisfied’. Negative affect was 
defined as the mean score of the items ‘insecure’, ‘irritated’, ‘lonely’, ‘anxious’, ‘down’, 
and ‘guilt’. Based on the questions ‘Where am I?’ and ‘With who am I’, two contextual 
variables ‘at home’ (at home=1, not at home=0) and ‘being alone’ (alone = 1, not alone 
= 0) were computed.  
 
Statistical analysis 
All statistical analyses were performed using SPSS version 24.0 for Windows25 and 
Stata version 1326. Descriptive analyses were conducted to assess response rates. To 
assess usability on a group level, associations between affective state, contextual 
factors, motor symptoms and ON/OFF state were studied in the full data set. ESM data 
have a hierarchical structure due to within-subject clustering: repeated measurements 
(level 1) are nested within individuals (level 2). Nesting of data violates the assumption 
of independent residuals, since observations within subjects are more similar than 
observations among different subjects. Therefore, multilevel linear regression analyses 
were performed using the Stata mixed command with subject as the macro level. The 
following motor symptoms were the dependent variables in the regression models: 
‘tremor’, ‘rigidity’, ‘walking problems’, ‘balance problems’ and ‘dyskinesia’. To control 
for time trends, a time variable was added to all regression models 
(beepcode=daynumber*10+beepnumber). Independent variables were positive and 
negative affect, as well as being at home and being alone.   
 
First, in order to assess whether ON/OFF state is a modifier in the association between 
affective state and contextual factors on the one hand and motor symptoms on the 
other hand, interaction effects of all independent variables with ON/OFF state (ON = 
1, OFF = 0) were analysed including each independent variable in a separate model. 
Importantly, convergence was not achieved after including random slopes of the 
independent variable, ON/OFF state and beepcode, and consequently, only models 
including a random slope for beepcode were run. As this results in too optimistic p-
values, permutation testing was performed in case of a statistically significant result. 
Permutation testing obtains the distribution of regression coefficients under the null 
hypothesis. To obtain >1000 valid p-values, 1100 permutation tests were performed. 
For this, the dependent variable was removed from the data and within-subject 
randomly reshuffled and merged to the original data, while keeping the multilevel  
 
 
 
Table 1. Demographic and disease-related characteristics of participating patients 
Sub.nr Sex Age 
(yrs) 
Disease 
dur. 
(yrs) 
Tremor 
Dom. 
LEDD UPDRS 
I 
UPDRS 
II  
UPDRS  
III 
UPDRS 
IV 
% OFF 
 
HY MMSE PAS BDI-II PDQ-8 
1 M 57 8 No 600 1 15 49 6 26-50 3 28 4 12 9 
2 M 53 7 Yes 800 4 12 21 10 1-25 2.5 28 17 14 21 
3 F 77 3 Yes 800 6 17 28 8 26-50 3 27 24 16 11 
4 F 62 6 Yes 712.5 5 11 34 4 26-50 3 29 11 15 14 
5 F 61 5 No 690 3 9 8 7 1-25 1.5 29 19 12 10 
6 M 73 11 Yes 1000 3 10 22 4 26-50 1.5 30 3 1 5 
7 M 65 6 Yes 1100 1 14 22 9 1-25 2,5 30 19 11 12 
8 M 63 8 No 1306 0 15 15 7 26-50 2 29 10 1 7 
9 M 50 5 No 557 4 8 25 6 1-25 2 30 10 8 9 
10 F 50 11 Yes 835 2 12 32 9 1-25 2 30 20 16 13 
11 M 64 10 No 1242 2 8 16 10 1-25 2 29 9 3 10 
Sub.nr = Subject nr, Disease dur. = disease duration, tremor dom. = tremor-dominant PD, LEDD = levodopa equivalent daily dose, UPDRS = Unified 
Parkinson Disease Rating Scale, % OFF = UPDRS IV question 39, HY = Hoehn and Yahr stage, MMSE = Mini Mental State Examination, PAS = Parkinson 
Anxiety Scale, BDI-II = Beck Depression Inventory II, PDQ-8 = Parkinson’s Disease Questionnaire 8.  
 
Table 2. Descriptive statistics of ESM variables used in the analysis 
 Mean Median SD Variance Range 
Positive affect 4.55 5 1.40 1.97 1  -7 
Negative affect 3.33 1.17 .55 .31 1 - 5 
Tremor 1.91 1 1.24 1.53 1 - 6 
Rigidity 1.59 2 1.23 2.12 1 - 7 
Balance Problems 2.49 1 1.46 1.50 1 - 7 
Walking problems 2.75 2 1.93 3.74 1 - 7 
Dyskinesia 1.93 1 1.30 1.68 1 - 7 
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structure. Next, the regression coefficient obtained from the real multilevel regression 
analysis was placed on that normal distribution to obtain p-values (i.e., the proportion 
of times that the coefficient in the permuted data was as large as or larger than the 
observed coefficient; multiplied by two to obtain a two-sided p-value)27. Second, 
associations between the independent variables and the severity of motor symptoms 
independent of ON/OFF state were analysed in the full data set by multilevel linear 
regression analyses, including all independent variables in one model. Third, in order 
to assess the usability of ESM on an individual level, linear regression analyses were 
performed in data from individual patients using the same variables included in the full 
dataset. Moreover, graphs were generated to illustrate individual moment-to-moment 
fluctuations in mood and motor symptoms and ON/OFF state. 
 
RESULTS 
Participants and descriptive statistics 
One participant was excluded from the analysis because of a response rate of 26%, 
which is below the generally accepted minimum response rate of 33% for ESM data 
sampling14. Among the remaining 11 participants a total of 412 questionnaires were 
completed, corresponding to a mean response rate of 74.9%. Between individual 
patients the response rate varied from 42% to 94% (supplementary table 2). The 
demographic and disease-related characteristics of the participants are summarised 
in table 1. The study population consisted of four females and seven males. Mean age 
was 62.3 years (SD=7.8); mean disease duration was 7 years (SD=2.6), and mean 
UPDRS part III score was 24.7 (SD=11.0). The median Hoehn and Yahr stage was 2 
(range 1.5 to 3)20. A total of 4 patients were on a stable dose of dopamine agonists 
during the course of the study (either ropinirole or pramipexole), 3 patients used 
levodopa/benserazide, 7 patients used levodopa/carbidopa, 1 patient used 
levodopa/carbidopa/entecapone and 4 patients used amantadine. On the PAS, five 
subjects (participants 2, 3, 5, 7 and 10) scored above the cut-off point of 14, indicating 
clinically relevant anxiety22. On the BDI-II, four subjects (participants 2, 3, 4 and 10) 
scored above the cut-off point of 14 for mild depression23. Mean scores for affective 
state and motor symptoms are shown in table 2. Of the 412 completed questionnaires, 
111 were completed in ‘OFF’ state (27%) and 301 in ‘ON’ state (71%). Even though 
motor fluctuations were present, one patient did not report any ‘OFF’ states. The 
percentage ‘ON’ varied from 46.7% to 100% in individual subjects.   
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Group level analyses 
Effect modification of ON/OFF state  
Dyskinesia was not analysed, since five patients did not suffer from dyskinesia. 
Interaction analyses showed a statistically significant interaction between ON/OFF 
state and being at home when analysing tremor (X2(1) = 4.8, p = 0.028) (supplementary 
table 3). However, following permutation analysis, the association was no longer 
statistically significant (supplementary table 4). There were no other significant 
interaction effects. 
 
Associations between affective state, contextual factors and motor symptom severity  
Multilevel linear regression analyses showed statistically significant negative 
associations between positive affect and all motor symptoms: higher scores on positive 
affect were associated with lower self-perceived severity of tremor, rigidity, balance 
problems and walking problems. In addition, being at home was associated with 
increased balance problems and rigidity, while being alone was associated with 
reduced rigidity (table 3).  
 
Table 3. Associations between motor symptoms, mood states and contextual factors 
(independent of ON/OFF state) 
 Tremor Rigidity 
 B SE p 95% CI B SE p 95% CI 
PA 
 
-0.16 0.06 0.007 -0.28 - -0.05 -0.26 0.07 0.000 -0.39 - -0.12 
NA 
 
0.12 0.12 0.29 -0.11 - 0.35 0.28 0.14 0.041a 0.01 – 0.55 
At home 
 
0.17 0.13 0.18 -0.08 - 0.43 0.41 0.15 0.008 0.10 - 0.71 
Being 
alone 
-0.14 0.12 0.21 -0.37- 0.09 -0.42 0.14 0.002 -0.69 - -0.02 
 Walking problems Balance problemsa 
 B SE p 95% CI B SE p 95% CI 
 
PA 
 
-0.23 0.07 0.001 -0.16 - -0.01 -0.09 0.04 0.032 -0.16 - -0.01 
NA 
 
0.18 0.13 0.17 -0.08 – 0.43 0.06 0.08 0.42 -0.08 – 0.21 
At home 
 
0.23 0.14 0.11 -0.53 – 0.51 0.22 0.08 0.010 0.05 – 0.51 
Being 
alone 
-0.21 0.13 0.10 -0.46 – 0.04 -0.14 0.08 0.06 -0.29 – 0.01 
PA = positive affect, NA = negative affect, Bold = significant result 
a This association was not significant anymore following sensitivity (permutation) analysis p = 0.076 
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DISCUSSION 
The present study aimed to study if routinely collected ESM data over a brief period of 
time can be used to study associations between affective state, contextual factors, 
motor symptoms and motor state (ON/OFF) in PD patients who suffer from motor 
fluctuations on a group and individual level. Revealing population based patterns may 
lead to more general treatment recommendations, while individual analyses can be 
used to establish a personalised treatment plan14. Ideally, assessments are kept as 
brief as possible, in order to reduce the burden and improve compliance rates of 
patients14.  
 
On the group level, ESM collected over a period of five consecutive days was able to 
identify clear associations between affective state, contextual factors and motor 
symptoms. Higher scores on positive affect were associated with lower self-perceived 
severity of tremor, rigidity, balance problems and walking problems. Being at home 
was associated with more balance problems and rigidity in general. The observed 
associations were independent of whether a patient was in an ‘ON’ or ‘OFF’ state.  
 
When analysing data of individual patients, only a few subjects showed statistically 
significant associations between affective state, contextual factors and motor 
symptoms, which were mostly, but not always, in the same direction as the findings on 
the group level.  
 
Group level 
The finding that ON/OFF state was not a modifier in the associations between affective 
state and motor symptoms was surprising. As mood symptoms are mostly related to 
OFF states9, the relationship between positive or negative feelings and the severity of 
motor symptoms might be different when a patient is OFF compared to ON, e.g. there 
might be increased symptom focus in OFF state when experiencing negative emotions, 
or an increased symptom focus when OFF may lead to a stronger response in negative 
emotions. However, OFF states might have been underrepresented in the present 
study, leading to lack of power (see methodological issues below). As there are only 
few reports examining motor fluctuations using ESM data in PD patients, it is hard to 
compare the present findings with results from other studies. A recent study by Fernie 
et al. (2019) examined emotional distress and motor states in PD patients using ESM 
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data and found that episodic distress is greater during OFF states compared to ON 
states, but worse during OFF-coming-ON compared to ON-wearing-OFF transitional 
states28. Unfortunately, the present study could not identify these transitional states. 
Moreover, the study by Fernie et al. (2019) specifically focused on emotional distress 
and their questionnaire did not include different motor symptoms or any items reflecting 
positive emotions28.  
 
Interestingly, we observed that positive affect was associated with reduced self-
perceived symptom severity for all motor symptoms, while negative affect was not 
associated with any of the motor symptoms. Since the present data are cross-
sectional, causal inferences cannot be made. Therefore, we do not know whether a 
better mood results in reduced self-perceived severity of motor symptoms, or whether 
reduced self-perceived severity of motor symptoms results in better mood. 
Nonetheless, it seems that the relationship between motor symptoms and positive 
affect is more significant in PD, compared to the relationship between negative affect 
and motor symptoms. This finding is in line with results from the network analysis we 
recently performed on ESM data from one PD patient which aimed to identify 
longitudinal associations between motor symptoms and mood states17. While feeling 
‘down’ did not influence motor symptom severity, ‘cheerfulness’ was significantly 
associated with better scores for tremor and rigidity in this N = 1 study17. The 
associations between mood and motor states were independent of whether a patient 
subjectively perceived to be in an ON or OFF state. The dosage and timing of 
medication may have served as a modifier between the observed associations. 
Previous studies have demonstrated mood changes related to L-dopa infusion in a 
dose-dependent fashion29-31. For future research it would be of clinical relevance to 
include questions regarding timing and dosage of medication. Moreover, most studies 
on the effects of affective state on motor symptoms in PD have focused on negative 
mood states, such as depression, anxiety and apathy, ignoring positive affect9. In the 
field of psychiatry, there is increasing evidence that the impact of interventions, both 
pharmacological and non-pharmacological, is mediated more by enhancing positive 
emotions, than by reducing negative emotions32, 33. It is, therefore, important to include 
positive affect in the design of future studies. Moreover, enhancing the frequency and 
persistence of positive affect in daily life might be a promising adjunctive non-
pharmacological target for reducing the burden of motor fluctuations. 
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Analyses of the associations between contextual factors on the one hand and self-
perceived motor symptoms on the other hand showed that, overall, subjects perceived 
more rigidity and balance problems when at home. Possibly, patients have a tendency 
to stay at home when experiencing balance problems. Balance problems are among 
the most distressing symptoms related to PD34, as they are often accompanied by fear 
of falling35, thereby limiting a patient’s mobility and independence. Alternatively, being 
at home could also contribute to increased symptom focus or an increased chance of 
being confronted with balance problems due to the presence of more obstacles in 
smaller rooms. The negative association between rigidity and being alone is more 
difficult to explain, as there were no other statistically significant associations between 
being alone and motor symptoms. In general, context-specific associations based on 
analyses of a group of patients are difficult to interpret without patient-feedback. 
Context is an important consideration for many symptoms and the purpose of including 
contextual factors in ESM sampling strategies is to reveal complex environmental 
dynamics that can potentially help individuals to optimise environmental interactions 
and benefit coping strategies32.  
 
Individual level  
Overall, we found less clear associations when analysing routinely collected ESM data 
in individual patients. While most associations between being at home and balance 
problems in individual patients were also positive but not significant, to our surprise, 
the only patient with a statistically significant association was in opposite direction 
compared to the findings on a group level. Regarding positive and negative affect, most 
associations were in the same direction compared to the group analyses, but not all. 
One could assume that those subjects that suffered from clinically relevant anxiety 
and/or depression at baseline would show more significant associations between 
negative affect and motor symptoms. Except for subject 10, who showed statistically 
significant associations for both positive and negative affect, there was only one other 
patient with baseline anxiety in whom negative affect was associated with increased 
balance problems. We think the most likely explanation for the failure to identify 
significant associations between symptoms in individual patients is lack of power. 
 
On the other hand, the graphs were able to display moment-to-moment fluctuations in 
mood and motor symptoms. For clinical practice, this might provide the clinician 
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sufficient information that was otherwise not available via retrospective interviews or 
routine cross-sectional assessments in which a single assessment of symptom 
severity is considered representative for a longer time frame. Graphical 
representations of symptoms might also give the patient more insight into particular 
circumstances in which fluctuations occur or are perceived as more disabling, 
especially when fluctuations have become unpredictable. Apart from using ESM data 
to visualise and monitor symptom change following medication adjustments, it can also 
be used to guide collaborate decision making between the patient and clinician, e.g. 
determining which information is most important to monitor by ESM or to support 
treatment target selection14, 32. 
 
Methodological issues 
This study has several limitations. First, the sample size was small. As ESM generates 
a large number of data due to intensive data collection, we were able to reveal group 
level associations. However, for the individual analyses, five days of ESM data 
collection is probably too short to obtain sufficient power. In order to be applicable in 
routine patient care, the sensitivity of the method needs to be increased. This may be 
done by collecting data over a longer period of time as previously shown in our N=1 
study, by increasing the compliance or by making the answers more sensitive to 
change (e.g. by increasing the number of potential scores on the Likert item or by using 
visual analogue scale scores). Similarly, the finding that ON/OFF state was not a 
modifier in the studied associations might also be due to lack of power, as only 27% of 
completed questionnaires were in OFF state. While highly fluctuating states might be 
under-sampled with an ESM sampling frequency of 10 times per day, slowly fluctuating 
states might be over-sampled14. It is possible that with the current ESM protocol motor 
fluctuations were not adequately represented. For that reason, we did not include 
ON/OFF state in the analyses of individual subjects. In order to adequately sample 
ON/OFF fluctuations, the interval between assessments should be adapted to fit the 
frequency and duration of the OFF periods. An alternative approach would be to allow 
the patient to complete ‘patient-generated beep assessments’ during OFF periods, or 
to program the assessments at fixed times. However, with the latter method one may 
run the risk of missing the fluctuating nature of symptoms. Third, we did not include 
intermediate or transitional motor states, such as ON-wearing-OFF or OFF-coming-
ON, which might reveal different and potential relevant associations between affective 
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states and motor symptoms. In addition, ON/OFF state was defined subjectively by 
each individual subject. The use of wearable devices to objectify motor fluctuations 
may be a valuable addition in this respect. Recently, a study showed that combining 
wearable sensors with ESM data is feasible36. Fourth, the current study had a cross-
sectional approach, which makes it impossible to study assess temporal or causal 
associations. Studying temporal associations requires much longer periods of data 
collection, which may be too long to be implemented in routine patient care. In the 
context of an N=1 study we collected ESM data for a longer period of time – one month- 
in a PD patient. Although we were able to reveal longitudinal associations between 
affective state and motor symptoms in this patient, his response rate declined more 
than 50% over the course of 30 days, which may reflect the burden that patients 
experience when collecting data over a longer period of time17. Fifth, four patients used 
a (stable) dose of dopamine agonists during the study, which may be a confounder 
when measuring mood states. With the analysis performed in the present study it is 
not possible to correct for such confounders. For future research and for clinical 
practice it would be useful to record the time of medication intake, as well as missed 
or delayed intakes, to monitor the effect of dopaminergic treatment on motor symptoms 
or mood fluctuations. Sixth, we could not include random effects for the slopes of all 
predictor variables included in the models of the multilevel linear regression analysis; 
i.e. both the interaction analyses and the main effects, which might lead to an 
overestimation of p-values. Moreover, the assumption of normality of residuals was not 
met for all variables (e.g. for balance problems). To obtain valid and interpretable 
results, we performed permutation testing. As these sensitivity analyses revealed 
similar results in all but two cases (the interaction between ON/OFF state and being at 
home when analysing tremor, and the association between rigidity and negative 
affect), we adopted the results from the multilevel linear regression analyses and did 
not perform further permutation testing on data of individual subjects. Seventh, in three 
subjects the contextual factor ‘being alone’ was removed from the linear regression 
model because those subjects were always alone when at home and in company when 
not at home. Thus, the regression coefficients presented in supplementary table 6 were 
in fact the association between being home alone and the respective outcomes. 
Finally, the results are based on a priori selected variables that aimed to represent 
positive and negative mood states, as well as contextual factors and should therefore 
be considered with caution. Selecting different (combinations of) items might lead to 
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different results. For clinical practice, items are ideally selected based on the specific 
situation of the patient in a collaborative process between clinician and patient.  
 
CONCLUSION 
The ultimate goal is to use ESM in a non-burdening way in routine patient care as a 
tool to facilitate patient self-monitoring and as a guidance for clinicians to personalise 
treatment. Whereas in this study, ESM collected over a period of five days appeared 
sensitive enough to reveal associations between motor symptoms, mood states and 
contextual factors on a group level, this approach was not powerful enough to reveal 
an adequate number of relevant association on an individual level. This implies that 
the method must be made more sensitive for application in routine clinical practice. 
Since ESM will probably play a more important role in future studies as well as in 
clinical practice, we argue that there is an urgent need of harmonisation, validation and 
optimisation of this technique for use in PD patients.  
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Supplementary materials 
 
Supplementary Table 1. ESM questionnaire 
Domain Item Description Score 
Mood 
 
 
 
 
 
 
 
 
1 I feel happy 1-7 (1= not, 4= moderate, 7= very) 
2 I feel insecure 1-7 
3 I feel relaxed 1-7 
4 I feel irritated 1-7 
5 I feel satisfied 1-7 
6 I feel lonely 1-7 
7 I feel afraid 1-7 
8 I feel down 1-7 
9 I feel guilty 1-7 
10 I rack my brain 1-7 
11 I feel suspicious 1-7 
12 I feel threatened 1-7 
13 In general, I feel well 1-7 
Parkinson 14 Currently I am: 0=”OFF”, 1=”ON” 
15 I experience tremor 1-7 
16 I experience rigidity 1-7 
17 Walking is difficult 1-7 
18 I experience balance problems 1-7 
19 I experience dyskinesia 1-7 
20 Personal complaints: Open question 
Context 21 Currently I am: Resting/ working/ housework/ hygiene/ 
eating, drinking/ relaxing/ 
conversating/ other  
22 I rather do something else 1-7 
23 Where am I? Home/ work/ friends place/ public 
place/ on the go 
24 With who am I? Nobody/ partner/ family/ friends/ 
collegues/ strangers 
25 I find this pleasant 1-7 
Somatic 26 I am hungry 1-7 
27 Since the last beep I used: Nothing /caffeine/ nicotine/ alcohol/ 
medication/ cannabis/ food/ other 
28 I am tired 1-7 
29 I am not feeling well 1-7 
30 I have pain 1-7 
31 I experience: Headache/ abdominal pain/ breathing 
difficulties/ muscle ache/ obstipation/ 
tinnitus/ dizziness/ dyspnea/ 
palpitations/ incontinence 
Events 32 The most important event since the 
last beep was: 
Open question 
33 The event was:  -3 - 3 (-3 = very displeasing, 0 = 
neutral, 3 = very pleasant ) 
34 The event was:  -3 - 3 (-3 = not important, 0 = neutral, 3 
= very important) 
35 The event was under my control 1-7 
36 I expected this event 1-7 
 37 This beep was unpleasant 1-7 
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Supplementary Table 2: Overview of response rates 
Subject Completed 
questionnaires (nr) 
Response 
percentage (%) 
ON / OFF (nr) Percentage ON 
(%) 
1 21 42 19 / 2 90.5 
2 26 52 23 / 3 88.5 
3 42 84 42 / 0 100 
4 35 70 18 / 17 51.4 
5 46 92 28 / 18 60.9 
6 47 94 27 / 20 57.4 
7 30 60 14 / 16 46.7 
8 39 78 26 / 13 66.7 
9 46 92 42 / 4 91.3 
10 45 90 36 / 9 80 
11 35 70 26 / 9 74.3 
Total 412 74.9 301 / 111 73.1 
Supplementary Table 3. Interaction effects ON/OFF state 
 Tremor Rigidity 
 B SE p 95% CI B SE p 95% CI 
PA 0.04 0.07 0.59 -0.11 - 0.18   -0.08 0.09 0.39 -0.10 - 0.02 
NA 0.08 0.19 0.69 -0.29 - 0.45 -0.26 0.23 0.25 -0.72 - 0.19 
At home -0.54 0.25 0.028 -.102 - .057   -0.35 0.30 0.25 -0.25 - 0.94 
Being alone -0.24 0.20 0.24 -0.63 - 0.16 0.33 0.25 0.19 -0.16 - 0.81 
 Walking problems Balance problemsa 
 B SE p 95% CI B SE p 95% CI 
PA -0.15 0.09 0.07 -0.32 - 0.02 -0.05 0.05 0.32 -0.16 - 0.01 
NA -0.09 0.22 0.70 -0.52 - 0.35 0.16 0.14 0.23 -0.10 - 0.43 
At home 0.31 0.29 0.29 -0.26 - 0.05 0.25 0.18 0.15 -0.09 - 0.60 
Being alone -0.04 0.24 0.87 -0.50 - 0.42 0.10 0.15 0.27 -0.12 - 0.43 
PA = positive affect, NA = negative affect, Bold = significant result p < 0.05 
 
Supplementary Table 4. P-values original analyses and permutation analyses  
 Tremor – 
ON/OFF 
Tremor Rigidity Walking 
problems 
Balance 
problems 
 P P-PT P P- PT P P- PT P P- PT P P- PT 
PA 
 
0.59 0.99 0.007 0.002 <0.001 0.006 0.001 <0.001 0.032 0.039 
NA 
 
0.69 0.54 0.29 0.21 0.041 0.076 0.17 0.19 0.42 0.37 
At 
home 
0.028 0.99 0.13 0.14 0.008 0.001 0.11 0.11 0.010 0.013 
Being 
alone 
0.24 0.99 0.12 0.23 0.002 <0.001 0.10 0.08 0.06 0.06 
PA = positive affect, NA = negative affect, PT = permutation testing 
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Supplementary Table 5: Associations between motor symptoms and mood states in 
individual patients 
  
 
Symptom 
Mood 
Pt 
+ N 
Positive affect  Negative affect 
B SE p 95% CI  B SE p 95% CI 
 
1 
N=21 
Tremor .102 .403 0.804 -.753-.957  -.224 .733 0.764 -1.778-1.330 
Rigidity -.473 .505 0.363 -1.544-.598  1.862 .918 0.060 -.084-3.808 
Walking  -1.027 .402 0.021 -1.880--.174  1.070 .731 0.163 -.481–2.620 
Balance  -.431 .322 0.199 -1.113-.251  .688 .585 0.257 -.552–1.927 
 
2 ab 
N=26 
 
Tremor -.138 .448 0.762 -1.073-.797  -.425 .617 0.498 -1.771-.861 
Rigidity .078 .414 0.853 -.786-.942  -.196 .570 0.735 -1.384-.993 
Walking  -.181 .162 0.277 -.518-.156  -.116 .222 0.607 -.580-.347 
Balance -.095 .229 0.681 -.574-.383  .0251 .315 0.937 -.632-.683 
 
3 ab 
N=42 
Tremor .025 .092 0.079 -.161-.210  .152 .203 0.457 -.258-.563 
Rigidity .042 .204 0.838 -.372-.456  .248 .452 0.587 -.668-1.163 
Walking  .039 .175 0.825 -.315-.393  .321 .386 0.412 -.462–1.104 
Balance  .073 .086 0.401 -.101-.246  -.126 .189 0.509 -.509-.257 
 
4 b 
N=35 
Tremor .568 .315 0.083 -.078–1.213  .768 .838 0.367 -.947–2.483 
Rigidity -.291 .310 0.356 -.925-.344  -.014 .824 0.986 -1.699–1.670 
Walking  .079 .337 0.815 -.609-.768  .393 .895 0.664 -1.436–2.223 
Balance  .025 .050 0.625 -.078-.127  -.035 .133 0.794 -.307-.237 
 
5 a 
N=46 
Tremor -.085 .042 0.050 -.169--.001  .056 .052 0.284 -.049-.162 
Rigidity -.372 .202 0.072 -.780-.035  -.263 .251 0.300 -.771-.244 
Walking  -.252 .178 0.165 -.612-.108  -.29 .222 0.200 -.737-.159 
Balance c . . . .  . . . . 
 
6 
N=47 
Tremor .105 .409 0.798 -.721-.931  -2.06 1.43 0.159 -4.95-.837 
Rigidity -.111 .198 0.577 -.511-.286  -1.483 .692 0.038 -2.882--.084 
Walking  -.148 .301 0.627 -.755-.460  .725 1.054 0.495 -1.403–2.855 
Balance  .076 .104 0.468 -.133-.286  -.244 .364 0.506 -.979-.490 
 
7 a 
N=30 
Tremor -2.42 .756 0.004 -3.977--.862  .083 1.38 0.952 -2.760–2.927 
Rigidity -.969 .466 0.048 -1.928 -.010  1.72 .850 0.054 -.030–3.472 
Walking  -1.032 .591 0.093 -2.250-.187  -.093 .108 0.932 -2.317–2.131 
Balance  -.070 .217 0.750 -.516-.377  1.190 .396 0.006 .375–2.005 
 
8 
N=39 
Tremor -.001 .053 0.980 -.109-.106  .109 .613 0.860 -1.137–1.356 
Rigidity -.679 .425 0.120 -1.543-.186  -2.911 4.918 0.558 -12.91–1.094 
Walking  -.702 .427 0.110 -1.571–.167  -1.926 1.945 0.699 -11.986–8.134 
Balance  -.636 .310 0.049 -1.268--.004  1.977 3.598 0.586 -5.343–9.296 
 
9 
N=46 
Tremor -.085 .054 0.125 -.194-.025  -.010 .085 0.908 -.182-.162 
Rigidity -.694 .206 0.002 -1.110--.278  .069 .324 0.833 -.588-.725 
Walking  -.417 .143 0.006 -.705-.128  .093 .225 0.683 -.363-.548 
Balance  -.241 .099 0.020 -.441--.040  -.016 .157 0.919 -.332-.300 
 
10 ab 
N=45 
Tremor -.104 .246 0.000 -1.536--.541  1.91 .634 0.004 .632-3.195 
Rigidity -.369 .131 0.008 -.631--.103  .751 .336 0.031 .070–1.431 
Walking  -.235 .100 0.025 -.438--.032  .612 .259 0.023 .089–1.126 
Balance  .058 .091 0.529 -.126-.242  .624 .234 0.011 .150–1.098 
 
11 
N=35 
Tremor -.237 .179 0.196 -.602-.129  .256 .337 0.452 -.432-.945 
Rigidity -.236 .313 0.457 -.876-.404  .959 .590 0.115 -.247-.2.163 
Walking  -.157 .304 0.610 -.778-.465  1.101 .572 0.064 -.070-.2.271 
Balance  .033 .149 0.826 .-.272-.339  .476 .281 0.101 -.099-.1.052 
N = number of completed questionnaires, Walking = walking problems, balance = balance problems. Each 
participant received 50 assessments over the course of 5 days. Bold= significant result p < 0.05 
a Subject suffered from clinically relevant anxiety as objectified by the Parkinson Anxiety Scale20 b Subject suffered 
from clinically relevant depression as objectified by the Beck Depression Inventory-II21 c Subject did not experience 
any balance problems during ESM data collection (score =1) 
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Supplementary Table 6: Associations between motor symptoms and contextual factors in 
individual patients 
  
 
Symptom 
Contextual factors 
Pt 
+ N 
At home  Being alone 
B SE p 95% CI  B SE p 95% CI 
 
1 
N=21 
Tremor .617 .596 0.316 -.647–1.881  . . . . 
Rigidity .392 .746 0.607 -1.191–1.974  . . . . 
Walking  .868 .595 0.164 -.393–2.129  . . . . 
Balance  .685 .476 0.169 -.323–1.693  . . . . 
 
2 ab 
N=26 
 
Tremor .046 .656 0.945 -1.322–1.414  .449 .696 0.527 -1.004–1.901 
Rigidity 1.155 .606 0.071 -.10–2.419  .242 .643 0.711 -1.100–1.584 
Walking  .017 .236 0.944 -.476-.509  -.133 .251 0.602 -.656-.390 
Balance  .680 .335 0.056 -.020–1.379  .054 .356 0.882 -.689-.796 
 
3 ab 
N=42 
Tremor .680 .395 0.093 -.119-1.480  . . . . 
Rigidity .093 .880 0.916 -1.689–1.876  . . . . 
Walking  -.017 .752 0.982 -1.541–1.508  . . . . 
Balance  .116 .368 0.755 -.631-.862  . . . . 
 
4 b 
N=35 
Tremor 1.114 .921 0.236 -.769–2.998  -.780 .402 0.062 -1.603-.043 
Rigidity .462 .905 0.613 -1.388–2.313  -.607 .395 0.135 -1.415-.201 
Walking  -.405 .983 0.683 -2.415–1.604  .423 .429 0.333 -.522–1.301 
Balance  .094 .146 0.524 -.204-.393  -.063 .064 0.332 -.193-.068 
 
5 a 
N=46 
Tremor .109 .074 0.148 -.040-.259  -.105 .079 0.189 -.264-.054 
Rigidity -.172 .357 0.633 -.893-.549  -.066 .380 0.863 -.834-.702 
Walking  -.206 .315 0.516 -.844-.431  -.104 .336 0.759 -.783-.575 
Balance  . . . .  . . . . 
 
6 
N=47 
Tremor -.465 .433 0.289 -1.340-.410  -.203 .316 0.525 -.842-.436 
Rigidity -.406 .209 0.059 -.829-.017  -.218 .153 0.162 -.527-.091 
Walking  -.052 .319 0.870 -.696-.591  .022 .233 0.924 -.448-.492 
Balance  .072 .110 0.516 -.150-.294  .012 .080 0.878 -.150-.175 
 
7 a 
N=30 
Tremor .375 1.030 0.719 -1.746–2.497  . . . . 
Rigidity .290 .634 0.651 -1.016–1.598  . . . . 
Walking  .923 .805 0.263 -.736-.583  . . . . 
Balance  -.700 .295 0.026 -1.309--.092  . . . . 
 
8 
N=39 
Tremor -.242 .084 0.007 -.414--.070  .061 .079 0.446 -.100-.223 
Rigidity 1.183 .680 0.091 -.201 2.566  -.734 .637 0.257 -2.030-.561 
Walking  1.186 .684 0.092 -.206–2.577  -.566 .640 0.383 -1.869-.736 
Balance  .948 .497 0.066 -.064–1.96  -.457 .465 0.334 -1.405-.491 
 
9 
N=46 
Tremor .251 .199 0.215 -.152-.654  -.125 .182 0.496 -.492-.242 
Rigidity 1.518 .758 0.052 -.015–3.050  -1.514 .691 0.034 -2.910--.118 
Walking  .758 .52 0.157 -.306–1.822  -.719 .479 0.141 -1.688-.250 
Balance  .369 .366 0.319 -.370–1.109  -.362 .333 0.284 -1.035-.312 
 
10 ab 
N=45 
Tremor .593 .414 0.161 -.246–1.430  -.751 .293 0.014 -1.342--.158  
Rigidity .290 .220 0.195 -.155-.735  -.068 .155 0.666 -.382-.247 
Walking  .096 .169 0.572 -.246-.439  .035 .120 0.768 -.206-.277 
Balance  -.085 .153 0.583 -.395-.225  .008 .108 0.939 -.211-.227 
 
11 
N=35 
Tremor .276 .527 0.605 -.802–1.353  .195 .347 0.578 -.515-.906 
Rigidity .909 .922 0.322 -.977–2.796  -.669 .608 0.280 -1.913-.575 
Walking  .652 .896 0.472 -1.180–2.484  -.709 .591 0.239 -1.197-.499 
Balance  .132 .440 0.767 -.769–1.032  .419 .290 0.160 -.175–1.013 
N = number of completed questionnaires, Walking = walking problems, balance = balance problems. Each 
participant received 50 assessments over the course of 5 days. Bold = significant result p < 0.05. In 3 subjects (1, 
3 and 7) ‘being alone’ was removed from the model because of a 100% correlation with ‘being at home’. a Subject 
suffered from clinically relevant anxiety as objectified by the Parkinson Anxiety Scale20, b Subject suffered from 
clinically relevant depression as objectified by the Beck Depression Inventory-II21, c Subject did not experience any 
balance problems during ESM data collection (score =1) 
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Supplementary figure 1: Moment-to-moment fluctuations in positive and negative affect and 
in tremor, rigidity, balance problems, walking problems and dyskinesia in individual patients 
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ABSTRACT 
Background: anxiety disorders occur in up to 35% of patients with Parkinson’s disease 
(PD) and have a negative effect on motor symptoms and quality of life. To date, no 
clinical trials specifically targeting anxiety in PD patients have been published. 
 
Objective: to describe the rationale and methodology of a randomised controlled trial 
(RCT) that aims to study the clinical effectiveness, alterations in brain circuitry, and 
cost-effectiveness of cognitive behavioural therapy (CBT) for anxiety in PD.  
 
Methods: this study is a prospective, two-centre RCT in which sixty PD patients with 
anxiety will be randomised to CBT treatment and clinical monitoring (intervention 
group) or to clinical monitoring only (control group). The CBT module used in this study 
was specifically developed to address symptoms of anxiety in PD patients. Participants 
will undergo standardised clinical, cognitive and behavioural assessment at baseline 
and at 2 follow-up measurements, as well as resting-state fMRI and DTI scanning 
before and after the intervention. The primary outcome measure is changes in severity 
of anxiety symptoms. Secondary outcome measures involve long-term changes in 
anxiety symptoms, changes in functional and structural connectivity between limbic 
and frontal cortices, and cost-effectiveness of the treatment. The study is registered at 
the ClinicalTrials.gov database under registration number NCT02648737. 
 
Conclusion: this study is the first that evaluates both the clinical effectiveness, cost-
effectiveness, as well as the biological impact of CBT for anxiety in PD patients that, if 
proven effective, will hopefully contribute to a better and evidence-based approach for 
these non-motor symptoms.  
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BACKGROUND 
Anxiety disorders occur in up to 35% of patients with Parkinson’s disease (PD) and 
have a negative effect on several motor symptoms including tremor, gait, dyskinesias, 
freezing, on-off fluctuations, and on quality of life in general1-3. However, anxiety 
disorders in PD patients are often not recognised and consequently not treated4, 5.  
 
Neurobiological studies of affective processing have demonstrated the involvement of 
an extensive frontal-subcortical limbic network6, which mainly depends on intact 
dopaminergic neurotransmission7. PD is primarily characterised by the progressive 
degeneration of dopaminergic systems and anxiety is believed to originate, at least in 
part, from the underlying pathological process of PD8, 9. Indeed, anxiety often appears 
prior to the appearance or recognition of motor symptoms9, and even non-anxious PD 
patients already show altered emotion regulation compared to healthy adults10. 
However, the fact that anxiety symptoms do not reliably improve by L-DOPA 
replacement therapy suggests that other mechanisms besides dopamine deficiency 
are involved in the aetiology of anxiety symptoms in PD11, 12, such as the noradrenaline 
and serotonin systems. Both these systems are implicated in affective processes and 
known to be substantially affected in the PD process13-15. On the other hand, both fears 
and social implications associated with motor symptoms of PD can provoke or 
exacerbate anxiety symptoms in PD16. Given this complex interaction between 
physiological and psychological factors and the diversity of the disease, 
psychotherapeutic treatment of anxiety requires adaptations that are tailored to the 
specific needs of PD patients17, 18.  
 
Cognitive behavioural therapy (CBT) is considered the gold standard in 
psychotherapeutic treatment of anxiety in the general population19, 20. CBT is defined 
as ‘An amalgam of behavioural and cognitive problem-based interventions guided by 
principles of applied science. The behavioural interventions aim to decrease 
maladaptive behaviours and increase adaptive ones by modifying their antecedents 
and consequences and by behavioural practices that result in new learning. The 
cognitive interventions aim to modify maladaptive cognitions, self-statements, or 
beliefs’21, 22. In PD, CBT has been proven to be an effective treatment for depression 
and impulse control disorders (ICD)23-25. PD patients who received CBT for depression 
in a randomised controlled trial reported not only a reduction in depression and 
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comorbid anxiety, but also a beneficial influence on coping and quality of life, compared 
to PD patients who only received clinical monitoring23. To date, no clinical trials 
specifically targeting anxiety in PD patients have been published. However, there have 
been several pilot studies for CBT and internet-based CBT in PD patients with mixed 
depressive and anxiety symptoms or mild to moderate depression or anxiety 
symptoms, respectively25-27. Both studies reported significant reductions in depressive 
symptoms, but not in anxiety symptoms, which may have been due to small sample 
sizes and lack of power26, 27. Another uncontrolled study investigating the use of a 
tailored CBT module for anxiety in 12 PD patients showed that CBT can reduce anxiety 
levels with persisting benefits at 3 and 6 month follow-up28. Although the previous 
studies are limited by their small sample size, and/or uncontrolled nature, they warrant 
further exploration of CBT for anxiety in PD patients25.  
 
In addition to clinical effectiveness, several imaging studies have demonstrated that 
psychotherapeutic interventions, including CBT, can modify neural correlates of 
affective processing29-32. CBT-induced increases in both functional30, 33 and structural 
connectivity34 between limbic and frontal cortices have been demonstrated in patients 
with social anxiety disorder (SAD), one of the most common anxiety disorders in PD1.  
Here, we describe the design of the study Cognitive Behavioural Therapy for Anxiety 
Disorders in Parkinson’s Disease, a two-centre randomised controlled trial (RCT) that 
aims to examine the clinical effectiveness, cost-effectiveness as well as changes in 
cerebral connectivity following CBT for anxiety in PD. The main research questions 
are: 
1) Is CBT treatment of anxiety in PD patients more effective than clinical monitoring 
in terms of change in anxiety levels, quality of life and well-being? 
2) Is CBT treatment cost-effective, compared to clinical monitoring? 
3) Does successful CBT treatment lead to changes in functional and structural brain 
connectivity between the frontal and prefrontal cortex and limbic structures such as 
the amygdala, cingulate gyrus and hippocampus? 
 
METHODS 
Study design 
This study is a prospective, open RCT with PD patients recruited in two centres in 
Europe (Maastricht University Medical Centre, Maastricht, the Netherlands and Lille 
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University Hospital, Lille, France). Sixty PD patients with anxiety and their caregivers 
(optional) will be randomised to CBT and clinical monitoring (intervention group) or 
clinical monitoring only (control group). A randomised block design with 6 blocks of 10 
participants will be applied. All participants will undergo standardised clinical, cognitive 
and behavioural assessment at baseline (t = 0), at the end of the intervention (t = 1) as 
well as 3 months after the intervention (t = 2). Moreover, participants randomised to 
the intervention group will receive an additional full assessment at 6 month follow-up 
(t = 3). At baseline (t = 0) and at the end of the intervention (t = 1) participants will 
undergo Magnetic Resonance Imaging (MRI) scanning, except in case of 
contraindications for undergoing MRI (e.g., deep brain stimulation, claustrophobia). 
The duration of the intervention will be approximately 10 - 12 weeks. Participants 
randomised to the control group will be given the option to receive CBT after the 3 
month follow-up assessment. This will be done as clinical care and not be part of the 
study. 
Study population 
In- and exclusion criteria 
Sixty patients with idiopathic PD according to the Queens Square Brain Bank criteria35 
and their caregivers (optional) will be prospectively enrolled. In- and exclusion criteria 
are listed in Table 1. In order to achieve a representative study sample, participants 
will be included irrespective of their disease stage or their current antiparkinsonian 
medication, provided a stable situation is present. In case a caregiver is involved, the 
caregiver should have daily contact with the study participant and have no serious 
medical or psychiatric conditions.   
 
Recruitment 
Patients will be recruited from the Movement Disorders clinics in the two participating 
centres. The treating neurologists will evaluate initial eligibility of the patients. 
Moreover, flyers with general information about the study and contact details of the 
researchers will be distributed in Movement Disorders clinics in other hospitals in the 
region and at several Parkinson support groups. After patients have been informed 
about the study and agreed to participate, a baseline assessment will take place, in 
which participants will be further screened to evaluate whether they meet all in- and 
exclusion criteria. A flowchart of the inclusion procedure is presented in Figure 1.  
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Table 1. In- and exclusion criteria  
Inclusion criteria - Idiopathic PD according to the Queens Square Brain Bank 
diagnostic criteria35  
 - Presence of clinically relevant anxiety symptoms, as 
operationalised by a Parkinson Anxiety Scale (PAS)3 persistent 
score > 9 and/or PAS avoidance score > 3 
 - Using a stable dose of levodopa or other antiparkinsonian 
medication for at least 1 month 
 - No other current psychological treatment for anxiety; 
psychopharmacotherapy is allowed if a stable dose is used at 
least 2 months prior to participation and the patient still meets 
inclusion criteria. During the trial the dosage should not be 
changed. Medication use and mental health care will be tracked 
throughout the study.  
 - Age between 35 and 80 years old 
Exclusion criteria - Parkinsonian syndromes or neurodegenerative disorders other 
than PD 
 - Dementia or severe cognitive decline, operationalised as a 
Montreal Cognitive Assessment (MoCa)36 score < 24 
 - Major depressive disorder (MDD) as defined by the DSM 5 
criteria37  
 - Abuse of alcohol, drugs or benzodiazepines 
PD = Parkinson’s disease, PAS = Parkinson Anxiety Scale, MoCa = Montreal Cognitive 
Assessment, MDD = Major Depressive Disorder; DSM 5= Diagnostic and Statistical Manual of 
mental disorders, 5th edition. 
 
Randomisation, blinding and treatment allocation 
After informed consent is obtained and the baseline measurement is performed, 
participants will be randomly assigned to one of two groups: the intervention group or 
control group. Randomisation will be performed over both centres together in order to 
compensate for between-centre differences in population and involves a randomised 
block design with 6 blocks of 10 participants. Randomisation is performed by the 
coordinating investigator using the website randomization.com. Assessments will be 
performed by a psychologist who is not involved with the treatment and blinded for the 
intervention. The participants will be instructed not to comment on the intervention they 
received.  
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Figure 1. Study flow chart.  
  
Check for eligibility 
Interested patients 
contacted 
Excluded: not 
eligible/unwilling 
Baseline assessment (t=0) 
Excluded: no informed 
consent/ no baseline 
assessment 
Randomisation procedure 
Post-intervention 
assessment (t=1) 
3-month follow-up 
assessment (t=2) 
CBT intervention (if desired) 
6-month follow-up 
assessment (t=3) 
Intervention group: 
CBT and clinical monitoring 
Control group: 
Clinical monitoring only 
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Intervention 
CBT Treatment 
Participants randomised to the intervention group will receive CBT and clinical 
monitoring. The CBT consists of 10 weekly individual sessions of 60 - 75 minutes, 
tailored to the preferences and needs of each patient. In each session, a registered 
psychologist will address specified aspects of (coping with) anxiety and related 
concerns with a specific focus on behaviour and thoughts associated with anxiety. Any 
other neuropsychiatric symptoms that are present, such as depressive symptoms or 
apathy, will be addressed as well, although the main focus will be on anxiety.  
 
The content of the CBT module was based on existing literature of CBT treatment of 
generalised anxiety disorder and social anxiety disorder and on published existing 
modules for CBT in anxiety and depression. Published existing modules include 
amongst others: psycho-education and awareness, motivational interviewing, 
behaviour activation, thought monitoring and restructuring, exposure, relaxation 
techniques, coping and problem solving skills, exercise, and sleep hygiene23, 26, 38-40. 
We adjusted these existing modules to better serve the specific needs, concerns, and 
circumstances of PD patients with anxiety. The resulting module was subsequently 
presented to small groups of PD patients and their caregivers (in ‘focus-groups’), as 
well as to representatives of the scientific section of the Dutch Parkinson Patient 
Foundation (Parkinsonpatiëntenvereninging) and to PD experts in both countries, in 
order to gather patient and professional feedback, respectively. The final CBT module, 
which consists of a treatment manual for therapists and a workbook for patients, was 
originally written in English and later translated to French and Dutch.  
 
All CBT sessions have a similar overall structure. Each session will start with setting 
the agenda for that particular session, after which the home assignments will be 
reviewed (in all but the first session). Then the new topic will be introduced and 
exercises related to the new topic will be practiced. Subsequently, the new home 
assignments for the upcoming week will be discussed as well as possible barriers or 
concerns for completing the new tasks and/or tasks from previous sessions. The first 
and last session will have some additional components related to the introduction and 
termination of the therapy, respectively. An overview of the sessions is provided in 
Table 2.  
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Table 2. Overview of the Cognitive Behavioural Therapy sessionsa 
Session 
1 Introduction and psycho-education about anxiety 
2 Monitoring anxiety 
3 Management of anxiety: introduction and the importance of self-management 
4 Management of anxiety: diaphragmatic breathing and mindful awareness 
5 Changing thoughts 
6 Management of anxiety: progressive muscle relaxation and imagery 
7 Problem solving 
8 Changing anxiety behaviour 
9 Review session 
10 Self-management plan and closure 
 Booster sessionb 
a A detailed treatment protocol and therapist manual have been developed. Moreover, 
participants will receive a workbook with handouts and worksheets. b Each patient will 
receive a booster session 1.5 month following the final treatment session. The aim of the 
booster session is the monitor the patient’s progress, to provide clinical assistance if 
necessary, and to encourage continued use of coping skills. 
 
Home assignments are an important part of CBT. In order to override dysfunctional 
patterns that promote anxiety and achieve change, repeated practice in daily life is 
necessary. Patients will receive a workbook during the first session. Each week the 
workbook will be supplemented with handouts and worksheets that correspond to the 
current topic. Even though patients with severe cognitive impairment (MoCa score <24) 
will be excluded from participation, cognitive problems are common in PD patients41, 
and probably a substantial proportion of the participants will experience cognitive 
problems to some degree. These usually relate to deficits in attention and executive 
function, although memory deficits and visuospatial functions are also frequent 40. 
Therefore, all sessions and accompanying handouts and worksheets have a clear 
structure and the psychologist will always check whether the information and 
assignments are clear to the participant and whether there are any barriers or concerns 
for completing the home assignments. If necessary, the psychologists will problem-
solve any issues. The therapy sessions will take place at the outpatients of the 
Movement Disorders Clinics of the two participating centres. In case medical or other 
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reasons make it difficult for the patient to visit the clinics, the treating therapist can visit 
the participants at home.  
 
Clinical monitoring 
Clinical monitoring has been recommended as a control situation when exploring the 
clinical effectiveness of a new or adjusted psychotherapeutic intervention43. All patients 
will receive clinical monitoring; those not randomised to the intervention group will 
receive clinical monitoring only. Clinical monitoring involves a phone call by an 
independent psychologist one month following the baseline assessment to inquire 
about current anxiety symptoms. Moreover, participants will receive general education 
material on coping with anxiety, derived from the Dutch/French psychiatric association 
webpages. Participants in the control group will remain under the care of their personal 
physicians, who will also monitor their medical and psychiatric status. During the 
intervention and follow-up period, all participants are asked to give notice when starting 
with any other form of psychotherapeutic interventions or psychopharmacotherapy for 
their anxiety. Those patients randomised to the control condition of clinical monitoring 
only, will be given the opportunity to receive CBT after the 3 month follow-up 
assessment. This treatment will be part of regular patient care and is covered by the 
patient’s health insurance. Hence, it will not be part of the study.  
 
Outcome measures 
The primary outcome for studying the clinical effectiveness of the CBT treatment is the 
difference between the intervention and control group in anxiety score changes 
between baseline (t = 0) and post-treatment (t = 1) as measured with the Hamilton 
Anxiety Rating Scale (HARS)42. Secondary outcome measures involve long-term 
clinical effectiveness, which will be assessed similarly, but then using the 3-month (t = 
2) and 6-month follow-up anxiety scores (t = 3, intervention group only). Moreover, 
changes in functional and structural cerebral connectivity between the frontal and 
prefrontal cortex and limbic structures such as the amygdala, cingulate gyrus and 
hippocampus before and after the intervention will be studied, as measured with 
resting-state MRI (rs-fMRI) and Diffusion Tensor Imaging (DTI). The difference in 
effectiveness between CBT and clinical monitoring in terms of disease-specific quality 
of life, generic health-related quality of life and well-being will be assessed using the 
Parkinson’s Disease Questionnaire-8 (PDQ-8)45, the EQ-5D-5L46 and Icepop 
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Capability measure for older people (ICECAP-O)47, respectively. Lastly, care resource 
utilisation will be obtained by an adapted version of the Resource Utilisation in 
Dementia48 questionnaire. Other study parameters involve changes in comorbid 
psychiatric symptoms, motor symptoms, sleep disturbance, coping, as well as 
caregiver burden. An overview of all questionnaires is provided in Table 3.  
 
Table 3. Questionnaires administered at t0, t1, t2 and t3 
Domain Instrument 
Anxiety Hamilton Anxiety Rating Scale44, Parkinson Anxiety Scale3, 
Liebowitz Social Anxiety Scale49, Mini International 
Neuropsychiatric Inventory section G and O50 
Global cognitive status Montreal Cognitive Assessment36 
Depression Hamilton Depression Rating Scale51 
Apathy Lille Apathy Rating Scale52 
Health-related quality of life Parkinson’s Disease Questionnaire45, EQ-5D-5Lc46   
Well-being ICECAP-Oc47  
Sleep and nocturnal 
disturbances 
Parkinson’s Disease Sleep Scale 253 
Coping strategies Brief Cope scale54, Thought Control Questionnaire55 
Health-related costs, 
patient and family related 
costs 
Adapted version of the Resource Utilisation in Dementiad48 
Motor symptom severity  
and PD disease stage 
MDS-UPDRS, Hoehn & Yahr staging56 
Caregiver burden Zarit burden interview57 
ICECAP-O = Icepop Capability measure for older people, MDS-UPDRS = Movement 
Disorder Society – Unified Parkinson’s disease rating scale, PD = Parkinson’s disease. a 
t=0: baseline measurement, t=1: post-intervention measurement, t=2: 3-month follow up. b 
t=3: 6-month follow-up for intervention group only, c Will be administered to both 
participants and caregivers, d In this version the formulation of items has been adjusted to 
PD instead of dementia and two questions regarding the use of speech therapy and home 
aids were added. 
 
The demographic and disease-related variables that will be collected during baseline 
include sex, date of birth, years of formal education, year of PD onset, side of onset, 
year of PD diagnosis, details on Parkinson medication (i.e., drug name, dose, 
frequency, levodopa equivalence) and other medication including psycho-
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pharmacology, alcohol use, medical history (i.e., cerebrovascular diseases, psychiatric 
disorders) and family medical history (i.e., PD, other neurological disorders, dementia, 
psychiatric disorders). Any change in Parkinson medication will be tracked during the 
whole study period.  
 
MRI scan 
MRI will be acquired using a 3T whole-body scanner (Achieva TX, Philips Healthcare, 
Best, the Netherlands) using a 32-channel head coil for signal reception. The MRI 
protocol includes an anatomical scan, rs-fMRI, DTI and B0 field map. The total MRI 
scan will take about 45 minutes. Details of the brain MRI protocol can be found in Table 
4. Imaging will be performed at the Department of Radiology of Maastricht University 
Medical Centre and at the Department of Radiology of Lille University Hospital. 
 
Data collection and management 
All personnel involved in the data collection will review the standard operating 
procedures (SOP) and manuals. Assessors are certified in Good Clinical Practice 
(GCP) and in performing the MDS-UPDRS part III56. Data will be collected on paper 
forms and entered into a web-based data entry portal of which a back-up will be stored 
electronically on a daily basis. The data of all participants will be handled confidentially. 
A subject identification code list will be used to trace data to an individual subject. The 
coordinating investigator will provide all data of subjects with a number that is not 
based on the patient’s initials and birth-date. The key to the code will be safeguarded 
by the coordinating investigator. All data will be stored for 15 years as required by law. 
 
Table 4. Brain MRI protocol 
Sequences 3D T1-weighted 
MP-RAGE 
Resting-state 
fMRI 
Diffusion 
tensor imaging 
B0 Field map 
Field of view (mm) 240x240 192x192 256x256 256x256 
Matrix 256x256 64x64 128x128 128x128 
Slices 231 40 66 66 
Inter-slicegap (mm) 0 0 0 0 
Voxel (mm3) 0.65×0.65×0.65 3x3x3 2x2x2 2x2x2 
TR/TE (ms) 12/3.3 2400/30 12000/56 660/4 
Flip angle 9° 90° 90° 80° 
B value (ms/mm2)  1000   
Nr of directions  32   
Nr = Number, fMRI = functional Magnetic Resonance Imaging 
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Power and sample size 
Power calculation was based on a standardised difference of 0.8 in HARS total score, 
with alpha set at 0.05 and power set at 0.80, and a predicted effect size of Cohen’s d 
(0.95), based on a previous RCT with CBT in PD23. The standardised difference is 
defined as the ratio of the difference of interest to the standard deviation in scores of 
the sample. The difference of interest was set 3 points on the HARS (being the 
difference in average scores between patients without anxiety and with mild anxiety2; 
standard deviation was estimated at 52, 23. Based on these quantities, the required 
number of patients to be included is 40 (20 per group). Including 30 patients per group 
would allow for a drop-out of approximately 30%. This is a conservative sample size 
calculation since, based on the only published RCT of CBT in depression in PD23, we 
expect that the effect size will be larger (>5 points) and drop-out will be lower (<10%). 
If subjects decide to leave the study prematurely they will not be replaced by new 
participants. The dropped out participants will be included in the analysis according to 
the intention-to-treat principle (ITT).  
 
No sample size calculation was made for the MRI analyses specifically, since 
longitudinal data to determine the sensitivity of different DTI parameters to change over 
time are lacking. However, taking the sample size of published studies in this area as 
reference32, 34, 58, 59, we expect to be overpowered for these analyses using the same 
sample size as for the analysis of clinical efficacy.  
 
Statistical analyses 
Unless indicated otherwise, analysis will be performed using IBM SPSS statistics 24.0, 
Stata 13, or more recent versions if available. Significance level of 0.05 will be used. 
The numerical variables will be described as means, median, standard deviations and 
ranges. Categorical variables will be described as frequencies and percentages. Data 
analyses of primary and secondary outcomes will be conducted using relevant 
univariate, multivariate and multilevel techniques.  
 
For the primary study parameter, between-group comparisons will be conducted on 
post-treatment data and 3 month follow-up data in order to compare within-subject 
changes in anxiety scores (HARS) relative to baseline between the intervention and 
control group. This will be done using separate repeated measures Analysis of 
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Covariance (rm-ANCOVA) for each of the two outcomes. Covariates include the use 
of benzodiazepines and antidepressants, Parkinson medication, which will be 
converted into levodopa equivalents using the algorithm of Tomlinson et al60, as well 
as significant differences in other relevant parameters.  
 
For the secondary parameters, between-group comparisons will be likewise conducted 
on post-treatment data and 3-months follow-up data to assess differences in changes 
relative to baseline between the intervention- and control group. To compare changes 
in anxiety scores and the secondary parameters between baseline and 66months 
follow-up in the intervention group, within-subject comparisons will be performed.  
 
For MRI scan analyses, between-group analyses using paired-sample and two-sample 
t-tests will be conducted to calculate differences in changes in cerebral connectivity 
pre- and post-intervention. Functional connectivity measures and graph topology 
indices will be extracted from rs-fMRI data61. Diffusion metrics (fractional anisotropy, 
radial and axial diffusivity) and structural connectivity computed from DTI data will be 
also used as descriptive variables in the statistical comparisons62.  
 
The economic evaluation will be performed following the Dutch guideline for economic 
evaluations in healthcare. The incremental cost-effectiveness ratio (ICER) will be 
calculated using standard unit price based costs in combination with the adapted RUD 
and EQ-5D-5L utility based QALYs. An ITT analysis, a 3-month time horizon and a 
societal perspective will be adopted. A bootstrap analysis will be used to reflect the 
uncertainty in this ICER.  
 
Drop-outs, missing values and adverse events 
Participants can leave the study at any time for any reason or no reason at all if they 
wish to do so without any consequences. The investigator can decide to withdraw a 
subject from the study for urgent medical reasons. If subjects decide to leave the study 
prematurely they will not be replaced by new participants. The dropped out participants 
will be included in the analysis according to the ITT. For the ITT analyses, missing 
values on the primary outcome will be imputed using multiple imputations. For this, ten 
imputed datasets will be generated using multivariate multiple imputation by chained 
equations (MICE)63 with demographic, clinical and baseline values of the primary 
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outcome as predictors of the missing outcome values as well as variables predicting 
missingness (e.g. age, illness severity, morbidity). This technique yields better (i.e. less 
biased) estimates for outcome analyses in RCTs than single imputation or complete 
case analysis with covariate adjustment for missingness, especially if data are not-
missing-at-random (i.e. missingness is related to unobserved variables)64. Subsequent 
analyses on imputed datasets will be performed in state 13 or higher65.  
 
Adverse events are defined as any undesirable experience occurring to a subject 
during the study, which may or may not be related to the trial procedure or experimental 
intervention. All spontaneously reported study-related adverse events by the subject 
or observed by the investigator or his staff will be recorded according to section 10, 
subsection 1 of the Dutch Research Involving Human Subjects Act (WMO). In case of 
a serious adverse event the sponsor, the Ethics committee and other relevant 
authorities such as the principal investigator and Toetsingonline will be notified 
immediately. A liability insurance which is in accordance with the legal requirements in 
the Netherlands (Article 7 WMO) and France has been signed. 
 
Medication adjustments 
Preferably, Parkinson medication is kept stable during the study. Nonetheless, if 
medication changes are presumed necessary by the treating neurologist, they are 
allowed to do so. Any changes in medication will be tracked during the intervention 
period and follow-up moments. Psychopharmacotherapy is allowed if, by the start of 
the study, a stable dose is used at least 2 months prior to participation and the patient 
still meets the inclusion criteria.  
 
Ethical approval, trial registration and monitoring 
The study is carried out in compliance with the Helsinki Declaration. The local ethics 
committee of Maastricht University Medical Centre (July, 2016) and Lille University 
Hospital (September, 2016) have approved the study protocol. Written informed 
consents will be obtained from all participants. The study is registered at the 
ClinicalTrials.gov database under registration number NCT02648737, as well at 
FoxTrialFinder under ID number 004701. The study will be monitored in both centres 
by Clinical Trial Center Maastricht according to the international ICH-GCP guidelines. 
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DISCUSSION 
The overall aim of this open, two-centre RCT is to evaluate the clinical effectiveness of 
a CBT module for the treatment of anxiety in patients with PD and provide additional 
information on cost-effectiveness and the underlying changes in functional and 
structural brain connectivity that occur during this treatment. The treatment module is 
specifically designed to serve the needs, concerns, and circumstances of PD patients 
with anxiety and is based on the knowledge and experience of PD experts. CBT will, if 
proven effective, provide PD patients with behavioural and anxiety management 
techniques that may give lasting benefits on anxiety symptoms, well-being, quality of 
life, and possibly on motor symptoms. In this multinational RCT design patients are 
recruited in two countries at both outpatient clinics and informal meeting points for PD 
patients. This way of recruiting facilitates generalizability, as a broader range of 
patients can be reached instead of solely patients with more severe PD symptoms that 
come from the Movement Disorders Clinics. 
 
While most studies investigating brain alterations following psychotherapeutic 
interventions use functional imaging methods, only few have examined structural brain 
correlates of CBT30, 31, 34. One study using structural and diffusion MRI measures 
observed reductions in parieto-occipital and prefrontal grey matter volumes, increases 
in fractional anisotropy in two anxiety-related white matter fiber tracts, as well as 
increases in structural connectivity in a frontolimbic network following a 10-week group-
based CBT protocol for SAD patients34. Albeit in the absence of a control group and in 
a different patient population, this study provided insight into how the brain adapts to 
psychotherapeutic treatments. Our study is the first one that aims at assessing both 
functional and structural brain alterations following CBT in PD patients using different 
MRI modalities, such as rs-MRI and DTI, in the presence of a control group. Therefore, 
this study has an additional value to earlier CBT trials in PD patients23, 26, 28, as it may 
provide increased understanding of the underlying biological mechanisms of both 
anxiety and response to treatment in PD patients. Moreover, it can provide additional 
insight into whether CBT effects differ between different anxiety disorders and patient 
populations. 
 
There are, however, also some limitations in this study design. Firstly, the follow-up 
duration of 3 months is relatively short to evaluate the long-term benefits of the CBT 
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treatment. However, we agreed it was ethically not acceptable to deny the control 
group CBT treatment for a period longer than 6 months following the start of the 
intervention. Alternatively, we added an additional follow-up moment (t = 3) for patients 
randomised to the intervention group 6 months after the CBT treatment, which will give 
the possibility to study within-subject changes over time and provide insight into long-
term benefits of the CBT treatment. Secondly, although there are no major risks 
associated with participation in the CBT intervention, participating in the study can be 
time-consuming and demanding for participants, especially considering the relatively 
high health care utilisation in PD patients. Some PD patients might not be able to travel 
independently and have to rely on others, such as partners, family members, friends 
or other caregivers. These factors make inclusion and treatment adherence 
challenging. We discussed the feasibility of the number of sessions in multiple PD 
focus groups and none of the participants, neither in the Netherlands nor in France, 
perceived the frequency of the sessions as too burdensome or as a reason not to 
participate. In case medical or other practical reasons hinder participants to visit the 
outpatient clinic, the therapist can visit the participant at the site where the participant 
resides. We do not expect this to influence the treatment. Thirdly, with the involvement 
of different therapists, there is a risk of therapist effects, which refers to the tendency 
of different therapist to obtain differential symptomatic change in the patients66. 
However, all of our therapists have received appropriate training, and a detailed 
treatment protocol and therapist manual have been developed, which has shown to 
minimise therapist effects67, 68. Despite our efforts to standardise the intervention as 
much as possible, the involvement of a caregiver during the CBT intervention might 
likewise moderate treatment outcome as it is optional and not necessary for 
participation in the study. The purpose of their attendance is primarily to offer 
caregivers the opportunity to learn about the treatment in which the participant is 
involved and to explore strategies through which they can support the participant if 
necessary. This can vary from motivating the participant to do the home assignments 
up to assisting them to fill out the worksheets in case physical reasons make this 
difficult. The caregiver attendance is limited to three educational sessions. 
 
In conclusion, this low risk intervention study has great relevance for clinical practice. 
It evaluates the clinical effectiveness of a CBT module for anxiety in PD and contributes 
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to a better understanding of the underlying biological mechanisms of anxiety in PD. 
Inclusion started March 2017 and we aim to complete the study in 2019. 
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In recent years, advances in both neuroimaging and electrophysiological techniques, 
as well as clinical experience, have resulted in new insights into the neural 
mechanisms underlying neurological and psychiatric disorders. Many findings have 
indicated associations between a dysfunction of cortico-basal ganglia-thalamocortical 
circuits and several motor, psychiatric, and cognitive symptoms that are often comorbid 
and trans diagnostic. The cortico-basal ganglia-thalamocortical circuits involve a series 
of parallel, partially segregated and integrated loops, including the motor circuits, 
involved in control of motor programmes, the dorsolateral prefrontal circuit, involved in 
associative and cognitive functions, and the orbitofrontal and anterior cingulate circuits, 
involved in limbic control and motivated behaviour1, 2. In this thesis, we studied two 
disorders that are linked to alterations in cortico-basal ganglia-thalamocortical circuits: 
Parkinson’s disease (PD) and obsessive-compulsive disorder (OCD).  
 
PD and OCD have several theoretical and clinical similarities. First of all, deep brain 
stimulation of the subthalamic nucleus (STN-DBS) is a neurosurgical treatment for both 
PD and OCD. Second, obsessive symptoms and traits are not uncommon in PD3, and 
patients with a longer disease duration have been found to have more severe 
obsessive-compulsive symptoms3, 4. Third, both PD and OCD are associated with 
cognitive rigidity, referring to the tendency to develop and perseverate in particular 
cognitive or behavioural patterns, even when, based on task-relevant information in 
the environment, that pattern is no longer effective5, 6. The cortico-basal ganglia-
thalamocortical circuits are believed to constitute the neural substrate of intact 
cognitive flexibility7. Fourth, at the phenotype level, both PD and OCD may be 
characterised by trans diagnostic mood symptoms, such as anxiety. A challenge is to 
find common and distinct neurobiological correlates of neuropsychiatric symptoms that 
are related to alterations to the above-mentioned circuits and to improve our 
understanding of the underlying neural mechanisms. DBS studies may help in studying 
dysfunctional brain circuits and their relation to the occurrence of emotional and 
cognitive symptoms. The first part of this thesis was aimed at increasing our 
understanding of the role of the STN in OCD symptomatology (Chapter 2 and 3), and 
to study underlying mechanisms of emotional and cognitive side-effects following STN-
DBS in PD (Chapter 4 and 5) based on observations from DBS studies.  
 
 
219 
 
The second part of this thesis focused on mood symptoms in PD. Mood symptoms, 
such as anxiety, can be very distressing to patients and may worsen motor symptoms 
or be perceived as more disabling than motor symptoms. Both mood symptoms and 
motor symptoms can fluctuate over the course of the day and are difficult to measure 
with routine cross-sectional assessments that are used in movement disorder clinics. 
Therefore, not much is known about the relationship between mood and motor 
fluctuations8, which makes treatment of these symptoms challenging. Moreover, there 
is currently no evidence-based treatment available to treat anxiety in PD. We aimed to 
explore the usability of the experience sampling method (ESM) in PD in studying 
associations between motor and mood symptoms in patients who suffer from motor 
fluctuations (Chapter 6 and 7). Finally, we aimed to develop a treatment module for 
anxiety in PD that is supported by the knowledge of the underlying aetiology and 
correlations of anxiety in PD (Chapter 8 and 9). The current chapter discusses the 
interpretation of the main findings, their scientific and clinical implications, as well as 
methodological considerations.  
 
Main findings part 1: DBS studies in OCD and PD 
The role of the STN in OCD circuitry 
In chapter 2 we performed a review of the functional role of the STN in the 
pathophysiology of OCD by integrating electrophysiological findings from STN-DBS 
studies in OCD as well as neuroanatomical information. Although literature on the role 
of the STN in OCD circuitry and its pathophysiological mechanisms is limited, recent 
findings are indicative of an electrophysiological dysfunction in the associative and 
limbic (i.e. non-motor) parts of the STN9. Compared to PD patients, STN neurons in 
OCD exhibit a lower firing rate, less frequent but longer bursts, increased burst activity 
in the anterior ventromedial area, an asymmetrical left-sided burst distribution, and a 
predominant oscillatory activity in the δ-band9, 10. Moreover, there is direct evidence for 
the involvement of the STN in both checking behaviour and OCD symptoms, which are 
both related to changes in electrophysiological activity in the non-motor STN9, 11. STN 
dysfunction seems to cause a disruption of information processing of associative and 
limbic processes, hence leading to obsessions and compulsions10, 11. These findings 
are in line with proposed models of decision-making and action-selection. These 
models suggest a key role for the STN through its central position within the cortico-
basal ganglia-thalamocortical circuits on one hand, and because of the integration of 
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multiple streams of information from the environment believed necessary for 
establishing priorities for action-planning and potential behaviour, as well as for the 
coordination of action, stream of thoughts and motivation12. We believe that through a 
combination of mechanisms, STN-DBS interrupts the disturbed information-processing 
that seems responsible for the pathological repetitive behaviours characteristics for 
OCD by restoring the imbalance between direct and indirect pathways, resulting in 
normalisation of connectivity within the cortico-basal ganglia-thalamocortical circuits, 
and consequently to a reduction in symptoms13. 
 
While the above findings suggest the STN to be a promising mechanism-based target 
for OCD, in Chapter 3 we present a case in which DBS programming of the STN turned 
out to be challenging. A patient with a 30-year history of treatment-refractory OCD 
underwent anteromedial STN-DBS. Despite a clear mood-enhancing effect, 
stimulation at voltages greater than 1.5 V caused severe and persistent motor side-
effects that resembled chorea and ballism. The aim of DBS is to tailor treatment on a 
patient-specific basis to deliver optimal therapeutic effects while avoiding stimulation-
associated side effects14, 15. While the underlying mechanisms and pathophysiology of 
DBS-induced motor side-effects are not well understood, we have listed several 
potential causes for the observed side-effects. Firstly, it is possible that STN-DBS 
resulted in an increase in striatal dopamine release and, subsequently, in 
hyperdopaminergic behaviours, such as dyskinesia. Second, due to individual 
differences in the structural and functional anatomy of STN subdivisions, it is possible 
that, although the anteromedial part of the STN was targeted, this part did not 
constitute the non-motor portion of the STN in our patient. Consequently, motor side-
effects may have developed either directly by stimulation of the motor portion of the 
STN or indirectly by current spreading of contact points in close proximity to the motor 
portion of the STN. Because in the present case the side-effects made optimal DBS 
programming impossible, the patient underwent stereotactic reimplantation of the 
electrodes at the Ventral Capsule / Ventral Striatum (VC/VS) region, with the deepest 
electrode contact point in the area of the Nucleus Accumbens (NAc), which resulted in 
a reduction of 50% in OCD symptoms two years following surgery. 
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Underlying mechanisms of emotional and cognitive side-effects of STN-DBS in PD 
patients 
Despite optimal improvement in motor functioning following STN-DBS in PD patients, 
there have been reports on the occurrence of neuropsychiatric, behavioural and 
cognitive changes after surgery. The underlying mechanisms contributing to changes 
in mood, behaviour and cognition following STN-DBS in PD are not well understood. 
Experimental studies have found substantial disturbance and inhibition of 5-HT 
neurotransmission during STN-DBS16, 17 and evidence for a STN- lateral habenula – 
dorsal raphe nucleus network, which modulates 5-HT function and behaviour that 
reflect key symptoms of depression18. Moreover, depression has generally been 
associated with a dysfunction of the 5-HT neurotransmitter system. Because 
depression is more frequent in PD patients compared to the general population19, and 
PD has been associated with changes in 5-HT20, we hypothesised that PD patients 
have a 5-HT vulnerability that, in combination with a decrease in 5-HT transmission 
elicited by STN stimulation, may increase susceptibility to develop depression and 
other psychiatric problems following STN-DBS.  
 
In Chapter 4 we aimed to study the role of 5-HT on mood and behaviour in PD patients 
with STN-DBS in a double-blind, placebo-controlled crossover study by temporarily 
reducing the level of available 5-HT in the brain by means of acute tryptophan depletion 
(ATD). Participants were tested in DBS-ON and DBS-OFF condition. We hypothesised 
that ATD in combination with STN-DBS (DBS-ON) might lead to lower mood, and other 
behavioural changes such as reduced inhibitory control and deficits in emotional 
processing. Due to lagging inclusion, the study was terminated after including 7 
patients. In these 7 patients, we found that 5-HT manipulation by ATD did not lead to 
dissociable effects on mood, emotional processing and inhibitory control. In fact, for 
the main outcome measure mood, we observed effects in opposite direction of what 
was hypothesised. Instead of a decrease in total mood disturbance, we found an 
increase in total mood disturbance in DBS-OFF condition. The return of motor 
symptoms as a result of switching the stimulator off turned out to be emotionally 
overwhelming for participants, which in turn masked possible subtle differential effects 
that ATD might have had on mood. Overall, apart from recruitment difficulties, we 
concluded that the study was not feasible due to the great patient burden of stopping 
the DBS stimulation, and that continuation would be ethically unacceptable, as any 
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further results that might have been found would not be in proportion to the difficulties 
and risks imposed on the research participants. While the findings of the study suggest 
that psychiatric side-effects following STN-DBS in PD patients cannot be directly linked 
to a reduction in 5-HT activity, these results should be interpreted with caution due to 
the small sample size.  
 
Besides mood, emotional processing and inhibitory control, we aimed to study 
underlying mechanisms of changes in cognition following STN-DBS in PD. Research 
on the factors contributing to cognitive changes following surgery have led to 
inconsistent findings. It has been proposed that surgical factors, such as cortical and 
subcortical lesions due to the lead trajectory, may contribute to cognitive changes 
following STN-DBS. In Chapter 5 we studied whether characteristics of the surgical 
trajectory, including the number of microelectrode recording (MER) trajectories, the 
STN length as measured by MER, and cortical entry points (sagittal and coronal 
angles) were associated with cognitive decline one year after surgery. We found a 
significant decline in a number of tests for executive function one year postoperatively, 
including a decline in verbal fluency, performance on the Stroop Colour-Word test and 
the Trail Making Test-B (TMT-B). Changes in TMT-B were associated with the coronal 
entry point in the right hemisphere. However, only 5 patients showed clinically relevant 
cognitive decline in TMT-B performance. No associations were found between the STN 
length or the number of MER passes and changes in neuropsychological functioning. 
This suggests that, from a cognitive point of view, the use of MER does not seem to 
impose an increased risk of decline one year following surgery. Whereas the electrode 
passage through the right prefrontal lobe may contribute to subtle changes in executive 
function, only few patients showed clinically relevant cognitive decline.  
 
Scientific and clinical implications part 1 
The development of DBS has opened new opportunities to access and interrogate 
dysfunctional brain circuits. Recording the electrical activity of the STN during DBS, 
testing its therapeutic potential of regulating the behavioural outcome of malfunctioning 
circuits, but also the occurrence of (unexpected) mood, cognitive and motor outcomes, 
have contributed to a better understanding of the functional role of the STN in the 
context of PD and OCD.   
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The findings from the OCD studies are consistent with the idea that OCD can be 
regarded a ‘circuit’ disorder. The observation that DBS of different structures along the 
proposed dysfunctional circuit (STN and VC/VS) can be effective in reducing obsessive 
and compulsive symptoms in the same patient seem to confirm this, and is consistent 
with findings of similar percentages of improvement following DBS in different target 
areas14, 15. Moreover, it is in line with theories suggesting that the mechanisms of DBS 
can be viewed from a network perspective, where DBS has effects on the target 
structure itself, but also on distal structures through disruption of disturbed information-
processing within the network21. Recently, new studies have emerged that reported 
changes in neurophysiological activity throughout the VS22 and STN23 following 
provocation of obsessions. In the latter study, the ventro-medial STN of OCD patients 
showed distinct theta oscillatory activity that decreased following provocation of OCD 
symptoms and was inversely correlated with symptom severity over time23. Identifying 
regions of distinct, and possibly unique, activity related to symptoms contributes not 
only to an increased understanding of the neural pathways involved in symptoms, but 
might also be used by neurosurgeons to ensure accurate surgical placement of the 
leads and careful programming to achieve maximal therapeutic effect. Ideally, with 
increased knowledge on the different target structures, their clinical efficacy, as well as 
adverse side-effects, clinicians may choose between several target areas in the future, 
depending on the main symptom targeted and the risk profile of the patient. Moreover, 
an individualised, patient-specific selection method based on, for example, 
preoperative diffusion-weighted imaging and tractography and functional MRI may 
improve DBS targeting. 
 
Concerning the DBS studies in PD, we did not find evidence for a role of the 5-HT 
neurotransmitter system in the occurrence of psychiatric side-effects following STN-
DBS as was reported by experimental studies16, 17, 24. While the findings from our study 
should be interpreted with caution due to methodological issues, it is also possible that 
the preclinical model used in experimental studies may not be an ideal model to study 
human PD and changes in 5-HT neurotransmission. There is evidence of a different 
neurophysiology of the 5-HT receptor system in animals25. Moreover, while most 
preclinical models use acute dopamine lesion models, the degenerative process in 
humans is already present years before the first symptoms emerge, which might lead 
to adaptive processes that are not present in animals25, 26. Studying whether STN-DBS 
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results in a decrease in 5-HT in PD patients, e.g. by studying 5-HT in cerebrospinal 
fluid before and after surgery, might be a valuable intermediate translational step when 
studying the effect of STN-DBS on 5-HT and related behaviour.  
 
Consistent with previous studies we found significant changes in executive function 
tests one year following surgery. Except for an association between the right coronal 
angle and changes in TMT-B, we found no associations between the number of MER 
trajectories used during surgery and the STN length as measured by MER. This finding 
is important for neurosurgeons, as it indicates that they do not have to be restrained 
by fear of cognitive side-effects when attempting to have more possibilities for 
postoperative stimulation parameters adjustments by the use of (multiple) MER. The 
angle of approach, however, might contribute to subtle dysfunction. While we cannot 
draw any conclusions about causality, and changes in cognition following STN-DBS 
are likely to be multifactorial, this finding warrants further research. Preferably, all 
factors contributing to cognitive decline following surgery, including patient inherent 
characteristics, as well as stimulation and surgical characteristics, should be integrated 
in future studies. Machine learning might be a promising tool to investigate the complex 
interplay between these factors in predicting which patients are at risk to show 
cognitive decline following STN-DBS. However, large sample sizes are required and 
while data sharing and multicentre studies could improve power, the interpretation of 
findings could be complicated by different neurosurgical approaches between centres 
to target the STN. Importantly, changes in cognitive decline were based on 
neuropsychological test performance and do not necessarily translate into impairment 
in daily activities. Only few patients showed clinically relevant decline following surgery, 
which seems to indicate that from a cognitive point of view, DBS is a relatively safe 
procedure.   
 
Main findings part 2: mood symptoms in PD 
 
The usability of ESM in PD  
Up to 50% of  PD patients develop motor fluctuations after long-term treatment with 
levodopa. Such fluctuations in motor symptoms are often accompanied by distressing 
mood fluctuations, such as fluctuations in anxiety and depressive symptoms8, 27. 
Research involving mood fluctuations, their underlying mechanisms, and their 
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relationship with motor fluctuations has so far led to inconsistent results8. Chapter 6 
aimed to explore whether it is possible to identify longitudinal associations between 
motor symptoms and mood states in a PD patient with motor fluctuations using ESM, 
and to generate a symptom network of these associations. ESM includes multiple 
short, repeated, within-subject assessments at random moments during the day that 
can include motor symptoms, mood states and contextual factors. In an n=1 study, a 
53-year old PD patient collected ESM data for 34 consecutive days. A set of dependent 
variables included several motor symptoms, on/off state, and the mood variables 
anxiety, cheerful and down. Network analyses revealed moment-to-moment variability 
and prospective associations between motor and mood states. The variables anxiety 
and cheerful appeared to play a more important role than the variable down, because 
they had stronger associations with several motor symptoms, including tremor and 
rigidity. These results suggest that affect plays an important role in the way motor 
symptoms are perceived.  
 
In routine patient care much briefer ESM sampling periods are commonly used, since 
longer periods are considered burdensome for patients. In Chapter 7 we aimed to 
explore the usability of routinely collected ESM data over a brief period of time in PD 
patients, and to explore the sensitivity to detect associations between mood states, 
contextual factors, motor symptoms and motor state on both a group and individual 
level. Eleven PD patients with motor fluctuations collected ESM data for five 
consecutive days. On a group level, ESM was able to identify clear associations 
between affective state, contextual factors and motor symptoms. Regardless of 
whether a patient was in an ‘on’ or ‘off’ state, higher scores on positive affect were 
associated with lower self-perceived severity of tremor, rigidity, balance problems and 
walking problems. Negative affect was not associated with any of the motor symptoms. 
These findings are in line with the results from the network analysis described in 
chapter 6, in which feeling down did not influence motor symptom severity, while 
cheerfulness was significantly associated with lower scores for tremor and rigidity. 
Although we were able to display moment-to-moment fluctuations in mood and motor 
symptoms in individual patients, analyses on an individual level revealed much less 
significant associations that mostly, but not always, were in line with the group level 
analyses. We think the most likely explanation for the failure to identify significant 
associations between symptoms in individual patients is lack of power.  
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Treatment of anxiety in PD 
Anxiety is a common problem in PD and results in reduced quality of life. At present, 
there is no evidence-based treatment available for anxiety in PD. Anxiety in PD is often 
the result of a complex interaction between physiological and psychological factors. 
Given this complexity, psychotherapeutic treatment of anxiety requires adaptations 
tailored to the specific needs of PD patients and supported by knowledge of the 
underlying aetiology of PD28. Chapter 8 presents the rationale and methodology of a 
two-centre randomised controlled trial (RCT) aimed at studying the clinical 
effectiveness, cerebral correlates, and cost-effectiveness of a specialised cognitive-
behavioural therapy (CBT) programme for anxiety in PD. PD patients with anxiety and 
their caregivers (optional) were randomised to CBT and clinical monitoring 
(intervention group) or clinical monitoring only (control group). All participants 
underwent standardised clinical, cognitive and behavioural assessment at baseline 
(t0), at the end of the intervention (t1) as well as 3 months after the intervention (t2). 
Moreover, participants randomised to the intervention group received an additional full 
assessment at 6-months follow-up (t3). At t0 and t1 participants underwent Magnetic 
Resonance Imaging scanning. The duration of the intervention was 10 to 12 weeks.  
 
Chapter 9 reports the development and content of the CBT programme. Focus group 
interviews were used to explore the needs and wishes of PD patients (and their 
caregivers) who suffer from anxiety with respect to the treatment of anxiety. During 
these focus group interviews, the following topics were discussed: (1) former 
experiences with CBT or other psychotherapeutic interventions; (2) content of the 
therapy sessions and relevant themes; (3) structure of the therapy sessions, including 
the number of sessions and the duration of each session; (4) home assignments; (5) 
potential (practical) barriers of undergoing CBT, and (6) caregiver participation. Based 
on the focus group interviews we made several adjustments. The final programme 
addresses (but is not limited to) anxiety symptoms that can be considered more or less 
specific for Parkinson patients, such as ‘wearing off’ anxiety, fear of falling or feeling 
judged by others in social situations. The CBT programme provides a range of 
cognitive and behavioural skills, including psycho-education, relaxation techniques, 
cognitive restructuring, problem solving, exposure, personal habits and self-
management, that can help patients in the process of adjusting to current and future 
impairments and changes, and empower patients to build confidence in their capacity 
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to deal with them. We developed a workbook for patients and a treatment manual for 
therapists, in which possible challenges during treatment are discussed, such as the 
uncertainty about disease progression, cognitive deficits, and barriers to continue the 
therapy programme and do the home assignments.  
 
Recently, we completed the final follow-up assessment of the RCT. In total, we 
included 48 PD patients. Of these, 24 were randomised to the intervention group and 
24 to the control group. Two patients, of which one was randomised to the intervention 
group and one to the control group, dropped out of the study during the intervention 
period. In between the first (t1) and second (t2) follow-up assessments, two more 
patients dropped out of the study, again one randomised to the intervention group and 
one patient randomised to the control group. Thus, a total of 46 patients completed the 
first follow-up and 44 patients completed the RCT. We are currently analysing the 
clinical and cost-effectiveness of the study, as well as changes in cerebral connectivity 
following CBT.   
 
Scientific and clinical implications part 2 
ESM allows for a more naturalistic and reliable assessment of fluctuating symptoms 
which may help in achieving optimal symptom control. While we were able to reveal 
statistically significant prospective associations when ESM data was collected for a 
longer period of time (chapter 6), ESM data collection as used in chapter 7 was 
apparently not sensitive enough to detect within-person associations. The sensitivity 
may be increased by collecting data over a longer period of time as shown in the n=1 
study, by increasing the compliance or by making the answers more sensitive to 
change (e.g. by increasing the number of potential scores on the Likert item or by using 
visual analogue scale scores). The ultimate goal is to use ESM in a non-burdening way 
in routine patient care as a tool to facilitate patient self-monitoring and as a guidance 
for clinicians for (personalised) treatment. There is an urgent need for harmonisation, 
validation and optimisation of this technique, since ESM will likely have a more 
important role in future studies as well as in clinical practice. ESM data may serve, for 
example, as a parallel ground truth to objective data, such as obtained by monitoring 
motor symptoms by wearable sensors29, since these alone may not be representative 
for the disease burden or experienced disability. In addition, combining objective and 
subjective data on motor and non-motor symptoms can potentially be used as input 
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signal for adaptive (or closed-loop) DBS29. Adaptive DBS aims to automatically adapt 
stimulation parameters to the fluctuating clinical state of the patient, where stimulation 
is only provided when necessary30. The idea is that adaptive DBS results in fewer 
stimulation-induced side-effects compared to conventional DBS.  
 
Finally, both ESM studies highlight the role of positive affect on self-perceived severity 
of motor symptoms. Since most studies in PD have focused on the role of negative 
mood states in relation to motor symptoms, we believe that it is necessary to include 
positive affect in the design of future studies. Moreover, enhancing the frequency and 
persistence of positive affect in daily life might be a promising adjunctive non-
pharmacological target for reducing the burden of motor fluctuations and increasing 
quality of life.   
 
Interestingly, besides reductions in negative affect, CBT for anxiety has been 
associated with improvements in positive affect31. While we are still awaiting the final 
results of the RCT investigating the effects of CBT for anxiety in PD, this study has, if 
proven effective, great relevance for clinical practice. It provides PD patients with 
behavioural and anxiety management techniques that may help them in dealing with 
current anxiety or new (disease-related) problems that can cause anxiety in the future. 
In addition, it may give lasting benefits on well-being, quality of life, and possibly on 
motor symptoms. It would be the first evidence-based treatment available for anxiety 
in PD. The manual for therapist describes the structure and content of the therapy in 
detail, and addresses several PD specific challenges that may occur during the course 
of CBT. Besides clinical and cost effectiveness, future studies could study the impact 
of CBT on different types of symptoms of anxiety.  
 
METHODOLOGICAL CONSIDERATIONS 
Methodological considerations, as well as strengths and limitations of the research 
presented in this thesis will be discussed in the following section.  
 
Study designs 
Multiple study designs were used in the studies presented in this thesis. The review in 
chapter 2 that described and discussed the state of the science regarding 
neuroanatomical and electrophysiological findings from DBS studies regarding the 
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functional role of the STN in relation to OCD symptomatology, is a narrative review. 
Selection bias may occur since it does not use a predetermined structured method to 
search, select, appraise and summarise study findings, as is being done in a 
systematic review32. For that reason, systematic reviews are often favoured over 
narrative reviews. One of the reasons for performing a narrative review rather than a 
systematic review was the recent publication of a systematic review and meta-analysis 
on DBS in different target areas for OCD15. While the systematic review provided 
valuable information of the treatments effects of DBS in OCD, it does not contribute to 
the understanding of how stimulation of a specific target area results in a reduction in 
OCD symptoms, and the involvement of that area in the pathophysiology of the 
disorder. The strength of our review is that it contributed to an increased understanding 
of the functional role of the STN in OCD symptomatology from a theoretical and 
contextual point of view. From this perspective, we believe that our review served a 
different purpose and should be seen as complementary to the available systematic 
reviews.  
 
In chapter 4 a randomised placebo-controlled, cross-over design was used, in which 
both the participant and researcher were blinded for the intervention (ATD or placebo 
mixture). Patients were tested in four different conditions: placebo + DBS-ON, Placebo 
+ DBS-OFF, TRP depleted + DBS-ON and TRP depleted + DBS-OFF. Crossover 
designs require fewer patients to be included due to increased power. Moreover, a 
wash-out period controlled for carry-over effects. However, a limitation of the design 
was that it required patients to be available for two full days. Moreover, due to the 
vulnerability of the research population we used strict in- and exclusion criteria. We 
experienced recruitment difficulties due to these requirements, which might have 
induced selection bias. Moreover, we underestimated the emotional impact of turning 
the stimulator off which not only influenced our results, but made participating in the 
study increasingly burdensome for patients. We had to conclude that the study was 
not feasible and continuation was ethically debatable. Turning the stimulator off is not 
uncommon for scientific purposes. Based on our findings, we argue that the emotional 
impact of being confronted with motor symptoms after turning the stimulator off should 
always be taken into account when designing a study and when interpreting its results. 
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The retrospective study described in chapter 5 allowed to examine data from routine 
clinical care. Unfortunately, due to uncontrollable factors such as differences in follow-
up time (e.g. neuropsychological assessment was performed at 18 months instead of 
12 months following surgery), many participants had to be excluded, resulting in a 
smaller sample size and, subsequently, reduced power.  
 
In chapter 6 we used an n=1 design of ESM data collected for a longer period of time 
(34 days), and in chapter 7 we used group vs. individual analyses of ESM data 
collected for a brief period of time (5 days). Group analyses may reveal population 
based patterns that may lead to more general treatment or research recommendations, 
such as studying the role of positive affect on the way motor symptoms are perceived, 
while individual analyses can be used to establish a personalised treatment plan33. 
While the results from the n=1 study and individual analyses cannot be generalised, 
they are very relevant for clinical practice. Using different study designs provided 
valuable information of the potentials of ESM in clinical practice, as well as flaws that 
still require improvement.  
 
In chapter 8 we describe the rationale and methodology of a two-centre RCT to test 
the clinical effectiveness of the treatment programme we developed for anxiety in PD. 
RCTs are considered the gold standard for providing convincing evidence. However, 
dropout in longitudinal RCTs is common and might threaten the validity of the results, 
especially when dropout rates are different between study groups. Possibly, patients 
assigned to the control group might drop out because they want/require immediate 
treatment for their anxiety symptoms. To prevent dropout, and because we found it 
ethically not favourable to have patients wait for a period longer than 6 months after 
the start of the study, we decided to have the last follow-up assessment 3 months 
following the end of the intervention. Since we are aware that 3 months follow-up time 
is short to draw conclusions regarding the long-term effectiveness of the treatment, we 
included a 6 months within-subject follow-up assessment for the patients who were 
randomised to the intervention group. 
 
Approaches to data-analysis 
All statistical approaches were carefully chosen in line with the research question 
posed. Besides descriptive statistics, t-tests, Wilcoxon-rank order tests, multiple 
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regression and repeated measures analysis of covariance (rm-ANCOVA), we also 
used more advanced statistical analyses, such as network analysis, multilevel linear 
regression analyses and permutation testing. An important limitation of the presented 
studies and data-analysis approaches is that we were not able to draw conclusions 
regarding causality.  In chapter 4, we used rm-ANCOVA. Given the small sample size, 
the results from this analysis should be interpreted with caution. In chapter 5, when 
comparing pre- and postoperative performance on neuropsychological tests, we did 
not correct for multiple comparison in order to reduce the risk of type II error given the 
importance of detecting any adverse effects of surgery. In chapter 6 and 7 we added 
an extra variable to control for time trends to all regression models. Given the 
exploratory nature of the study described in chapter 6, we did not control for multiple 
comparisons. In chapter 7, we experienced convergence issues after running the 
regression models. Moreover, the assumption for normality was not met for all 
variables. To overcome these limitations and obtain valid and interpretable results, we 
performed permutation testing.  
 
Interventions and measurement instruments 
The study in chapter 4 used the acute tryptophan depletion (ATD) paradigm to study 
the effects of a temporarily reduction of the level of available serotonin (5-HT) in the 
brain on mood, emotional processing and inhibitory control. While the ATD paradigm 
is a popular method to study the effects of low 5-HT in humans, there is some 
controversy about the extent to which ATD alters 5-HT function (see34 for a review on 
ATD in humans). One of the most important limitations of ATD is that 5-HT depletion 
cannot be localised to particular regions in the brain34, which might not only impact the 
effect of ATD on different outcome parameters, but makes it difficult to mimic STN-
DBS induced 5-HT changes as observed in experimental studies. Moreover, studies 
have found that in many circumstances, ATD does not lower mood and the 
mechanisms of these differential effects are currently unknown34. It means that the 
results from a tryptophan depletion study should be interpret with caution.  
 
In chapter 6 and 7 we used ESM to study associations between mood and motor 
symptoms and contextual factors in PD. ESM allowed us to measure the subjectively 
perceived severity of fluctuating mood and motor symptoms, which are usually not 
captured by routine cross-sectional assessments that might cause response bias. 
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Combining ESM with wearable sensor data to objectify the motor symptoms could 
improve the validity of the method. Moreover, in both studies we experienced that 
assessments in off-state were limited, which reduced the power when analysing the 
modifying role of motor state on the associations between motor and mood states. An 
alternative is to programme the assessments at fixed times or to ask the patient to only 
answer the questionnaire when being off. However, this prevents capturing the 
fluctuating nature of symptoms. Moreover, reactivity due to predictability may occur, 
which can induce behavioural changes33.  
  
CONCLUDING REMARKS 
With this thesis we provided small pieces of the puzzle regarding the functional role of 
the STN in the pathophysiology of OCD, and of factors that may (or may not) contribute 
to changes in mood and cognition following STN-DBS in PD patients. Moreover, we 
showed that ESM is a promising method to study associations between motor and 
mood symptoms in PD patients. We provided recommendations to improve the 
sensitivity of the method in order to be a potential instrument to use for personalising 
treatment in routine patient care. Finally, we developed a treatment programme for 
anxiety in PD, which is currently underdiagnosed and undertreated. We do not at this 
time have the final results of the RCT investigating the clinical and cost effectiveness 
of the programme, however, preliminary analysis (not included in this thesis) showed 
promising results. While more research is needed in the topics of this thesis, I believe 
that our findings contribute to improved patient care and eventually to an increase in 
quality of life of patients with OCD and PD.  
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Neuropsychiatric symptoms are associated with a dysfunction of cortico-basal ganglia-
thalamocortical circuits and include a broad range of psychiatric symptoms, such as 
depressive mood, euphoria, agitation and aggression, anxiety, sleep disturbance and 
disinhibition, and frequently occur in neurological, neurodegenerative, and psychiatric 
disorders. The basal ganglia are a group of interconnected sub-cortical nuclei and 
consist of the caudate nucleus, putamen, pallidal complex, nucleus accumbens, 
substantia nigra (pars compacta and reticulate) and the subthalamic nucleus (STN). In 
this thesis, we studied two disorders that are linked to alterations in cortico-basal 
ganglia-thalamocortical circuits: Parkinson’s disease (PD) and obsessive-compulsive 
disorder (OCD).  
 
PD is a common neurodegenerative disorder with an estimated prevalence of 1-2% of 
the population of 65 years and older. Apart from the classical motor symptoms, such 
as resting tremor, rigidity, bradykinesia, and postural instability, many PD patients 
suffer from neuropsychiatric symptoms such as depression and anxiety. OCD is a 
neuropsychiatric disorder characterised by chronic intrusive and distressing thoughts 
or impulses (obsessions) and repetitive and ritualistic thoughts or mental acts 
(compulsions). Deep brain stimulation of the STN (STN-DBS) is a neurosurgical 
treatment for both PD and OCD. The first part of this thesis was aimed at increasing 
our understanding of the role of the STN in OCD symptomatology based on 
observations from DBS studies, and to study underlying mechanisms of emotional and 
cognitive side-effects following STN-DBS in PD. The second part of this thesis focused 
on mood symptoms in PD and aimed at studying the relationship between mood and 
motor symptoms in PD, and to develop a psychotherapeutic treatment programme for 
anxiety in PD.  
 
Chapter 1 is a general introduction into the theme and aims of this thesis. It provides 
information about PD and OCD, (neuropsychiatric) symptoms, treatment including 
DBS, as well as the research questions and outline of this thesis.  
 
Part 1 
Chapter 2 provides a narrative review on the functional role of the STN in OCD. By 
reviewing the literature of the last years, we believe that through its central position 
within the cortico-basal ganglia-thalamocortical circuits, the STN has a coordinating 
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role in decision-making and action-selection mechanisms. Dysfunctional information-
processing at the level of the STN is responsible for some of the core symptoms of 
OCD. Research confirms an electrophysiological dysfunction in the associative and 
limbic (non-motor) parts of the STN. Moreover, there is evidence for the involvement 
of the STN in both checking behaviour and OCD symptoms, which are both related to 
changes in electrophysiological activity in the non-motor STN. Through a combination 
of mechanisms, DBS of the STN seems to interrupt the disturbed information-
processing, leading to a normalisation of connectivity within the cortico-basal ganglia-
thalamocortical circuits and consequently to a reduction in symptoms. Based on the 
results of the studies described in this review, it can be concluded that the STN is a 
mechanism-based target for DBS in OCD. 
 
Chapter 3 presents a case study of a patient with treatment-resistant OCD who 
underwent anteromedial STN-DBS. Despite a clear mood-enhancing effect, 
stimulation caused motor side-effects including bilateral hyperkinesia, dyskinesias and 
sudden large amplitude choreatic movements of arms and legs when stimulating at 
voltages above circa 1.5V. DBS at lower amplitudes and at other contact points failed 
to result in a significant reduction of obsessions and compulsions. To our knowledge, 
such severe and persistent motor side-effects have not yet been described for 
anteromedial STN-DBS. Due to the limitation in programming options, we decided to 
re-operate and target the ventral capsule/ventral striatum (VC/VS), which resulted in a 
substantial reduction in key obsessive and compulsive symptoms without serious side-
effects.  
 
Chapter 4 aimed to investigate the role of 5-HT on mood, emotional processing, 
inhibitory control and motor symptoms in PD patients with STN-DBS by temporarily 
reducing the level of available 5-HT in the brain by acute tryptophan depletion (ATD) 
in a double-blind, placebo-controlled crossover study. Due to lagging inclusion the 
study was terminated after including 7 patients. In these 7 patients, we found that 5-
HT manipulation by ATD did not lead to dissociable effects on any of the outcome 
measures, suggesting that psychiatric side-effects following STN-DBS in PD patients 
cannot be directly linked to a reduction in 5-HT activity. These results, however, should 
be interpreted with caution given the small sample size.  
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In Chapter 5 we aimed to explore whether characteristics of the surgical trajectory 
were associated with cognitive decline in PD patients one year following STN-DBS. A 
total of 49 PD patients who underwent bilateral STN-DBS were retrospectively 
analysed. Cognitive change scores were related to the number of microelectrode 
recording (MER) trajectories, the STN length as measured by MER, and cortical entry 
points. One year postoperatively, significant declines were found in several executive 
function tests: verbal fluency, Stroop Colour-Word test and Trail Making Test B (TMT-
B). Changes in TMT-B were associated with the coronal entry point in the right 
hemisphere. However, only 5 patients showed clinically relevant cognitive decline in 
TMT-B performance. These results imply that the use of MER does not impose an 
increased risk of cognitive decline after STN-DBS. Although the electrode passage 
through the right prefrontal lobe may contribute to subtle changes in executive function, 
only few patients showed clinically relevant cognitive decline, which implies that from 
a cognitive point of view, STN-DBS in PD may be considered a relatively safe 
procedure.  
 
Part 2 
In Chapter 6 the experience sampling method (ESM) was used to explore longitudinal 
associations between motor symptoms and mood states in a PD patient suffering from 
motor fluctuations. For this purpose, one patient collected ESM data for 34 consecutive 
days. Network analysis revealed that anxiety and cheerfulness had a central position 
within the symptom network. Higher anxiety was prospectively associated with 
increased rigidity and tremor, and with feeling down. Cheerfulness was associated with 
less tremor. Balance problems were not influenced by cheerfulness nor anxiety, but 
increased balance problems were associated with reduced cheerfulness at the next 
assessment. Feeling down did not influence self-reported motor symptom severity at 
the next assessment. Revealing longitudinal associations between motor and mood 
states based on ESM data may have relevance for treatment strategies, e.g. by 
establishing a personalised treatment plan.  
 
Chapter 7 explored the usability of routinely collected ESM data over a brief period of 
time to detect associations between motor fluctuations, affective state, and contextual 
factors in PD patients with motor fluctuations on a group and individual level. Group 
analyses may reveal population based patterns that may lead to more general 
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treatment or research recommendations, while individual analyses can be used to 
establish a personalised treatment plan. On a group level, multilevel analyses showed 
significant associations between all motor symptoms and positive affect. Being at 
home was associated with increased balance problems and rigidity. These 
associations were independent on whether a patient was in ON or OFF state. Analyses 
on an individual level revealed much less significant associations that mostly, but not 
always, were in line with the results on a group level. This exploratory study showed 
that ESM is able to reveal associations between affective state, motor symptoms and 
contextual factors in a group of PD patients with motor fluctuations, but less so in 
individual patients. Since the ultimate aim is to use ESM as an aid to personalise 
treatments, the sensitivity of the approach needs to be increased. 
 
Chapter 8 describes the rationale and methodology of a prospective, two-centre 
randomised controlled trial (RCT) that aims to study the clinical effectiveness, 
alterations in brain circuitry, and cost-effectiveness of cognitive behavioural therapy 
(CBT) for anxiety in PD. PD patients with anxiety will be randomised to CBT treatment 
and clinical monitoring (intervention group) or to clinical monitoring only (control group). 
The CBT programme used in this study was specifically developed to address 
symptoms of anxiety in PD patients. Participants will undergo standardised clinical, 
cognitive and behavioural assessment at baseline and at 2 follow-up measurements, 
as well as resting-state functional magnetic resonance imaging and diffusion tensor 
imaging before and after the intervention. The primary outcome measure is changes 
in severity of anxiety symptoms. Secondary outcome measures involve long-term 
changes in anxiety symptoms, changes in functional and structural connectivity 
between limbic and frontal cortices, and cost-effectiveness of the treatment. If proven 
effective, this study will hopefully contribute to a better and evidence-based approach 
for these non-motor symptoms. 
 
In chapter 9 we aimed to explore the needs of PD patients who suffer from anxiety 
and their caregivers regarding the treatment of anxiety. Three focus group interviews 
in two countries involving 12 PD patients and 8 caregivers were conducted. Besides 
discussing the content of the treatment, emphasis was put on the structure of the 
therapy and potential barriers of undergoing therapy. Based on the interviews and a 
review of the literature, a specialised CBT programme was developed. The programme 
SUMMARY 
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focuses on general and Parkinson-specific anxiety symptoms and involves classical 
elements of CBT, such as psycho-education, relaxation, cognitive restructuring, 
problem solving strategies and exposure, but also personal habits that may influence 
levels of anxiety and a self-management plan to maintain gains and prevent relapse.  
 
Chapter 10 summarises and discusses the main findings of all previous chapters in 
the light of current scientific research. Methodological considerations and limitations 
are addressed and clinical and scientific implications are provided. 
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Neuropsychiatrische symptomen omvatten een breed scala aan symptomen, zoals 
een depressieve stemming, euforie, agitatie en agressie, angst, slaapstoornissen en 
disinhibitie. Deze symptomen komen veelvuldig voor in neurologische, neuro-
degeneratieve en psychiatrische stoornissen. Neuropsychiatrische symptomen zijn 
geassocieerd met een dysfunctie van cortico-basale ganglia-thalamocorticale circuits. 
De basale ganglia zijn een groep subcorticale kernen die met elkaar verbonden zijn, 
waaronder de nucleus caudatus, het putamen, de globus pallidus, de substantia nigra 
of zwarte kern en de nucleus subthalamicus (STN). In dit proefschrift richten we ons 
op twee stoornissen die geassocieerd zijn met veranderingen van cortico-basale 
ganglia-thalamocorticale circuits: de ziekte van Parkinson (ZvP) en obsessief-
compulsieve stoornis (OCS).   
 
De ZvP is een veelvoorkomende neurodegeneratieve aandoening met een prevalentie 
van ongeveer 1-2% bij mensen van 65 jaar en ouder. Naast de klassieke motorische 
symptomen, zoals rusttremor, bradykinesie, rigiditeit en posturale instabiliteit, hebben 
veel parkinsonpatiënten last van neuropsychiatrische symptomen zoals depressie en 
angst. Er is momenteel veel onduidelijk over de onderliggende mechanismen van 
stemmingssymptomen bij Parkinson. Tevens is er geen evidence-based behandeling 
beschikbaar voor angst bij Parkinson. OCS is een neuropsychiatrische stoornis die 
gekenmerkt wordt door terugkerende dwang-gedachten (obsessies) en 
dwanghandelingen (compulsies). Obsessies zijn ongewenste, zich opdringende en 
steeds terugkerende gedachten, beelden of impulsen. Compulsies zijn herhaalde 
handelingen of mentale acties die ten doel hebben om de obsessie onder controle te 
houden, ongemak en/of angst te verminderen of mogelijke negatieve gebeurtenissen 
te voorkomen. Diepe hersenstimulatie van de STN (STN-DBS) is een 
neurochirurgische ingreep voor zowel de ZvP als OCS. Het eerste deel van dit 
proefschrift richtte zich op het vergroten van kennis omtrent de rol van de STN bij de 
pathofysiologie van OCS en om de onderliggende mechanismen van emotionele en 
cognitieve bijwerkingen van STN-DBS bij parkinsonpatiënten te onderzoeken. Het 
tweede deel van dit proefschrift richtte zich op stemmingssymptomen bij de ZvP en 
had ten doel om de relatie tussen stemmings- en motorische symptomen bij de ZvP te 
onderzoeken, en om een psychotherapeutische behandeling voor angst bij Parkinson 
te ontwikkelen.  
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Hoofdstuk 1 bevat een algemene inleiding in het onderwerp en de doelstellingen van 
dit proefschrift. Het bevat informatie over de achtergrond van de ZvP en OCS, 
(neuropsychiatrische) symptomen, behandelingen inclusief diepe hersenstimulatie, 
evenals de onderzoeksvragen en opbouw van dit proefschrift.  
 
Deel 1 
Hoofdstuk 2 bevat een review over de functionele rol van de nucleus subthalamicus 
(STN) in OCS. Op basis van literatuuronderzoek denken we dat de STN, via zijn 
centrale positie binnen de cortico-basale ganglia-thalamocorticale circuits, een 
coördinerende rol heeft bij besluitvormingsprocessen en bij de selectie van 
handelingen. Een verstoorde informatieverwerking op het niveau van de STN is 
verantwoordelijk voor de kernsymptomen van OCS. Onderzoek heeft aangetoond dat 
er sprake is van een elektrofysiologische dysfunctie in de associatieve en limbische 
(niet-motorische) gedeelten van de STN. Via een combinatie van mechanismen 
onderbreekt DBS de verstoorde informatieverwerking, wat leidt tot een normalisatie 
van de verbindingen binnen de cortico-basale ganglia-thalamocorticale circuits en 
uiteindelijk tot een vermindering van symptomen. Op basis van de resultaten die 
beschreven zijn in dit review kunnen we concluderen dan de STN een op 
mechanismen gebaseerde target voor DBS in OCS is.  
 
Hoofdstuk 3 beschrijft een casus van een patiënt met therapieresistente OCS die DBS 
onderging in het anteromediale gedeelte van de STN. Ondanks een duidelijke 
stemmingsverbetering leidde stimulatie boven 1.5V tot motorische bijwerkingen, 
inclusief bilaterale hyperkinesie, dyskinesie en plotselinge choreatische bewegingen 
van de armen en benen. DBS op lagere amplitudes of andere contactpunten leidde 
niet tot een vermindering in obsessies of compulsies. Voor zover we weten zijn zulke 
ernstige en persisterende motorische bijwerkingen na DBS van de anteromediale STN 
niet eerder beschreven. Vanwege de beperkingen in de DBS-programmering is 
besloten de patiënt opnieuw te opereren en de DBS te implanteren in de regio van de 
ventrale capsula en het ventrale striatum (VC/VS), wat resulteerde in een substantiële 
afname in obsessieve en compulsieve symptomen zonder significante bijwerkingen.   
 
In Hoofstuk 4 hebben we gekeken naar de invloed van serotonine (5-HT) op 
stemming, emotionele informatieverwerking, inhibitie controle en motorische 
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symptomen bij parkinsonpatiënten die worden behandeld met STN-DBS. Hiervoor 
hebben we in een dubbel-geblindeerde gerandomiseerde cross-over studie het 
serotoninegehalte tijdelijk kunstmatig verlaagd en stemmings- en gedragstaken 
afgenomen. We zijn vroegtijdig, na het includeren van 7 patiënten, met deze studie 
moeten stoppen, omdat weinig patiënten in aanmerking kwamen voor de studie of 
bereid waren deel te nemen. Bij deze 7 patiënten vonden we geen effecten van 5-HT 
manipulatie op stemming en gedrag, wat suggereert dat psychische bijwerkingen na 
STN-DBS in PD niet een direct gevolg zijn van een afname in 5-HT activiteit. De 
resultaten dienen echter met de nodige voorzichtigheid te worden geïnterpreteerd 
vanwege de lage steekproefomvang.  
 
In Hoofdstuk 5 hebben we onderzocht of afnames in cognitief functioneren (gemeten 
als veranderscores op cognitieve taken) 1 jaar na STN-DBS in parkinsonpatiënten 
geassocieerd zijn met kenmerken van het chirurgische traject, waaronder het aantal 
microelectroden (MER) dat gebruikt werd voor finetuning van de doellokalisatie tijdens 
DBS, de anatomische lengte van het STN traject zoals gemeten door MER, en de 
corticale ingangspunten (coronaal en sagittaal).  In deze retrospectieve studie werden 
49 patiënten met ZvP die bilaterale STN-DBS hebben ondergaan geanalyseerd. Eén 
jaar na de operatie werden significante afnames gezien in een aantal taken die 
executief functioneren meten: verbal fluency, Stroop Colour-Word test en Trail Making 
Test B (TMT-B). Veranderingen in prestaties op de TMT-B waren geassocieerd met 
het coronale ingangspunt in de rechter hemisfeer. Echter bleek er maar bij 5 patiënten 
sprake te zijn van een klinisch relevante cognitieve afname in prestaties op de TMT-B 
taak. Deze resultaten impliceren dat het gebruik van MER niet tot een verhoogd risico 
op een afname in cognitief functioneren leidt na STN-DBS. Hoewel de passage van 
de DBS-electrode door de rechter prefrontale kwab mogelijk bijdraagt aan subtiele 
veranderingen in executief functioneren, lieten maar een klein aantal patiënten een 
klinisch relevante afname in cognitief functioneren zien, wat impliceert dat vanuit een 
cognitief oogpunt STN-DBS bij ZvP een relatief veilige procedure is.   
 
Deel 2 
In Hoofdstuk 6 hebben we gebruik gemaakt van de experience sampling methode 
(ESM) om longitudinale associaties tussen motorische en stemmingssymptomen te 
bestuderen in een parkinsonpatiënt met motorische fluctuaties. Gedurende 34 
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achtereenvolgende dagen heeft 1 parkinsonpatiënt ESM data verzameld. Een 
netwerkanalyse toonde aan dat angst en opgewektheid een centrale positie hadden 
binnen het symptoomnetwerk van deze patiënt. En hogere mate van angst was 
prospectief geassocieerd met verhoogde stijfheid en tremor, en met zich down voelen. 
Opgewektheid was geassocieerd met verminderde tremor. Balansproblemen werden 
niet beïnvloed door opgewektheid of angst, maar een toename in balansproblemen 
was geassocieerd met een verminderde opgewektheid tijdens het volgende 
meetmoment. Zich down voelen was niet geassocieerd met de zelf-gerapporteerde 
ernst van motorische symptomen tijdens het volgende meetmoment. Het blootleggen 
van longitudinale associaties tussen motorische en stemmingssymptomen op basis 
van ESM data is relevant voor het bepalen van behandelstrategieën, bijvoorbeeld voor 
het maken van een persoonlijk behandelplan.  
 
In Hoofdstuk 7 hebben we de bruikbaarheid van routinematig verzamelde ESM data 
onderzocht om op groeps- en individueel niveau associaties tussen motorische 
symptomen, affectieve symptomen en contextuele factoren in kaart te brengen bij 
parkinsonpatiënten met motorische fluctuaties. Groepsanalyses kunnen mogelijke 
patronen op populatieniveau aan het licht brengen die kunnen leiden tot meer 
algemene behandel- of onderzoeksaanbevelingen. Individuele analyses kunnen 
gebruikt worden om een gepersonaliseerd behandelplan tot stand te brengen. De 
analyse op groepsniveau liet significante associaties zien tussen alle motorische 
symptomen en positief affect. ‘Thuis zijn’ was geassocieerd met een toename in 
balansproblemen en rigiditeit. De associaties waren onafhankelijk van of een patiënt 
in een ON of OFF-fase was. De analyses op individueel niveau lieten veel minder 
significante associaties zien, die in de meeste gevallen, maar niet altijd, 
overeenkwamen met de resultaten op groepsniveau. Deze exploratieve studie toont 
aan dat ESM in staat is om op groepsniveau associaties tussen affectieve symptomen, 
motorische symptomen en contextuele factoren te weergeven, maar dat dit een stuk 
minder is bij individuele patiënten. Aangezien het uiteindelijke doel van ESM erop 
gericht is om ingezet te worden als hulpmiddel bij het personaliseren van 
behandelingen, is het van belang dat de sensitiviteit van de methode verhoogd wordt.  
 
Hoofdstuk 8 beschrijft de rationale en methode van een prospectief, multi-centrum 
gerandomiseerd gecontroleerd onderzoek dat erop gericht is om de klinische 
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effectiviteit, de kosteneffectiviteit en veranderingen in hersencircuits te onderzoeken 
van cognitieve gedragstherapie (CGT) voor angst bij de ZvP. Parkinsonpatiënten met 
angst worden verdeeld (gerandomiseerd) in twee groepen: CGT en klinische 
monitoring (interventie groep) of alleen klinische monitoring (controle groep). Het CGT-
programma dat in deze studie gebruikt wordt is specifiek ontwikkeld om angst bij 
parkinsonpatiënten te behandelen. Participanten zullen tijdens de start van de studie 
en tijdens twee follow-up momenten een gestandaardiseerde klinische, cognitieve en 
gedragsmeting ondergaan. Tevens vindt er zowel vooraf als na de studie MRI-
onderzoek plaats. De primaire uitkomstmaat zijn veranderingen in de ernst van 
angstsymptomen. Secundaire uitkomstmaten zijn veranderingen in angstsymptomen 
op de lange termijn, veranderingen in limbische en frontale hersencircuits, en 
kosteneffectiviteit. Indien aangetoond wordt dat de behandeling effectief is, zal deze 
hopelijk bijdragen aan een betere evidence-based behandeling voor angstsymptomen 
bij Parkinson.   
 
In Hoofstuk 9 hebben we de behoeften van parkinsonpatiënten met angstklachten 
met betrekking tot de behandeling van angstklachten geëxploreerd. Hiervoor hebben 
we drie focusgroepen in twee landen georganiseerd waaraan 12 parkinsonpatiënten 
en 8 mantelzorgers hebben deelgenomen. Naast het bespreken van de inhoud van de 
behandeling zijn ook de structuur van de behandeling en mogelijke barrières om 
behandeling te ondergaan aan bod gekomen. Op basis van de interviews en een 
beoordeling van de literatuur hebben we een gespecialiseerd CGT-programma 
ontwikkeld. Het CGT-programma richt zich op algemene en Parkinson-specifieke 
angstsymptomen. Het bevat klassieke CGT-elementen, zoals psycho-educatie, 
ontspanningstechnieken, cognitief herstructureren, probleemoplossende strategieën 
en exposure, maar ook persoonlijke gewoonten die angstlevels kunnen beïnvloeden 
en een zelfmanagement plan om terugval te voorkomen.  
 
In Hoofdstuk 10, de Algemene Discussie, zijn alle hoofdbevindingen uit de eerdere 
hoofdstukken samengevat. Daarnaast worden de methodologische aspecten, 
implicaties voor de klinische praktijk en aanbevelingen voor toekomstig onderzoek 
besproken.  
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This first part of this thesis focused on Deep brain stimulation (DBS) studies in 
obsessive-compulsive disorder (OCD) and Parkinson’s disease (PD) in order to study 
underlying mechanisms of neuropsychiatric symptoms. The second part of this thesis 
focused on mood symptoms in PD by exploring the usability of the experience sampling 
method (ESM) in PD patients, and by developing a treatment programme for anxiety 
in PD patients. This valorisation paragraph describes how the obtained knowledge 
from the research in this thesis can be made valuable for clinical and societal use.  
 
Societal relevance 
Neuropsychiatric symptoms include a broad range of psychiatric symptoms that are 
believed to be mediated by changes in brain functions. Certain conditions that were 
once considered to be manifestations of psychodynamic conflict are now considered 
neuropsychiatric disorders, such as OCD. Moreover, it is increasingly recognised that 
neuropsychiatric symptoms, such as anxiety and a depressive mood, are an integral 
part of PD, the second most common neurodegenerative disorder.  
 
Neuropsychiatric symptoms have a large impact on health-related quality of life, which 
reflects the impact of a disease or symptoms on several aspects of a patient’s life, 
including their physical, mental and social well-being. Moreover, according to the World 
Health Organization (WHO), neuropsychiatric disorders are the third leading cause of 
disability-adjusted life years (DALYs). According to the National Institute of Mental 
Health, DALY is a measure of overall disease burden, expressed as the total number 
of years lost to illness, disability, or premature death within a given population. This 
high disease burden of neuropsychiatric symptoms has a considerable impact on the 
global economic burden. In PD, for example, neuropsychiatric symptoms complicate 
treatment and require additional and complex interventions.  
 
Despite the impact of neuropsychiatric symptoms on the health status of patients and 
global health care costs, treatments specifically developed and validated for 
neuropsychiatric symptoms are still scarce. This is partly because underlying 
mechanisms of neuropsychiatric symptoms are largely unknown. The findings reported 
in this thesis improve our understanding of underlying mechanisms of neuropsychiatric 
symptoms in PD and OCD, which is crucial in order to adapt and tailor treatment. 
Moreover, new methods and interventions have been introduced to improve care for 
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patients. Improved care will in turn contribute to an increase in quality of life of patients, 
and eventually to a decrease in health care costs and societal burden.  
 
Target audience 
Our findings are relevant for OCD and PD patients, clinicians, psychologists, health 
insurance companies and researchers.  
 
The findings from the DBS studies (chapter 2 to 5) are relevant for patients, since the 
findings might improve the surgical procedure, and subsequently improve treatment 
outcome. Knowledge of the neural substrates underlying obsessive and compulsive 
symptoms (chapter 2), as well as observed side-effects following DBS of a specific 
target, the STN, (chapter 3) might help clinicians to achieve maximal therapeutic effect. 
The same holds for DBS for PD. Studying underlying mechanisms (chapter 4) and 
potential risk factors (chapter 5) of emotional and cognitive side-effects following DBS 
might be helpful for patient selection and improving the surgical procedure. In chapter 
5 we show that neurosurgeons do not have to feel restrained by fear of cognitive side-
effects when using multiple MERs in order to attempt to have more possibilities for 
postoperative stimulation settings. 
 
The findings from the ESM studies (chapter 6 and 7) are relevant for PD patients and 
their health care team, as ESM has to potential to improve care. Due to the 
unpredictable fluctuating nature of both motor and mood symptoms in PD, it is 
challenging to capture and study their association, and adjust treatment accordingly. 
In chapter 7 we showed that ESM allows to study associations between affective state, 
motor symptoms and contextual factors on a group level in PD. Findings on a group 
level may lead to more general treatment recommendations. Moreover, we showed 
that on an individual level ESM can be used to visualise and monitor symptom change 
over the course of the day. In chapter 6 we showed that ESM data collected over a 
longer period of time can be used to generate symptom networks displaying 
prospective associations between mood and motor symptoms. The information 
collected by ESM can lead to an increased awareness and understanding in patients 
and clinicians regarding particular circumstances in which symptoms occur or are 
perceived as more disabling. This might benefit collaborative decision making between 
the patient and clinician, help personalising treatment and give the patient a ‘sense of 
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control’. Our findings could also be of interest to insurance companies and policy 
makers, given that ESM has proven potential as an E-health tool for PD patients.   
 
Finally, results from the CBT studies are valuable for PD patients who suffer from 
anxiety, psychologists working with these patients, health insurance companies and 
researchers. The CBT treatment, if proven effective, will hopefully provide PD patients 
with behavioural and anxiety management techniques that may give lasting benefits 
on anxiety symptoms, well-being, quality of life, and possibly on motor symptoms. The 
findings from the focus group interviews are particularly relevant for psychologists 
working with PD patients, as it provides insight into the specific needs of PD patients 
and potential barriers of undergoing therapy. Psychologists might tailor their method 
based on these findings. Moreover, the paper provides a detailed description of the 
CBT programme that was developed for PD patients suffering from anxiety, including 
factors that may complicate treatment, as well as ways how to deal with these during 
therapy. On top of that, the workbook and manual for therapists are available upon 
request in three different languages and we aim to develop a website to distribute our 
manual, so we hope that PD patients around the world benefit from the therapy. While 
the paper discussing the effectiveness of the intervention is currently in preparation, 
the findings are relevant for health insurance companies, as most health insurance 
companies apply evidence-based approaches to coverage decisions. Finally, the 
protocol describing the methodology of the study (chapter 8) might be relevant for 
researchers by facilitating the development of similar trials studying the effect of 
psychotherapeutic interventions for different target groups. 
 
Products/innovation 
The research described in this thesis can be considered innovative in several ways. 
First of all, we were the first to report severe and persistent motor side-effects following 
STN-DBS in an OCD patient. Reporting these side-effects are of crucial importance, 
as it might guide neurosurgeons in target selection.   
 
Another innovative approach within this thesis concerned the usability of ESM in PD 
patients. The ESM method originated in psychiatry, and has recently been applied in 
a number of other diseases, such as migraine, stroke and COPD. In this thesis, we 
demonstrated that ESM is useful to study associations between motor and mood 
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symptoms, and contextual factors on a group and individual level in PD. Moreover, we 
were the first to study prospective associations between motor and mood symptoms 
in PD in an n=1 design. The findings demonstrate how recall bias can be prevented 
and they bring us one step closer to personalise treatment to the individual patient.  
 
Despite its high prevalence, there is currently no evidence-based treatment available 
for anxiety in PD. Psychotherapeutic interventions that are available have not been 
studied in a controlled design or only in small sample sizes. The primary focus of our 
study was to assess the clinical effectiveness of a specialised CBT programme for 
anxiety in PD and possible changes in cerebral connectivity (chapter 8). The 
development of the CBT programme was based on literature, existing CBT modules 
and focus group interviews with patients, in order to tailor the programme to better 
serve their specific needs, concerns and circumstances (chapter 9). This study is the 
first in its kind to test both CBT effectiveness in a controlled trial and to record possible 
structural and functional brain changes induced by CBT, which may lead to an 
increased understanding of the underlying neurobiological mechanisms of both anxiety 
and response to treatment in PD patients.  
 
Implementation 
The knowledge acquired from the studies in this thesis will be implemented in health 
care practice on one hand, and used for continuation of research on the other hand. 
The findings from the OCD studies contributed to a shift in target selection for DBS in 
our hospital from the STN to the ventral capsule/ventral striatum. Moreover, a database 
has been created for all OCD patients who received DBS in our hospital, in order to 
collect data regarding target location, active electrodes, symptom improvement, side-
effects, medication, etc. This dataset is now used for research purposes with the aim 
to uncover best practices and improve outcome. The findings from the studies 
regarding the cognitive side-effects following STN-DBS in PD resulted in the 
continuation of the use of microelectrode recording as a way of optimising lead 
implantation. Moreover, we continue to collect data from PD patients who received 
STN-DBS in order to increase our sample size and apply advanced statistical methods 
and machine learning algorithms to discover underlying mechanisms of side-effects 
and clinical outcome.  
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The application of ESM in the field of PD care is still in its infancy. This thesis provides 
a valuable contribution to our knowledge of the usability of ESM for research purposes 
and health care practice in PD. ESM can be used to capture the fluctuating nature of 
motor and mood symptoms in PD and to study their association in relation to contextual 
factors. Moreover, revealing population based patterns via ESM may lead to more 
general treatment recommendations, while individual analyses of ESM data can be 
used to establish a personalised treatment plan. However, we also found that the 
sensitivity of the method needs to be improved for further implementation, for which 
we have made several recommendations. In the future, ESM data may potentially 
serve as a parallel ground truth to objective data, such as obtained by monitoring motor 
symptoms by wearable sensors, since these alone may not be representative for the 
experienced disability. In addition, combining objective and subjective data on motor 
and non-motor symptoms can potentially be used as input signal for adaptive DBS. 
Adaptive DBS aims to automatically adapt stimulation parameters to the fluctuating 
clinical state of the patient, where stimulation is only provided when necessary. The 
idea is that adaptive DBS results in fewer stimulation-induced side-effects compared 
to conventional DBS. 
 
The CBT programme aimed at treating anxiety in PD is currently in use in our hospital. 
To disseminate our findings among health care professionals we gave presentations 
and workshops at conferences. Moreover, we presented our programme at several 
Parkinson café’s in the region in order to create awareness regarding anxiety and its 
treatment among PD patients and health care professionals. The CBT programme, 
including the workbook and manual for therapists, is available in three different 
languages so we hope it will find its way into widespread clinical use. We are currently 
finalising our paper regarding the clinical effectiveness of the programme. Meanwhile, 
we are studying the cost-effectiveness of the treatment, as well as changes in cerebral 
connectivity associated with successful treatment in order to unravel the underlying 
neurobiological mechanisms of anxiety in PD.  
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gemaakt met onderwerpen die we moesten bespreken: het was identiek! Je kritische 
blik en je vlotte en uitgebreide commentaar op papers hebben mij ontzettend geholpen. 
Bedankt voor je geduld en vertrouwen in mij! 
 
Anja, onze samenwerking begon toen jij met zwangerschapsverlof was. Ik moest een 
groot (en leuk) project overnemen. Het was in het begin een hele uitdaging, iets mee 
ontwikkelen zonder goed te weten wat jij voor ogen had en het proberen zo goed 
mogelijk te doen. Maar naar mijn gevoel is het als vanzelf gegaan. Niet lang nadat je 
terug was voelde de samenwerking voor mij als een geoliede machine. Later werd je 
mijn co-promotor, een andere rol die ook als vanzelf gegroeid is. Het waren gezellige 
gesprekken met een koffie erbij (dat moet ook), maar tegelijkertijd momenten waar ik 
even op adem kon komen en mijn ei kwijt kon. Je hebt altijd stil gestaan bij hoe het 
 
261 
 
met me gaat en bewaakt dat ik niet te veel hooi op mijn vork nam. Dank voor je steun 
en wat tof dat we nu als collega’s bij de Medische Psychologie een kantoor en vele 
koffiemomenten delen. 
 
Leden van de beoordelingscommissie, hartelijk dank voor het lezen en beoordelen van 
mijn proefschrift.  
 
Beste Annelien, een speciaal woord van dank voor jou. Ik heb je leren kennen toen ik 
nog bachelor student was en vanaf het begin heb je mij onder je hoede genomen, 
zowel bij het begeleiden van onderzoek als bij het klinische werk. Jou zien werken met 
patiënten is ontzettend inspirerend. Overal waar ik kom, wordt met lof over je 
gesproken, en terecht! Je bent mijn grote voorbeeld. Dankjewel voor alle leerzame, 
licht chaotische en gezellige gesprekken en dat je me de kans hebt gegeven om te 
groeien op zowel persoonlijk als professioneel vlak. Ik zal onze fantastische trip naar 
de Davos sessies in Zwitserland nooit vergeten, wat was dat gezellig! Op nog vele 
toekomstige samenwerkingen! 
 
Dank aan de overige leden van het DBS-team die me geholpen hebben bij de inclusie 
van patiënten voor mijn onderzoeken, het verzamelen van data en samples of het 
schrijven van artikelen: Nicole Bakker, Mark Kuijf, Mark Janssen, Mayke Oosterloo, 
Linda Ackermans, Pieter Kubben, Koen Schruers, Mirella Waber en Daisy Ramakers. 
Naast jullie praktische bijdrage heb ik geregeld met jullie mee mogen kijken tijdens 
jullie werkzaamheden. Ik heb hier ontzettend veel van geleerd. Bedankt voor deze 
belangrijke bijdrage!  
 
Ik wil graag alle co-auteurs bedanken die bij hebben gedragen aan de totstandkoming 
van de artikelen in dit proefschrift. Marjan Drukker, jouw kennis en ervaring op het 
gebied van ESM was van onschatbare waarde. Bedankt voor de vlotte en 
gedetailleerde antwoorden op al mijn vragen en je statistische bijdrage aan de ESM-
studies. Jos Adam, heel erg bedankt voor je uitgebreide uitleg bij de anti-cue task en 
je begeleiding bij de analyses. Marjolein de Vugt, dank voor je klinische supervisie bij 
de CBT-studies, waar ik voor het eerst behandelervaring als psycholoog heb 
opgedaan. Je begeleiding was ontzettend fijn en leerzaam! 
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Ron Mengelers en Nico Rozendaal, bedankt voor jullie belangrijke ondersteuning bij 
de verschillende studies. Niet alleen hebben jullie geholpen met het ontwikkelen van 
programma’s, bij iedere stap dachten jullie met ons mee. Dat was ontzettend fijn! 
 
Janine Portier, Colin van der Heijden en Rianne Esselink: samen met Annelien hebben 
we met veel passie aan het Beter in Balans project gewerkt. Dit belangrijke project 
gericht op het verbeteren van de psychosociale zorg rondom een DBS-operatie is geen 
onderdeel van dit proefschrift, maar heeft wel een zeer belangrijke bijdrage geleverd 
aan mijn visie op de zorg. Dank jullie wel voor de ontzettend prettige en gezellige 
samenwerking. Jullie zijn stuk voor stuk inspirerend en ik hoop in de toekomst nog veel 
vaker met jullie samen te werken.  
 
Rachel, Rowan, Anne en Laura, heel erg bedankt voor jullie hulp als student bij de 
verschillende projecten in dit proefschrift.  
 
Collega’s van de afdeling Neurochirurgie van MHeNS wil ik bedanken voor hun 
ondersteuning tijdens mijn promotieonderzoek. Gedurende mijn tijd als PhD-student is 
het team gegroeid van, ‘we passen nog allemaal in een kantoor tijdens de Monday 
morning meeting’ tot ‘er is geen zaal beschikbaar die ruim genoeg is voor iedereen’. 
De afgelopen jaren heb ik vanwege mijn overige werkzaamheden wat meer afstand 
genomen van de groep, maar ik wil toch even stilstaan bij een paar naaste collega’s 
en wat voor mij de mooiste momenten van mijn PhD waren: dear Sarah, dear friend. 
We started as roomies, somewhere along the road introduced babyshowers to the 
group (I will never forget Yasin’s face when he walked into the MPR room with 3 other 
neurosurgeons he wanted to show the lab, hilarious!), and became the ‘mama’s of the 
group’. Thank you for always being there, for the good and the bad moments. Without 
your support, I could not have done it. Now let’s finally plan that playdate with the kids! 
 
Milaine, Millie, Mil, wat ben jij toch een tof mens. Je humor en gevatte opmerkingen 
kwamen altijd op de momenten dat ze het hardst nodig waren. Met veel bewondering 
kijk ik terug naar jouw doorzettingsvermogen, je veelzijdige skills (je bent ook goed met 
een hamer), maar vooral hoe je onverstoord door kon werken op momenten dat Fred, 
Gusta en ik onze mond niet konden houden. Dank je wel voor alles! 
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Freddie, Fred (Fred Fred Fred Fred), monsieur! Nooit vergeet ik onze introductiedag 
op het lab (hier hoef ik me niet verder over uit te wijden). We zijn op dezelfde dag aan 
onze PhD begonnen en hebben de eerste jaren een kantoor gedeeld. Hierdoor kregen 
we de goede en slechte momenten van elkaar mee. Dank voor je steun en wat ik vooral 
onthoud is dat er niets is dat niet opgelost kan worden met een heliumballon, een fles 
whisky, een lekker etentje of een marsepeinen varken.  
 
Gusta, Gustie, mijn lieve roomie, vriendin en tevens paranimf. Jij bent echt een van de 
meest sprankelende personen die ik ken. Ja, zelf als je nors en wild achter je laptop 
zat te typen, bracht je een glimlach op ons gezicht. Van veel werken kwam het niet 
altijd als je weer terug kwam bij ons op kantoor na een huisartsenstage (totdat je er 
genoeg van had en een BOSE noisecancelling headphone aanschafte), maar echt, 
het was onvergetelijk: het spiegelen met Fred, de congrestripjes, dat sauna bezoek in 
Duitsland (omg), het samen koken, de vele wijntjes, yoga op kantoor, een promotiefilm 
met barbies en stiekeme filters, golfen met alpaca’s, maar vooral ook hele fijne 
gesprekken. Dank je wel voor je steun en alle gezellige momenten.   
 
Dr. Majed, what a personality you are, so generous and always smiling! You made 
every birthday in the group a true feast with glitters and big cakes. The dinners at your 
place were over the top fantastic, and who knew you could run that fast! I will never 
forget that moment on the bridge at our conference trip to Cologne. I am truly happy to 
know you. Jeroen, dank je dat je weer wat gezelligheid terugbracht in het team nadat 
er zo velen waren weggegaan. Jij introduceerde weer de bbq’s, etentjes, lekkere 
drankjes (vaak eigengemaakt) die we allen hard nodig hadden. Beth, wow, I haven’t 
seen you for ages. I hope you are happy and shining in Amsterdam. Liancy Peng, we 
were all sad that you left us, but happy that you found a PhD position that better fitted 
your background and preferences. It was so much fun having you as a colleague. 
Margot, Sylvana, Jackson, Jana, Roman, Christian, Faris, Mohammed, Amee, Stijn, 
Faisal, Raghu and old colleagues, thank you all for the good times and support! A 
special word to the two ladies from Barcelona. Dear Sol, you are such a fantastic 
person. We shared some very special moments during your stay here that I will never 
forget! Thank you for your kindness, support and friendship. Maria, your presence just 
lighted up the room during your stay with us. You are such a smart, kind and lovely 
person. You are going to be a great doctor.  
DANKWOORD 
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Govert, dank je wel voor je oprechte interesse in ieders project en je kritische wijze 
van vragen stellen. Het hield de kwaliteit van onze wetenschappelijke meetings hoog 
en stimuleerde ons om constant up-to-date te blijven. Mark, ondanks dat je een steeds 
prominentere rol kreeg binnen onze groep, heb je je nooit te goed gevoeld om uren 
achter een computer te zitten en een database te vullen (uiteraard met een goede 
koffie erbij). Bedankt voor je steun, interesse en hulp bij de verschillende projecten. 
Ali, dear friend, from the beginning of my PhD you were so kind to me. Thank you for 
all your support these years! 
 
Lieve Danique en Elles, mijn roomies in de tweede periode van mijn promotie-
onderzoek. We kennen elkaar al sinds onze stage bij de geheugenpoli en zijn gewoon 
verder gegaan waar we gebleven waren. Wat hebben we het toch gezellig met elkaar 
gehad: de uitspraken op de whiteboards, de krokettenteller, de mooiste 
Kerstversiering, de altijd aanwezige chocolade op kantoor, de fijne gesprekken. Wat 
fijn dat we alles met elkaar konden delen. Elles, jij verliet ons als eerste voor een 
nieuwe baan bij MetGGZ, maar het lot bracht ons al gauw voor de derde keer weer bij 
elkaar. Wat geweldig dat we nu samen de opleiding tot GZ-psycholoog volgen en weer 
klasgenoten zijn. Lieve Danique, mijn paranimf! Wat hebben we toch veel meegemaakt 
gedurende de afgelopen periode. Ik heb zo veel bewondering voor jouw 
doorzettingsvermogen en daadkracht. Je bent inmiddels ook klaar met je PhD en hebt 
al een mooie baan als psycholoog. Ergens voel ik dat we ooit weer collega’s worden, 
maar voor nu waardeer ik onze vriendschap heel erg.  
 
Niky, Liselot, Sanne, dank jullie wel voor de gezelligheid en de heerlijke etentjes. 
Liselot, wat hebben we gelachen tijdens de summer course in Toscane, die 
cheesecake, Ik kan nog huilen van het lachen als ik de foto’s terugzie.  
 
Mijn liefste vriendinnen: Anna, Eva, Madelon, Merel, Renee. De verhalen over mijn 
PhD waren vast niet altijd even interessant, maar bedankt voor het aanhoren en voor 
de zo nodige ontspanmomenten en gezelligheid tussen door.  
 
Maarten en Lieke, bedankt voor jullie steun en hulp de afgelopen jaren. Dat jullie altijd 
in mij geloofd hebben, betekent veel voor me.  
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Lieve pap en mam, misschien begrepen jullie niet altijd tot in detail waar mijn studies 
over gingen, maar jullie zijn altijd heel geïnteresseerd geweest in hoe het allemaal ging 
en ik heb altijd gevoeld hoe trots jullie op me zijn. Ik kan altijd bij jullie terecht en jullie 
steun, ook de praktische, is van onschatbare waarde voor mij. Zonder jullie was me dit 
niet gelukt, dank jullie wel!  
 
Dear Ehsan, you are by far the best part of this PhD story. Who would have guessed I 
would find my husband at the corridor of division 3. You have been my rock throughout 
this period. You have always believed in me and are my biggest supporter. I can not 
put into words how much your support and love means to me. Thank you for 
everything! Sophia, my little sunshine, mijn krullebolletje, your smile always lights up 
the room and made me forget about all my PhD frustrations in a second. Wat ben ik 
toch gek op jou.  
 
  
 
 
 
  
 
 
 
 
 Curriculum Vitae 
 
 
CURRICULUM VITAE 
268 
 
  
 
269 
 
Anne Evangelia Philomena Mulders was born on 
December 22, 1986 in Heerlen. After graduating from 
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to study Health Sciences with a focus on Mental Health at Maastricht University. After 
obtaining her bachelor degree in 2013 (cum laude), she obtained a master degree in 
Neuropsychology in 2014 (cum laude) and a master degree in Mental Health in 2015 
(cum laude), at Maastricht University. During her master degrees she performed a 
clinical internship at the memory clinic of Maastricht University Medical Center 
(MUMC+), as well as a research internship studying deep brain stimulation (DBS) for 
Parkinson’s Disease (PD). In 2015, she started working as a PhD candidate at the 
department of Psychiatry and Neuropsychology and the department of Neurosurgery 
under supervision of prof. dr. Albert Leentjens, prof. dr. Yasin Temel and dr. Anja 
Moonen. During her PhD she focused on cognitive and emotional side-effects following 
DBS in PD, the relationship between motor and mood symptoms in PD, and the 
treatment of anxiety in PD. On top of that, she studied DBS for obsessieve-compulsive 
disorder. Next to her PhD trajectory, she was involved in the development and 
implementation of several psychosocial interventions for PD patients and their 
caregivers: ‘Parkinson Partner in Balans’, an online self management programme for 
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2013 
Rob Havermans: Bipolar disorder in daily life; Mood and cortisol responses to naturally occurring 
events. Supervisor: Prof.dr. M. de Vries; Co-Supervisor: Dr. N. Nicolson.   
  
Véronique Moers-Hornikx: Deep brain stimulation and the cerebellum. Supervisors: Prof.dr. J. Vles / 
Prof.dr. Y. Temel; Co-Supervisor: Dr. G. Hoogland.   
  
Nicole Veldhorst-Janssen: Intranasal delivery of rapid acting drugs. Supervisors: Prof.dr. M. Marcus 
/ Prof.dr. C. Neef; Co-Supervisor: Dr. P.H. van der Kuy.   
  
Stéphanie Knippenberg: Vitamin D and Multiple Sclerosis: immunological and clinical outcome. 
Supervisor: Prof.dr. J. Cohen-Tervaert; Co-Supervisors: Dr. J. Damoiseaux /  Dr. Y. Bols.   
  
Erik D. Gommer: Dynamic Cerebral Autoregulation: from methodology towards clinical 
application. Supervisors: Prof.dr. W.H. Mess / Prof.dr. R.B. Panerai, UK; Co-Supervisor: Dr.ir. J.P.H. 
Reulen.   
  
Olga A.H. Reneerkens: Can PDE inhibition improve cognition ? Translational insights. Supervisor: 
Prof.dr. H.W.M. Steinbusch; Co-Supervisor: Dr. J. Prickaerts.  
   
Lyzel S. Elias-Sonnenschein: Clinical and biomarker correlates of genetic risk factors for 
Alzheimer’s disease. Supervisor: Prof.dr. F.R.J. Verhey; Co-Supervisor: Dr. P.J. Visser.  
  
Diego F. Mastroeni: Epigenetic Dysregulation and the Pathophysiology of Alzheimer’s Disease. 
Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. P.D. Coleman, Sun City, Arizona; Co-Supervisors: 
Dr. B.P.F. Rutten / Dr. D.L.A. van den Hove.   
  
Leonidas Chouliaras: Epigenetic Regulation in Aging and Alzheimer’s disease: A translational 
perspective. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-Supervisors: Dr. B.P.F. Rutten / Dr. D.L.A. 
van den Hove.  
  
Liesbeth Knaepen: Perinatal events and altered pain sensitivity in later life. Supervisors: Prof.dr. 
E.A.J. Joosten / Prof.dr. D. Tibboel, EUR; Co-Supervisor: Dr. J. Patijn.   
  
Marisela Martinez-Claros: Hippocampal plasticity and corticosterone: From dendrites to 
behaviour. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-Supervisors: Dr. J.L. Pawluski / Dr. J. 
Prickaerts.  
  
Marcus D. Lancé: A circle of improvement in bleeding management: from laboratory to clinic and 
back. Supervisors: Prof.dr. M.A.E. Marcu / Prof.dr. J.W.M. Heemskerk;  Co-Supervisor: Dr. Y.M.C. 
Henskens.   
  
Hilde Braakman: Imaging the brain; neuronal correlates of cognitive impairment in children with 
frontal lobe epilepsy. Supervisors: Prof.dr. A.P. Aldenkamp /  Prof.dr. J.S.H. Vles; Co-Supervisors: 
Dr.ir. W.H. Backes / Dr. P.A.M. Hofman.   
  
Willem H. van Zwam: Aneurysmal subarachnoid hemorrhage: imaging strategies and cost-
effectiveness aspects in diagnostic work-up and post-therapeutic follow-up. Supervisors: Prof.dr. 
J.T. Wilmink / Prof.dr. J.E. Wildberger; Co-Supervisor: Dr. P.A.M. Hofman.  
  
Klara De Cort: The Pathogenesis of Panic Disorder. Supervisors: Prof.dr. I. Myin-Germeys / Prof.dr. 
E.J.L. Griez; Co-Supervisors: Dr. K.R.J. Schruers / Dr. I. Van Diest, Leuven.   
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Kim van Wijck: Mind the Gap; experimental studies on splanchnic hyperfusion and 
gastrointestinal integrity loss in man. Supervisors: Prof.dr. W.A. Buurman /  Prof.dr. C.H.C. Dejong; 
Co-Supervisor: Dr. K. Lenaerts.  
  
Yvette Roke: Antipsychotic-induced hyperprolactinemia in children and adolescents with mainly 
autism spectrum disorders. Prevalence, symptoms, clinical consequences and genetic risk 
factors. Supervisors: Prof.dr. P.N. van Harten / Prof.dr. J.K. Buitelaar (RUN); Co-Supervisor: Dr. A. 
Boot (UMCG).   
  
Fleur Goezinne: Retinal detachment surgery: pre and postoperative prognostic factors. 
Supervisors: Prof.dr. F. Hendrikse / Prof.dr. C.A.B. Webers; Co-Supervisor: Dr. E.C. La Heij 
(Amsterdam).  
  
Ralph L.J.G. Maassen: The Merits of Videolaryngoscopy during Glottic Visualisation for 
Endotracheal Intubation. Supervisors: Prof.dr. M. Marcus / Prof.dr. A. van Zundert (University of 
Queensland).  
  
Maria J. de Sousa Guerreiro: The role of sensory modality in age-related distraction. Supervisor: 
Prof.dr. C.M. van Heugten; Co-Supervisor: Dr. P.W.M. van Gerven.   
  
Ine Rayen: Effects of developmental fluoxetine exposure on neurobehavioral outcomes. 
Supervisor: Prof.dr. H.W.M. Steinbusch; Co-Supervisors: Dr. J.L. Pawluski / Dr. T.D. Charlier (Ohio 
University, USA).   
  
Nynke M.G. Bodde: Psychogenic non-epileptic seizures; a separate disorder or part of a 
continuum? Supervisors: Prof.dr. R. van Oostenbrugge / Prof.dr. K. Vonck (UZ Gent);  Co-Supervisors: 
Dr. R. Lazeron / Dr. A. de Louw (Epilepsiecentrum Kempenhaeghe, Heeze).   
  
Alejandro M. Gomez: Novel strategies for making myasthenia less gravis: targeting plasma cells 
and the neuromuscular junction. Supervisor: Prof.dr. M.H. De Baets;  Co-Supervisors: Dr. M. Losen 
/ Dr. P. Martinez-Martinez.  
  
Mohammad S. Rahnama’i: Prostaglandins  and Phosphodiesterases in the Urinary Bladder Wall. 
Supervisors: Prof.dr. Ph. Van Kerrebroeck / Prof.dr. S. de Wachter (Universiteit Antwerpen); Co-
Supervisor: Dr. G. van Koeveringe.   
  
Mariken B. de Koning: Studying biomarkers in populations at genetic and  clinical high risk for 
psychosis. Supervisors: Prof.dr. T. Amelsvoort / Prof.dr. J. Booij (AMC).  
  
Fabien Boulle: Epigenetic regulation of BDNF/TrkB signaling in the pathophysiology and 
treatment of mood disorders. Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. L. Lanfumey 
(Universiteit Parijs); Co-Supervisors: Dr. D. van den Hove / Dr. G. Kenis.  
  
2014 
Iris Nowak-Maes: Tinnitus; assessment of quality of life & cost-effectiveness. Supervisors: Prof.dr. 
M. Peters / Prof.dr. B. Kremer; Co-Supervisors: Dr. M. Joore / Dr. L. Anteunis.  
     
Marjolein Huijts: Cognitive function in patients with cerebral small vessel disease. Supervisor: 
Prof.dr. R.J. van Oostenbrugge; Co-Supervisors: Dr. A.A. Duits / Dr. J. Staals.   
      
Markus Gantert: Fetal inflammatory injury as origin of long term disease: Lessons from animal 
models. Supervisors: Prof.dr. B. Kramer / Prof.dr. L. Zimmermann; Co-Supervisor: Dr. A. Gavilanes.   
     
THESIS DEFENSES FROM MHeNs 
278 
 
Elke Kuypers: Fetal development after antenatal exposures: Chorioamnionitis and maternal 
glucocorticoids. Supervisors: Prof.dr. B.W. Kramer / Prof.dr. H.W. Steinbusch / Prof.dr. Suhas G. 
Kallapur (University of Cincinnati, Ohio, USA).  
  
Pieter Kubben: Ultra low-field strength intraoperative MRI for Glioblastoma Surgery. Supervisor: 
Prof.dr. J.J. van Overbeeke; Co-Supervisor: Dr. H. van Santbrink.   
  
Laura Baijens: Surface electrical stimulation of the neck for oropharyngeal dysphagia in 
Parkinson’s disease: therapeutic aspects and reliability of measurement. Supervisor: Prof.dr. B. 
Kremer; Co-Supervisor: Dr. R. Speyer, Townsville.   
  
Janneke Hoeijmakers: Small fiber neuropathy and sodium channels; a paradigm shift. Supervisor: 
Prof.dr. R.J. van Oostenbrugge; Co-Supervisors: Dr. C.G. Faber / Dr. I.S.J. Merkies.   
  
Stephanie Vos: The Role of biomarkers in preclinical and prodromal Alzheimer’s disease. 
Supervisor: Prof.dr. F.R. Verhey; Co-Supervisor: Dr. P.J. Visser.   
  
Muriël Doors: The Value of Optical Coherence Tomography in Anterior Segment Surgery. 
Supervisors: Prof.dr. R.M. Nuijts / Prof.dr. C.A. Webers; Co-Supervisor: Dr. T.T.J.M. Berendschot.  
  
Anneke Maas: Sleep problems in individuals with genetic disorders associated with intellectual 
disability. Supervisors: Prof.dr. I. Curfs / Prof.dr. R. Didden.  
  
Sebastiaan van Gorp: Translational research on spinal cord injury and cell-based therapies; a 
focus on pain and sensorimotor disturbances. Supervisors: Prof.dr. B. Joosten / Prof.dr. M. van 
Kleef; Co-Supervisors: Dr. J. Patijn / Dr. R. Deumens, KU Leuven.   
   
Andrea Sannia: High risk newborns and brain biochemical monitoring. Supervisor: Prof.dr. J.S.H. 
Vles; Co-Supervisors: Dr. D. Gazzolo, Alessandria, Italy /  Dr. A.W.D. Gavilanes.   
   
Julie A.D.A. Dela Cruz: Dopamine mechanisms in learning and memory: Evidence from rodent 
studies. Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. R.J. Bodnar, New York; Co-Supervisor: Dr. 
B.P.F. Rutten.  
  
René Besseling: Brain wiring and neuronal dynamics; advances in MR imaging of focal epilepsy. 
Supervisors: Prof.dr. A.P. Aldenkamp / Prof.dr.ir. W.H. Backes; Co-Supervisor:  dr. J.F.A. Jansen.   
  
Maria Quint-Fens: Long-term care after stroke; development and evaluation of a longterm 
intervention in primary care. Supervisors: Prof.dr. J.F.M. Metsemakers /  Prof.dr. C.M. van Heugten / 
Prof.dr. M. Limburg, Almere; Co-Supervisor:  dr. G.H.M.I. Beusmans.   
  
Veronique Moulaert: Life after survival of a cardiac arrest; the heart of the matter. Supervisors: 
Prof.dr. J.A. Verbunt / Prof.dr. C.M. van Heugten / Prof.dr. D.T. Wade, Oxford, UK.   
   
Feikje Smeets: The hallucinatory-delusional state: a crucial connection in the psychosis 
symptom network. Supervisor: Prof.dr. J. van Os; Co-Supervisor: Dr. T. Lataster.  
  
Lies Clerx: Alzheimer’s disease through the MR-eye; novel diagnostic markers and the road to 
clinical implementation”. Supervisor: Prof.dr. F. Verhey; Co-Supervisors: Dr. P.J. Visser / P. Aalten.   
  
Sonny Tan: The subthalamic nucleus in Parkinson’s disease. Supervisors:  Prof.dr. Y. Temel / 
Prof.dr. H.W.M. Steinbusch / Prof.dr. T. Sharp, Oxford, UK /  Prof.dr. V. Visser-Vandewalle, Koln.  
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Koen van Boxem: The use of pulsed radiofrequency in the management of chronic lumbosacral 
radicular pain. Supervisors: Prof.dr. M. van Kleef / Prof.dr. E.A.J. Joosten; Co-Supervisor: Assoc. 
Prof.dr. J. van Zundert.   
   
Jérôme Waterval: Hyperostosis cranialis interna. Supervisors: Prof.dr. J.J. Manni / Prof.dr. R.J. 
Stokroos.   
  
Sylvie Kolfschoten-van der Kruijs: Psychogenic non-epileptic seizures; the identification of 
neurophysiological correlates. Supervisors: Prof.dr. A.P. Aldenkamp / Prof.dr. K.E.J. Vonck, 
Universiteit Gent; Co-Supervisors: Dr. J.F.A. Jansen / Dr. R.H.C. Lazeron, Kempenhaeghe.  
  
Wouter Pluijms: Spinal cord stimulation and pain relief in painful diabetic: polyneuropathy, a 
translational approach. Supervisors: Prof.dr. M. van Kleef /  Prof.dr. E.A. Joosten; Co-supervisor: Dr. 
C.G. Faber.  
  
Ron Handels: Health technology assessment of diagnostic strategies for Alzheimer’s disease. 
Supervisors: Prof.dr. F.R.J. Verhey / Prof.dr. J.L. Severens (EUR); Co-Supervisor: Dr. M.A. Joore / Dr. 
C.A.G. Wolfs.   
  
Evelyn Peelen: Regulatory T cells in the pathogenesis of Multiple Sclerosis: potential targets for 
vitamin D therapy. Supervisors: Prof.dr. R.M.M. Hupperts / Prof.dr. J.W. Cohen Tervaert; Co-
Supervisor: Dr. J.G.M.C. Damoiseaux / Dr. M.M.G.L.Thewissen, Diepenbeek.   
  
Reint Jellema: Cell-based therapy for hypoxic-ischemic injury in the preterm brain. Supervisors: 
Prof.dr. B.W.W. Kramer / Prof.dr. H.W.M. Steinbusch; Co-Supervisor: Dr. W.T.V. Germeraad / Dr. P. 
Andriessen, Veldhoven.  
  
Maria Wertli: Prognosis of Chronic Clinical Pain Conditions: The Example of Complex Regional 
Pain Syndrome 1 and Low Back Pain. Supervisors: Prof.dr. M. van Kleef;  Co-Supervisor: Dr. F. 
Brunner, Zürich / Dr. R. Perez, VUmc.   
  
Dagmar Zeef: An experimental model of Huntington’s disease: Validation & Stimulation. 
Supervisors: Prof.dr. Y. Temel / Prof.dr. H.W.M. Steinbusch; Co-supervisor: Dr. A. Jahanshahi.  
  
Jeroen Decoster: Breaking Down Schizophrenia into phenes, genes and environment. Supervisors: 
Prof.dr. I. Myin-Germeys / Prof.dr. M. De Hert, KU Leuven; Co-Supervisor: Dr. R. van Winkel.  
  
Eaja Anindya Sekhar Mukherjee: Fetal Alcohol Spectrum Disorders: exploring prevention and 
management. Supervisor: Prof.dr. L.M.G. Curfs; Co-Supervisor: Prof. S. Hollins, St. George’s 
University of London, UK.   
  
Catherine van Zelst: Inside out; On stereotype awareness, childhood trauma and stigma in 
psychosis. Supervisors: Prof.dr. Ph. Delespaul / Prof.dr. J. van Os.  
  
Ibrahim Tolga Binbay: Extended Psychosis Phenotype  in the Wider Social Environment. 
Supervisor: Prof.dr. J. van Os; Co-Supervisor: Dr. M. Drukker.   
  
Frank Van Dael: OCD matters in psychosis. Supervisors: Prof.dr. J. van Os /  Prof.dr. I. Myin-Germeys.  
  
Pamela Kleikers: NOXious oxidative stress: from head toe too and back. Supervisors: Prof.dr. 
H.H.H.W. Schmidt / Prof.dr. H.W.M. Steinbusch; Co-Supervisor: Dr. B. Janssen.  
  
José Luis Gerardo Nava: In vitro assay systems in the development of therapeutic interventions 
strategies for neuroprotection and repair. Supervisors: Prof.dr.med. J. Weis / Prof.dr. H.W.M. 
Steinbusch; Co-Supervisor: Dr. G.A. Brook, RWTH Aachen.  
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Eva Bollen: Cyclic nucleotide signaling and plasticity. Supervisors: Prof.dr. H.W.M. Steinbusch / 
Prof.dr. R. D’Hooge, KU Leuven; Co-Supervisor: Dr. J. Prickaerts.   
  
2015  
Jessica A. Hartmann: A good laugh and a long sleep; Insights from prospective and ambulatory 
assessments about the importance of positive affect and sleep in mental health. Supervisor: 
Prof.dr. J. van Os; Co-Supervisors: C.J.P. Simons / Dr. M. Wichers.   
  
Bart Ament: Frailty in old age; conceptualization and care innovations. Supervisors: Prof.dr. 
G.I.J.M. Kempen / Prof.dr. F.R.J. Verhey; Co-Supervisor: Dr. M.E. de Vugt.   
  
Mayke Janssens: Exploring course and outcome across the psychosis-continuum. Supervisor: 
Prof.dr. I. Myin-Germeys; Co-Supervisor: Dr. T. Lataster.  
  
Dennis M.J. Hernau: Dopayours is not dopamine: genetic, environmental and pathological 
variations in dopaminergic stress processing. Supervisor: Prof.dr. I. MyinGermeys; Co-Supervisors: 
Prof.dr. F.M. Mottaghy / Dr. D. Collip.   
  
Ingrid M.H. Brands: The adaptation process after acquired brain injury Pieces of the puzzle. 
Supervisors: Prof.dr. C.M. van Heugten / Prof.dr. D.T. Wade, Oxford UK;  Co-Supervisors: Dr. S.Z. 
Stapert / Dr. S. Köhler.  
  
Francesco Risso: Urinary and salivary S100B monitoring in high risk infants. Supervisor: Prof.dr. 
J.S.H. Vles; Co-Supervisors: Dr. D. Gazzolo, Genoa,Italy / Dr. A.W.D. Gavilanes.  
  
Alessandro Borghesi: Stem and Progenitor Cells in Preterm Infants: Role in the Pathogenesis and 
Potential for Therapy. Supervisor: Prof.dr. L. Zimmermann; Prof.dr. B. Kramer; Co-Supervisors: Dr. D. 
Gazzolo, Genoa,Italy / Dr. A.W.D. Gavilanes.  
  
Claudia Menne-Lothmann: Affect dynamics; A focus on genes, stress, and an opportunity for 
change. Supervisor: Prof.dr. J. van Os; Co-Supervisors: Dr. M. Wichers / Dr. N. Jacobs.   
  
Martine van Nierop: Surviving childhood new perspectives on the link between childhood trauma 
and psychosis. Supervisors: Prof.dr. I. Myin-Germeys / Prof.dr. J. van Os;  Co-Supervisor: Dr. R. van 
Winkel.  
  
Sylvia Klinkenberg: VNS in children; more than just seizure reduction. Supervisors: Prof.dr. J. Vles 
/ Prof.dr. A. Aldenkamp; Co-Supervisor: Dr. H. Majoie.  
  
Anouk Linssen: Considerations in designing an adult hearing screening programme. Supervisor: 
Prof.dr. B. Kremer; Co-Supervisors: Dr. L. Anteunis / Dr. M. Joore.   
  
Janny Hof: Hearing loss in young children; challenges in assessment and intervention. 
Supervisors: Prof.dr. B. Kremer / Prof.dr. R. Stokroos / Prof.dr. P. van Dijk, RUG;  Co-Supervisor: Dr. L. 
Antheunis.   
  
Kimberly Cox-Limpens: Mechanisms of endogenous brain protection; Clues from the 
transcriptome. Supervisors: Prof.dr. J. Vles / Prof.dr. L. Zimmermann; Co-Supervisor: Dr. A. Gavilanes.  
  
Els Vanhoutte: Peripheral Neuropathy outcome measures; Standardisation (PeriNomS) study part 
2: Getting consensus. Supervisors: Prof.dr. C. Faber / Prof.dr. P. van Doorn;  Co-Supervisor: Dr. I. 
Merkies, Spaarne ziekenhuis Hoofddorp.  
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Mayienne Bakkers: Small fibers, big troubles; diagnosis and implications of small fiber 
neuropathy. Supervisors: Prof.dr. C. Faber / Prof.dr. M. de Baets; Co-Supervisor: Dr. I. Merkies, 
Spaarne ziekenhuis Hoofddorp.  
  
Ingrid Kramer: Zooming into the micro-level of experience: An approach for understanding and 
treating psychopathology. Supervisor: Prof.dr. J. van Os;  Co-Supervisors: Dr. M. Wichers, UMC 
Groningen / Dr. C. Simons.  
  
Esther Bouman: Risks and Benefits of Regional Anesthesia in the Perioperative Setting. 
Supervisors: Prof.dr. M. van Kleef / Prof.dr. M. Marcus, HMC, Qatar / Prof.dr. E. Joosten; Co-Supervisor: 
Dr. H. Gramke.  
  
Mark Janssen: Selective stimulation of the subthalamic nucleus in Parkinson’s disease; dream 
or near future. Supervisors: Prof.dr. Y. Temel / Prof.dr. V. Visser-Vandewalle, Keulen / Prof.dr. A. 
Benazzouz, Bordeax, France.  
  
Reina de Kinderen: Health Technology Assessment in Epilepsy; economic evaluations and 
preference studies. Supervisors: Prof.dr. S. Evers / Prof.dr. A. Aldenkamp;  Co-Supervisor: Dr. H. 
Majoie / Dr. D. Postulart, GGZ O-Brabant.   
  
Saskia Ebus: Interictal epileptiform activity as a marker for clinical outcome. Supervisors: Prof.dr. 
A. Aldenkamp / Prof.dr. J. Arends, TUE / Prof.dr. P. Boon, Universiteit Gent, België.  
  
Inge Knuts: Experimental and clinical studies into determinants of panic severity. Supervisor: 
Prof.dr. I. Myin-Germeys; Co-Supervisor: Dr. K. Schruers; Influencing panic.   
  
Nienke Tielemans: Proactive coping post stroke: The Restored4Stroke Self-Management study. 
Supervisors: Prof.dr. C. van Heugten / Prof.dr. J. Visser-Meily, UMC Utrecht;  Co-Supervisor: Dr. V. 
Schepers, UMC Utrecht.  
 
Tom van Zundert: Improvements Towards Safer Extraglottic Airway Devices. Supervisors: Prof.dr. 
A.E.M. Marcus / Prof.dr. W. Buhre / Prof.dr. J.R. Brimacombe, Queensland, Australia / Prof.dr. C.A. 
Hagberg.  
  
Tijmen van Assen: Anterior Cutaneous Nerve Entrapment Syndrome Epidemiology and surgical 
management. Supervisors: Prof.dr. G.L. Beets / Prof.dr. M. van Kleef / Dr. R.M.H. Roumen / Dr. M.R.M. 
Scheltinga, MMC Veldhoven.  
  
Rohit Shetty: Understanding the Clinical, Immunological and Genetic Molecular Mechanisms of 
Keratoconus. Supervisors: Prof.dr. R.M.M.A. Nuijts / Prof.dr. C.A.B. Webers.  
  
Christine van der Leeuw: Blood, bones and brains; peripheral biological endophenotypes and their 
structural cerebral correlates in psychotic disorder. Supervisor: Prof.dr. J. van Os; Co-supervisor: 
Dr. M. Marcelis.  
  
Sanne Peeters: The Idle Mind Never Rests; functional brain connectivity across the psychosis 
continuum. Supervisor: Prof.dr. J. van Os; Co-supervisor: dr. M. Marcelis.  
  
Nick van Goethem: α7 nicotinic acetylcholine receptors and memory processes: mechanistic and 
behavioral studies. Supervisor: Prof.dr. H.W.M. Steinbusch; Cosupervisor: Dr. J. Prickaerts.  
  
Nicole Leibold: A Breath of fear; a translational approach into the mechanisms of panic.  
Supervisor: Prof.dr. H.W.M. Steinbusch; Co-supervisors: Dr. K.R.J. Schruers / Dr. D.L.A. van den Hove.  
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Renske Hamel: The course of mild cognitive impairment and the role of comorbidity. Supervisor: 
Prof.dr. F.R.J. Verhey; Co-supervisors: Dr. I.H.G.B. Ramakers / Dr. P.J. Visser.  
  
Lucia Speth: Effects of botulinum toxin A injections and bimanual task-oriented therapy on hand 
functions and bimanual activities in unilateral Cerebral Palsy. Supervisors: Prof.dr. J. Vles; Prof.dr. 
R. Smeets; Co-supervisor: Dr. Y. Janssen-Potten, Adelante Hoensbroek.  
  
Yuan Tian: The effects of Lutein on the inflammatory pathways in age-related macular 
degeneration (AMD). Supervisors: Prof.dr. C. Webers; Prof.dr. A. Kijlstra, WUR; Cosupervisor: Dr. M. 
Spreeuwenberg; Dr. H. Tange.  
  
Peggy Spauwen: Cognition and Type 2 diabetes; the interplay of risk factors. Supervisors: Prof.dr. 
F. Verhey; Prof.dr. C. Stehouwer; Co-supervisor: Dr. M. van Boxtel  
  
Marc Hilhorst: Crescentic glomerulonephritis in ANCA associated vasculitis. Supervisors: Prof.dr. 
J. Cohen-Tervaert; Co-supervisor: Dr. P. van Paassen Martin Gevonden: The odd one out: exploring 
the nature of the association between minority status and psychosis. Supervisors: Prof.dr. J-P. 
Selten; Prof.dr. J. Booij, Uva; Prof.dr. I. Myin-Germeys  
  
Bart Biallosterski: Structural and functional aspects of sensory-motor Interaction in the urinary 
bladder. Supervisors: Prof.dr. Ph. Van Kerrebroeck; Prof.dr. S. De Wachter, UvAntwerpen; Co-
supervisors: Dr. G. van Koeveringe; Dr. M. Rahnama’i.  
  
Alexandra König: The use of information and communication technologies (ICT) for the 
assessment of patients with Alzheimer’s Disease and related disorders. Supervisors: prof.dr. F. 
Verhey; prof.dr. Ph. Robert, Nice, Fr; Co-supervisors: dr. P. Aalten; dr. R. David, Nice. Fr.  
  
Michelene Chenault: Assessing Readiness for Hearing Rehabilitation. Supervisors: prof.dr. M.P.F. 
Berger; prof.dr. B. Kremer; Co-supervisor: dr. L.J.C. Anteunis.  
  
Anand Vinekar: Retinopathy of Prematurity. Recent advances in tele-medicine screening, risk 
factors and spectral domain optical coherence tomography imaging. Supervisor: prof.dr. C.A.B. 
Webers; Co-supervisor: dr. N.J. Bauer  
  
Fleur van Dooren: Diabetes and Depression: exploring the Interface between Pathophysiological 
and Psychological factors. Supervisors: prof.dr. F.R.J. Verhey; prof.dr. J.K.L. Denollet, UvT; prof.dr. 
F. Pouwer, UvT; Co-supervisor: dr. M.T. Schram.  
  
Gabriëlla Pons van Dijk: Taekwondo and physical fitness components in  middle-aged healthy 
volunteers; the Sekwondo study. Supervisors: prof.dr. J. Lodder; prof.dr. H. Kingma; Co-supervisor: 
dr. A.F. Lenssen.  
  
Yara Pujol López: Development and psychoneuroimmunological mechanisms in depression. 
Supervisor: prof.dr. H.W.M. Steinbusch; Co-supervisors: Dr. G. Kenis; Dr. D. van den Hove; Dr. Aye Mu 
Myint, München.  
  
Romina Gentier: UBB+1; an important switch in the onset of Alzheimer’s disease. Supervisors: Prof. 
H. Steinbusch; Prof. D. Hopkins; Co-supervisor: Dr. F. van Leeuwen.  
  
Sanne Smeets: Insights into insight: studies on awareness of deficits after acquired brain injury. 
Supervisor: Prof. C. van Heugten; Prof. R. Ponds; Co-supervisor: Dr. I. Winkens  
  
Kim Beerhorst: Bone disease in chronic epilepsy: fit for a fracture. Supervisor: Prof. A. Aldenkamp; 
Prof. R. van Oostenbrugge; Co-supervisor: Dr. P. Verschuure.  
  
Alex Zwanenburg: Cerebral and cardiac signal monitoring in fetal sheep with hypoxicischemic 
encephalopathy. Supervisor: Prof. T. Delhaas; Prof. B. Kramer; Co-supervisors: Dr. T. Wolfs; Dr. P. 
Andriessen, MMC.  
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Ismail Sinan Guloksuz: Biological mechanisms of environmental stressors in psychiatry. 
Supervisor: Prof. J. van Os; Co-supervisors: Dr. B. Rutten; Dr. M. Drukker.  
  
Seyed Ehsan Pishva MD: Environmental Epigenetics in mental health and illness. Supervisor: 
Prof.dr. J. van Os; Co-supervisors: Dr. B.P.F. Rutten; Dr. G. Kenis.  
  
Ankie Hamaekers: Rescue ventilation using expiratory ventilation assistance; innovating while 
clutching at straws. Supervisors: Prof.dr. W.F. Buhre; Prof.dr. M. van Kleef.  
  
Rens Evers. 22q11.2 deletion syndrome: intelligence, psychopathology and neurochemistry at 
adult age. Supervisors: Prof.dr. L.M.G. Curfs; Prof.dr. T. v. Amelsvoort.  
  
Sarah-Anna Hescham. Novel insights towards memory restoration. Supervisor: Prof.dr.  Y. Temel; 
Co-supervisor: Dr. A. Blokland; Dr. A. Jahanshahi.  
  
João P. da Costa Alvares Viegas Nunes. Insulin receptor sensitization improves affective  
pathology in various mouse models. Supervisor: Prof.dr. H.W.M. Steinbusch; Cosupervisors: Dr. K-
P. Lesch; Dr. T. Strekalova; Dr.B.H. Cline, Oxford.  
  
Yanny Ying-Yee Cheng. Clinical Outcomes After Innovative Lamellar Corneal Transplantation 
Surgery. Supervisor: Prof.dr. R.M.M.A. Nuijts; Co-supervisor:  Dr. J.S.A.G. Schouten.  
  
2016 
Oliver Gerlach. Parkinson’s disease, deterioration during hospitalization. Supervisor: Prof.dr. R. 
van Oostenbrugge; Co-supervisor: Dr. W. Weber.  
  
Remo Arts. Intracochlear electrical stimulation to suppress tinnitus. Supervisor: Prof.dr. R.J. 
Stokroos; Co-supervisor: Dr. E.L.J. Georg.   
  
Mitchel van Eeden. The €- Restore4stroke study: Economic evaluation of stroke care in the 
Nethrelands. Supervisors: prof.dr. mr. S.M.A.A. Evers; prof.dr. C.M.v. Heugten; Co-supervisor: dr. 
G.A.P. v. Mastrigt.  
  
Pim Klarenbeek. Blood pressure and cerebral small vessel disease. Supervisor: Prof.dr. R.J. van 
Oostenbrugge; Co-supervisor: Dr. J. Staals.   
  
Ramona Hohnen. Peripheral pharmacological targets to modify bladder contractility. Supervisor: 
Prof.dr. Ph.E.V. van Kerrebroeck; Co-supervisors: Dr. G.A. van Koeveringe;  Dr. M.A. Sahnama’i; Dr. 
C. Meriaux.   
  
Ersoy Kocabicak. Deep brain stimulation of the subthalamic nucleus: Clinical and scientific 
aspects. Supervisors: Prof.dr. Y. Temel; Prof.dr. K. van Overbeeke; Co-supervisor: Dr. A. Jahanshahi.   
  
Sven Akkerman. Temporal aspects of cyclic messenger signaling in object recognition memory; 
a pharmalogical approach. Supervisor: Prof.dr. H.W.M. Steinbusch;  Co-supervisors: dr. J. Prickaerts; 
dr. A. Blokland.  
  
Anja Moonen. Emotion and Cognition in Parkinson’s disease; etiology and neurobiological 
mechanisms. Supervisor: Prof.dr. F.R.J. Verhey; Co-supervisor: dr. A.F.G. Leentjens.   
  
Anna Schüth. Three-dimensional bladder tissue morphology. Supervisors: Prof.dr. G.A. van 
Koeveringe; Prof.dr. M. v. Zandvoort, Aachen; Prof.dr. Ph. V. Kerrebroeck.  
  
Elisabeth van der Ven. Ethnic minority position as risk indicator for autism- Spectrum and 
psychotic disorders. Supervisors: Prof.dr. J.P. Selten; Prof.dr. J. van Os.  
  
Zuzana Kasanova. Environmental reactivity for better or worse; The impact of stress and reward 
on neurochemistry, affect and behavior across the psychosis continuum. Supervisor: Prof.dr. I. 
Myin-Germeys, KU Leuven/UM; Co-supervisor: dr. D. Collip.  
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Danielle Lambrechts. Ketogenic diet therapies; treatment for children and adults with refractory 
epilepsy. Supervisors: Prof.dr. H.J.M. Majoie; Prof.dr. J.S.H. Vles; Prof.dr. A.P. Aldenkamp; Co-
supervisor: dr. A.J.A. de Louw, Kempenhaghe, Heeze.  
  
Frank van Bussel. Advanced MRI in diabetes; cerebral biomarkers of cognitive decrements. 
Supervisors: Prof.dr.ir. W.H. Backes; Prof.dr. P.A.M. Hofman; Co-supervisor: dr. J.F.A. Jansen.  
  
Lisa Schönfeldt. Neurostimulation to treat brain injury? Supervisors: Prof.dr. Y. Temel; Prof.dr. S. 
Hendrikx, Hasselt; Co-supervisor: dr. A. Jahanshahi.  
  
Rianne Geerlings. Transition in patients with childhood-onset epilepsy; a long way to adulthood. 
Supervisor: Prof.dr. A.P. Aldenkamp; Co-supervisors:dr. A.J.A. de Louw,  dr. L.M.C. Gottmer, 
Kempenhaeghe.  
  
Nele Claes. B cells as multifactorial players in multiple sclerosis pathogenesis: insights from 
therapeutics. Supervisors: Prof.dr. V. Somers, Hasselt; Prof.dr. R. Hupperts Co-supervisors: Prof.dr. 
P. Stinissen, dr. J. Fraussen, Hasselt.  
  
Olaf Schijns. Epilepsy surgery and biomarkers from history to molecular imaging. Supervisors: 
Prof.dr. J.J. van Overbeeke; Prof.dr. H. Clustermann, Aachen; Co-supervisors: dr. G. Hoogland; dr. 
M.J.P. v. Kroonenburgh.  
  
Lizzy Boots. Balanced and Prepared; development and evaluation of a supportive ehealth 
intervention for caregivers of people with early-stage dementia. Supervisors: Prof.dr. F.R.J. 
Verhey; Prof.dr. G.I.J.M. Kempen; Co-supervisor: dr. M.E. de Vugt.  
  
Wouter Donders. Towards patient-specific (cerebro-) vascular model applications. Supervisors: 
Prof.dr. T. Delhaas; Prof.dr.ir. F.N. van de Vosse, TUE; Co-supervisor:  dr.ir. W. Huberts.  
  
Sizzle Vanterpool. The implications of intrauterine invasion by microbes for placental Pathology 
and the occurrence of adverse pregnancy outcomes. Supervisor: Prof.dr. B.W. Kramer. Co-
supervisors:  dr. J.V. Been, Erasmus MC Rotterdam, dr. U von Rango.  
  
Manuela Heins. The Relationship between Social Adversity, Psychosis, and Depression across 
an Individual’s Life Span. Supervisor: Prof.dr. I. Myin-Germeys.  
  
Christianus van Ganzewinkel. NEONATAL PAIN; Out of Sight, Out of Mind? Supervisor: Prof.dr. 
B.W.W. Kramer; Co-supervisor: dr. P. Andriessen, MMC Veldhoven.  
  
Anne-Hilde Muris. Hype or hope? Vitamin D in multiple sclerosis; A clinical and immunological 
perspective. Supervisor: Prof.dr. R.M.M. Hupperts; Co-supervisor:  dr. J.G.M.C. Damoiseaux.  
  
Gerard Bode. The link between ceramide transporters, innate Immunity and Alzheimer’s disease. 
Supervisor: Prof.dr. M.H.V. de Baets; Co-supervisors: dr. P. Martinez, dr. M. Losen.   
   
Jo Stevens. Advanced diagnostics and therapeutics for Alzheimer’s disease. Supervisor: Prof.dr. 
M. de Baets; Co-supervisors: dr. M. Losen, dr. P. Martinez-Martinez.  
   
Rosan Luijcks. Stress and pain in muscles and brain; developing psychophysiological paradigms 
to examine stress and pain interactions.  Supervisors: Prof.dr. J.J. van Os; Prof.dr.ir. H.J. Hermens, 
UT; Co-supervisor: dr. R. Lousberg.  
  
M.C. Haanschoten. Towards efficient cardiac surgery – the integrating role of anesthesiology and 
intensive care. Supervisors: Prof. dr. W. Buhre; Prof. dr. A. van Zundert (Queensland); Co-supervisors: 
Dr. M.A. Soliman Hamad; Dr. A. van Straten (Catharina zkhs.)  
   
Harmen Jan van de Haar. Microvascular and blood-brain barrier dysfunction in Alzheimer’s 
disease. Supervisor: Prof.dr.ir. W. Backes; Prof.dr. F. Verhey; Co-supervisor: Dr. J. Jansen; Dr.ir. M. v. 
Osch, LUMC.  
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Coenraad Itz. Chronic low back pain, considerations about: Natural Course, Diagnosis, 
Interventional Treatment and Costs. Supervisor: Prof.dr. M. van Kleef; Prof.dr. F. Huygen, EUR; 
Cosupervisor: Dr. B. Ramaekers.  
  
Willemijn Jansen. The Path of Alzheimer’s disease: from neuropathology to clinic.  Supervisor: 
Prof.dr. F. Verhey; Co-supervisors: Dr. P.J. Visser; Dr. I. Ramakers.  
  
Ligia dos Santos Mendes Lemes Soares. Phosphodiesterase inhibitors: a potential therapeutic 
approach for ischemic cerebral injury. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-supervisors: Dr. 
R.M. Weffort de Oliveira, Brazil; Dr. J. Prickaerts  
  
Martijn Broen. Anxiety and depression in Parkinson’s disease. Supervisor: Prof.dr. R.J. van 
Oostenbrugge; Co-supervisors: Dr. A.F.G. Leentjens; Dr. M.L. Kuijf.  
  
Sandra Schipper. Extrasynaptic receptors as a treatment target in epilepsy. Supervisor: Prof.dr. 
J.H.S. Vles; Co-supervisors: Dr. G. Hoogland; Dr. S. Klinkenberg; Dr. M.W. Aalbers, RUG.  
  
João Casaca Carreira. Making sense of Antisense Oligonucleotides Therapy in Experimental 
Huntington’s disease. Supervisor: Prof.dr. Y. Temel; Co-supervisors: Dr. A. Jahanshahi; Dr. W. van 
Roon-Mom, LUMC.  
  
Dominique IJff. Trick or Treat? Cognitive side-effects of antiepileptic treatment. Supervisors: 
Prof.dr. A.P. Aldenkamp; Prof.dr. M. Majoie; Co-supervisors: Dr. J. Jansen; Dr. R. Lazeron, 
Kempenhaeghe.  
  
Alfredo Ramirez. Neurogenetic approach in neurodegenerative disorders. Supervisors: Prof.dr. 
B.P.F. Rutten; Prof.dr. H.W.M. Steinbusch; Prof.dr. M.M. Nöthen, University of Bonn.   
  
Nienke Visser. Toric Intraocular lenses in cataract surgery. Supervisor: Prof.dr. R.M.M.A. Nuijts; Co-
supervisor: Dr. N.J.C. Bauer.  
  
Jakob Burgstaller. Prognostic indicators for patients with degenerative lumbar spinal stenosis. 
Supervisor: Prof.dr. M. van Kleef; Co-supervisors: Dr. M.M. Wertli, University of Zurich; Dr. H.F. Gramke.  
  
Mark van den Hurk. Neuronal Identity and Maturation: Insights from the Single-Cell 
Transcriptome. Supervisors: Prof.dr. H.W.M. Steinbusch; Prof.dr. B.P.F. Rutten; Cosupervisors: Dr. G. 
Kenis; Dr. C. Bardy, Adelaide.  
  
Maria Nikiforou. Prenatal stress and the fetal gut. Potential interventions to prevent adverse 
outcomes. Supervisors: Prof.dr. B.W. Kramer; Prof.dr. H.W. Steinbusch; Cosupervisor: Dr. T.G. Wolfs.  
  
Janneke Peijnenborgh. Assessment of cognition, time perception, and motivation in children. 
Supervisors: Prof.dr. J.S.H. Vles; Prof.dr. A.P. Aldenkamp; Co-supervisors: Dr. J. Hendriksen; Dr. P. 
Hurks.  
  
Joany Millenaar. Young onset dementia; towards a better understanding of care needs and 
experiences. Supervisors: Prof.dr. F. Verhey; Prof.dr. R. Koopmans, RUN; Cosupervisors: Dr. M. de 
Vugt; Dr. C. Bakker, RUN.  
  
2017 
Adriana Smits. Perinatal factors and hearing outcome. Supervisors: Prof.dr. R.J. Stokroos; Prof.dr. 
B.W. Kramer; Prof.dr. B. Kremer.  
  
Angela Bouwmans. Transcranial sonography in parkinsonian disorders: clear window or blurred 
vision. Supervisor: Prof.dr. W.H. Mess; Co-promotores: Dr. W.E.J. Weber; Dr. A.F.G. Leentjens.  
  
Björn K. Stessel. Patient centred care after day surgery: scope for improvement. Supervisors: 
Prof.dr. W. Buhre; Prof.dr. B. Joosten. Co-supervisor: Dr. A.H. Gramke.  
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Jan Guy Bogaarts. Quantitative EEG and machine learning methods for the detection of epileptic 
seizures and cerebral asymmetry. Supervisor: Prof.dr. W.M. Mess; Co-supervisor: Dr.ir. J.P.H. 
Reulen; Dr.ir. E.D. Gommer.  
   
Martin M. Müller. Pregnancy derived products for treatment of perinatal brain injuries. Supervisors: 
Prof.dr. B.W.W. Kramer; Prof.dr. D. Surbek, Bern; Co-supervisors: Dr. T. Wolfs; Dr. G. Gavilanes.  
  
Daan Ophelders. Novel treatment strategies for the protection of the preterm brain; Rebalancing 
inflammation and regeneration. Supervisor: Prof.dr. B. Kramer; Co-supervisor:  Dr. T. Wolfs; Dr. R. 
Jellema.  
  
Rosalie van Knippenberg. Experience sampling in dementia care; an innovative intervention to 
support caregivers in daily life. Supervisors: Prof.dr. F. Verhey; Prof.dr. R. Ponds; Prof.dr. I. Myin-
Germeys, KU Leuven; Co-supervisor: Dr. M. de Vugt.  
  
Claudia Vingerhoets. Investigating neurobiological mechanisms underlying comorbid cognitive 
symptoms in psychosis and substance use. Supervisors: Prof.dr. T. van Amelsvoort; Prof.dr. J. 
Booij, UvA; Co-supervisor: Dr. O. Bloemen  
  
Dennis Oerlemans. Evolution of Neuromodulation for Lower Urinary Tract Dysfunction; Past, 
Present and Future. Supervisors: Prof.dr. Ph. van Kerrebroeck; Prof.dr. G. van Koeveringe. Co-
supervisors: Dr. E. Weil; Dr. T. Marcelissen.  
  
Marion Levy. Evaluation of BDNF/TrkB signaling as a common target in the treatment of major 
depression and Alzheimer’s disease. Supervisors: Prof.dr. H. Steinbusch; Prof. L. Lanfumey, 
Université Paris Descartes, France. Co-supervisors: Dr. G. Kenis; Dr. D. van den Hove.  
  
Patrick Domen. Stay connected: a family-based diffusion imaging study in psychotic disorder. 
Supervisor: Prof.dr. J. van Os. Co-supervisor: Dr. M. Marcelis  
  
Geor Bakker. Innovative Approaches to Understanding the Neurobiology of Psychosis. 
Supervisors: Prof.dr. T. van Amelsfoort; Prof.dr. J. Booij, UvA. Co-supervisor: dr. M. Caan, UvA; dr. O. 
Bloemen.  
  
Wilma Boevink. HEE! Over Herstel, Empowerment en Ervaringsdeskundigheid in de psychiatrie. 
Supervisors: Prof.dr. J. van Os; Prof.dr. Ph. Delespaul. Co-supervisor: dr. H. Kroon.  
  
Nataliia Markova . Modified swim test as a mouse depression paradigm of enhanced Cognitive 
processing: the role of GSK3β. Supervisor: Prof.dr. H. Steinbusch; Prof.dr. K-P. Lesch, University of 
Wuerzburg. Co-supervisor: Dr. T. Strekalova.  
  
Merijn van de Laar. Individual differences in insomnia; implications of Psychological factors for 
diagnosis and treatment. Supervisor: Prof.dr. A. Aldenkamp; Prof.dr. D. Pevernagie, Universiteit Gent. 
Co-supervisor: Dr. S. Overeem, TUE.  
  
Willem Buskermolen. If only I could tell …; Measuring predictors for challenging  behaviour in 
people with both intellectual disability and hearing impairment.  Supervisor: Prof.dr. A. Aldenkamp. 
Co-supervisor: Dr. J. Hoekman, UL.  
  
Kay Deckers. The role of lifestyle factors in primary prevention of dementia; an epidemiological 
perspective. Supervisor: Prof.dr. F. Verhey. Co-supervisor: Dr. M.  van Boxtel; Dr. S. Köhler.  
  
Brechje Dandachi-FitzGerald. Symptom validity in clinical assessments. Supervisors: Prof.dr. R. 
Ponds; Prof.dr. F. Verhey.  
  
Maurice Theunissen. Understanding factors affecting postoperative Quality of Life. Supervisors: 
Prof.dr. M. Peters, Prof.dr. M. Marcus. Co-supervisor: Dr. H. Gramke.  
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Anna Cleutjens. COgnitive-Pulmonary Disease? Neuropsychological functioning in patients with 
COPD. Supervisors: Prof.dr. E. Wouters, Prof.dr. R. Ponds. Co-supervisors: Dr. D. Janssen, Horn, Dr. 
J. Dijkstra.  
  
Laura Serpero. Next Generaton Biomarkers in Perinatal Medicine: S100B Protein. Supervisors: 
Prof.dr. D. Gazzalo, Alessandria, Italy; Prof.dr. B..W.W. Kramer. Co-supervisor: Dr. A.W.D. Gavilanes.   
  
Alessandro Varrica. S100B Protein and Congential Heart Diseases: Brain Aspects. Supervisors: 
Prof.dr. D. Gazzalo, Alessandria, Italy; Prof.dr. J.S.H. Vles; Prof.dr. L.J.I. Zimmermann. Co-supervisor: 
Dr. A.W.D. Gavilanes.   
  
Pim R.A. Heckman. Targeting phosphodiesterase type 4 for improving cognitive frontostriatal 
function: a translational approach. Supervisor: Prof.dr. J.G. Ramaekers. Cosupervisors: Dr. J.H.H.J.. 
Prickaerts; Dr. A. Blokland.   
  
Sven van Poucke. Platelets, form sample to big data; exploring granularity in platelet research. 
Supervisors: Prof.dr. M.A.E. Marcus; Prof.dr. W. Buhre. Co-supervisor: Dr. M. Lancé.  
  
Désirée M.J. Vrijens. Dysfunctions of the Lower Urinary Tract and Affective Symptoms. 
Supervisors: Prof.dr. Ph.E.V. van Kerrebroeck; Prof.dr. G.A. van Koeveringe. Co-supervisors: Dr. C. 
Leue.  
  
Tamar van Veenendaal. Neurotransmitters & Networks. An MR view on epilepsy and antiepileptic 
drugs. Supervisors: Prof.dr.ir. W.H. Backes; Prof.dr. A.P. Aldenkamp. Cosupervisor: Dr. J.F.A. Jansen.  
  
Evelien M. Barendse. Autism Spectrum Disorders in High functioning Adolescents; Diagnostic 
considerations (AHA). Supervisors: Prof.dr. A.P. Aldenkamp;  Prof.dr. R.P.C. Kessels, Radboud 
University.  
  
Roy Lardenoije. A venture into the epigenetics of aging and Alzheimer’s Disease. Supervisors: 
Prof.dr. B.P.F. Rutten; Prof.dr. H.W.M. Steinbusch. Co-supervisors: Dr. D. van den Hove; Dr. C.A. 
Lemere, USA.  
  
Charlotte L. Mentzel. The course recognition and treatment of movement disorders in severe 
mental illness. Supervisors: Prof.dr. P.N. van Harten; Prof.dr. M.A.J. de KoningTijssen, UMCG. Co-
supervisor: Dr. P.R. Bakker.   
  
Tim Batink. Third Wave Behaviour Therapy: Process Measures and Contextual Interventions. 
Supervisors: Prof.dr. F.P.M.L. Peeters; Prof.dr. J.J. van Os; Prof.dr. M.C. Wichers, UMC Groningen.   
  
Kevin L.J. Rademakers. Detrusor Underactivity: From Theory To Clinical Assessment. Supervisors: 
Prof.dr. G.A. van Koeveringe; Prof.dr. Ph.E.V. van Kerrebroeck. Co-supervisor: Dr. M. Oelke.  
  
Iris M.J. Lange. Should I stay or should I go ? Brain mechanisms underlying fear and safety 
learning, and explosure therapy outcome. Supervisors: Prof.dr. K.R.J. Schruers; Prof.dr. T.A.M.J. 
van Amelsfoort. Co-supervisor: Dr. L. Goossens.  
  
Ruben G.F. Hendriksen. Evidence for a dystrophin-associated encephalopathy in Duchenne 
Muscular Dystrophy. Supervisor: Prof.dr. J.S.H. Vles. Co-supervisors: Dr. G. Hoogland; Dr. M.W. 
Aalbers, UMC Groningen.  
  
Michael Gofeld. Strengths and limitations of the lumbar spine ultrasound-guided interventions. 
Supervisor: Prof.dr. M. van Kleef. Co-supervisor: Dr. M. Sommer.  
  
Willem A.R. Zwaans. Strategies for chronic inguinal pain. Supervisor: Prof.dr. M. van Kleef. Co-
supervisors: Dr. R.H.M. Roumen; Dr. M.R.M. Scheltinga, MMC Veldhoven.  
  
Linda M. Rolf. Mapping the effects of vitamin D in multiple sclerosis A 3D Perspective. Supervisor: 
Prof.dr. R.M.M. Hupperts. Co-supervisors: Dr. J.G.M.C. Damoiseaux; Dr. J.J.F.M. Smolders, CWZ 
Nijmegen.   
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Maarten van Beek. Spinal Cord Stimulation in Clinical and Experimental Painful Diabetic 
Polyneuropathy. Supervisors: Prof.dr. E.A. Joosten; Prof.dr. M. van Kleef. Cosupervisor: Dr. S.M.J. 
van Kuijk.  
  
Melina Barkhuizen. Genetic and perinatal risk factors for movement disorders. Supervisors: prof.dr. 
B.W.W. Kramer, prof.dr. H.W.M. Steinbusch, Prof.dr. A.F. Grobler. Cosupervisor: dr. A.W.D.Gavilanes-
Jimenez.  
  
Renske Uiterwijk. Cognitive function and cerebral small vessel disease in hypertension. 
Supervisor: prof.dr. R.J. van Oostenbrugge. Co-supervisor: Dr. J.E.A. Staals.  
  
Elles Douven. Depression and apathy after stroke. Supervisor: prof.dr. F.R.J. Verhey. Cosupervisors: 
Dr. P. Aalten, dr. J. Staals.  
  
Mauro Pessia. Brain K+ Channels: from molecular and physiological  features to autism spectrum 
disorder and intellectual disability. Supervisors: prof.dr. H.W.M. Steinbusch, prof.dr. M.B. Donati, It.   
  
Carsten Leue. Hyperarousal in the Hospital and what to do about it:  the MED-PSYCHNET - a 
transitional network approach  fostering personalized care in psychosomatic medicine. 
Supervisors: Prof.dr. J. van Os, Prof.dr. A. Masclee. Co-supervisors: Dr. J. Strik, Dr. J. Kruimel  
  
Andrea S. Herrera Soto. Aminochrome, an endotoxin for inducing a new rat  model of Parkinson’s 
Disease. Supervisor: prof.dr. H.W.M. Steinbusch. Co-supervisors: Prof.dr. Juan Segura-Aquilar; prof. 
G. Diaz-Veliz, Santiago of Chile  
  
Eline E.B. de Clerck. Ocular neurodegenerative changes and macular  cysts in prediabetes and 
type 2 diabetes. Supervisors: Prof.dr. C.A.B. Webers, Prof.dr. C.D.A.  Stehouwer. Co-supervisor: Dr. 
J.S.A.G. Schouten  
  
Steven T.H. Honings. Exploring psychosis and multidirectional violence:  a prospective study in 
the general population. Supervisor: Prof.dr. J. van Os. Co-supervisor: Dr. M. Drukker  
  
2018 
Sau May Wong. Advances in Microvasculair MRI Techniques: Breaking the Pathophysiological 
Barriers in Cerebral Small Vessel Disease. Supervisor: Prof.drir. W.H. Backes, Porf.dr. R.J. van 
Oostenbrugge. Co-supervisor: Dr. J.F.A. Jansen  
  
Mark B.N. van Winkel. Lonely at heart and stressed in company of Others; the influence of daily 
life social experiences and emotions on depression. Supervisors: prof.dr. F. Peeters; prof.dr. I. Myin-
Germeys, KU Leuven/UM; prof.dr. M. Wichers, UMC Groningen  
  
Harsha Birur Laxmana Rao. Revisiting the vascular theory of glaucoma using optical coherence 
tomography angiography. Supervisors: prof.dr. C.A.B. Webers; prof.dr. R.N. Weinreb, University of 
California, San Diego  
  
Babette L.R. Reijs. Cognitive correlates of cerebrospinal fluid biomarkers for Alzheimer’s disease. 
Supervisor: prof.dr. F.R.J. Verhey. Co-supervisors: Dr. P.J. Visser; dr. I.H.G.B. Ramakers  
  
Rachel Slangen. Spinal cord stimulation in painful diabetic peripheral Neuropathy. Clinical- and 
cost-effectiveness. Supervisors: prof.dr. M. van Kleef; Prof.dr. C. Dirksen; prof.dr. C. Faber  
  
Ganne Chaitanya. Epilepsy: A network disorder. Supervisors: prof.dr. A.P. Aldenkamp; prof. P. 
Satishchandra, NIMHANS, Bangalore, India. Co-supervisors: Dr. J.F.A. Jansen; Dr. S. Zinger, TUE  
  
Sumitha Rajendrarao. New Insight into the Multifaceted Pathogenic Mechanisms of Sporadic 
Amyotrophic Lateral Sclerosis. Supervisors: prof.dr. B.W. Kamer; prof.dr. H.W. Steinbusch. Co-
supervisor: prof. T.R. Raju, NIMHANS, Bangalore, India  
  
Suzanne Roggeveen. Interference of mobile phone with electrophysiology and emotions; results 
from short-term experimental studies. Supervisor: Prof.dr. J. van Os. Co-supervisor: Dr. R. Lousberg.   
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Matthias Walter. Multi-methodological approaches to investigate lower urinary tract function in 
health and disease. Supervisors: Prof.dr. Ph.E.V.A. van Kerrebroek; Prof.dr. G.A. van Koeveringe; 
Prof.dr. A. Curt, Zürich, CH.  
  
Lalit Gupta. Inhomogeneities in spontaneous brain fluctuations. Supervisors: Prof.dr.ir. WH. 
Backes; Prof.dr. P.A.M. Hofman. Co-supervisor: Dr. J.F.A. Jansen.  
  
Chaitra Jayadev. Impact of imaging the pediatric retina. Supervisor: Prof.dr. C.A.B. Webers. Co-
supervisor: Dr. N.J.C. Bauer; Dr. A. Vinekar.   
  
Annelie Klippel. Navigating through complexity; processes and mechanisms underlying the 
development of psychosis. Supervisors: Prof.dr. I. Myin-Germeys, KU-Leuven; Prof.dr. M.C. Wichers, 
UMC Groningen. Co-supervisor: Dr. U. Reininghaus.   
  
Kürşat Altinbaş. Reconstructing The Diagnostic Framework of Bipolarity. Supervisor: Prof.dr. J. van 
Os. Co-supervisor: Dr. I.S. Gülöksüz.  
  
Andrea J.R. Balthasar. Eyes of the needle; Spectral tissue sensing, an innovative technology for 
detecting various tissue types during percutaneous needle-based procedures in locoregional 
anesthesia and pain medicine. Supervisor: Prof.dr. M. van Kleef. Co-supervisor: Dr. G-J. van Geffen, 
Radboud UMC Nijmegen.  
  
Walmari Pilz. Shedding light on oropharyngeal dysphagia in myotonic dystrophy type 1. 
Supervisor: Prof.dr. B. Kremer. Co-supervisors: Dr. L.W.J. Baijens; Dr. V. Lima Passos.  
  
Nynke J. van den Hoogen. Repetitive painful procedures in the neonate: Treatment and adult pain 
sensitivity. Supervisors: Prof.dr. E.A.J. Joosten, Prof.dr. D. Tibboel, Erasmus MC-Sophia, Rotterdam. 
Co-supervisor: Dr. J. Patijn.  
  
Carlota Mestres Gonzalvo. Medication optimisation; Methodological aspects and new strategies. 
Supervisors: Prof.dr. F.R.J. Verhey, Prof.dr. P.H.M. van der Kuy, Erasmus MC Rotterdam. Co-
supervisors: Dr. R. Janknegt, Zuyderland MC.  
  
Carolin Hoffmann. The Brain under Attack: Autoantibodies in Psychotic Disorders. Supervisors: 
Prof.dr. P. Martinez, Prof.dr. B. Rutten, Prof.dr. J. van Os, UU/UM.  
  
Jindra M. Bakker. On the bumpy road of happiness: Mechanisms of daily life reward processing 
and how it can be changed. Supervisors: Prof.dr. M. Wichers, UMC Groningen, Prof.dr. I. Myin-
Germeys, KU Leuven/UM. Co-supervisor: Dr. L. Goossens.   
  
Marasha-Fiona de Jong. Between mood and matter; studies on the interface between mood 
disorders and physical conditions. Supervisor: Prof.dr. F.P.M.L. Peeters. Cosupervisors: Prof.dr. 
Mischoulon.   
  
Anouk Smeets. New insights in deep brain stimulation for Tourette syndrome. Supervisor: Prof.dr. 
Y. Temel. Co-supervisors: Dr. L. Ackermans, Dr. A.A. Duits, de. A.F.G. Leentjens.  
  
Margaretha Skowron. Cisplatin resistance in urothelial carcinoma; Understanding and targeting 
inherent and acquired mechanisms. Supervisors: Prof.dr. G.A. van Koeveringe, Prof.dr. P. Albers, 
Heinrich-Heine Univ. Düsseldorf. Co-supervisors: Dr. J.G.H. van Roermund, Dr. A. Romano.  
  
Thierry Mentzel. Capturing the cacophony of movement. Supervisors: Prof.dr. P.N. van Harten, 
Prof.dr. H.A.M. Daanen, VUA. Co-supervisor: Dr.mr. O.J.N. Bloemen, GGZ Hilversum/UM.  
  
Petronella de Meij. Quality indicators for the assessment of pain clinic care: A step forward? 
Quality from professionals and pain patients’ perspective (QiPPP). Supervisors: Prof.dr. G.D.E.M. 
van der Weijden, Prof.dr. M. v. Kleef. Co-supervisor: Dr. A.J.A. Köke.  
 
Thomas Vaessen. Stress sensitivity in psychosis: assessment, mechanism & intervention. 
Supervisor: Prof.dr. I. Myin-Germeys, KU Leuven/UM.  
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Yori van der Steen. Dissecting the psychosis continuum; risk factors along the pathway from 
experiences to disorder. Supervisor: Prof.dr. I. Myin-Germeys, KU Leuven/UM, Prof.dr. R. van Winkel, 
KU Leuven.  
  
Aryo Zare. Unveiling the sensory connections between the bladder and the brain that involve the 
periaqueductal gray matter. Supervisor: Prof.dr. G.A. van Koeveringe; Cosupervisor: Dr. A. 
Jahanshahi.  
  
Magdalena Weidner. Brain serotonin throughout development – for better and for worse. 
Supervisors: Prof.dr. H.W.M. Steinbusch, Prof.dr. K.P. Lesch, JM.Univ. Würzburg. Cosupervisor: Dr. 
D.L.A. van den Hove.  
  
Catherine Vossen. Cortical processing of pain; the role of habituation. Supervisors: Prof.dr. E.A. 
Joosten, Prof.dr. J. van Os, UU/UM. Co-supervisor: Dr. R. Lousberg.  
  
Whitney Freeze. Microvascular contributions to dementia; Exploring the role of bloodbrain barrier 
leakage in cerebral small vessel disease and Alzheimer disease. Supervisors: Prof.dr. F.R.J. 
Verhey, Prof.dr.ir. W.H. Backes. Co-supervisor: Dr. H.I.L. Jacobs.  
  
Simone Schüller. Characterization of Stem and Immune Cell Ontogeny to Inform Prevention and 
Treatment of Infections in Preterm Newborns. Supervisors: Prof.dr. B.W.W. Kramer, Prof.dr.med. A. 
Berger, Wien. Co-supervisor: Dr. E. Villamor.  
  
Michael J. Kemna. Predicting relapses in ANCA associated vasculitis. Supervisor: Prof.dr. J.W. 
Cohen Tervaert. Co-supervisors: Dr. J. Damoiseaux, Dr. P. van Paassen.   
  
Artemis Iatrou. Epigenetics in mental and neurodegenerative disorders. Supervisor: Prof.dr. B.P.F. 
Rutten. Co-supervisors: Dr. D.L.A. van den Hove, Dr. G. Kenis.   
  
Laura Wielders. Prevention & Treatment of Cystoid Macular Edema after Cataract Surgery. 
Supervisor: Prof.dr. R.M.M. Nuijts. Co-supervisors: Dr. J.S.A.G. Schouten, CWZ Nijmegen, Dr. B. 
Winkens.   
  
Daisy Hoofwijk. The way to understanding Chronic Postsurgical Pain; From clinical and 
psychological predictors to incorporating genetics. Supervisor: Prof.dr. W.F.F.A. Buhre; Prof.dr. 
E.A.J. Joosten; Co-Supervisor: dr. H.-F. Gramke; dr. A.A.A. Fiddelers.  
  
Loes Leenen. Self-management in Epilepsy; The Goal is: “Live with a Z(s)mile. Supervisors: Prof.dr. 
H.J.M. Majoie; Prof.dr.mr. S.M.A.A. Evers; Prof.dr. C.M. van Heugten.  
  
Chiara Peila. ‘Effects of Pasteurization and Refrigerated Storage on Human Milk Neurobiomarkers 
Concentrations. Supervisors: Prof.dr. D. Gazzallo, Alessandria, It./MUMC+; Prof.dr. G. Visser, UU; 
Prof.dr. E. Bertino, Alessandria, It.   
  
Raymond van de Berg. The Vestibular Implant: Feasibility in humans. Supervisor: Prof.dr. H. 
Kingma; Co-supervisor: dr. J.-P. Guyot, Université de Genève, CH.  
  
Nils Guinand. The Vestibular Implant: a more stable horizon for patients with a bilateral vestibular 
deficit? Supervisors: prof.dr. H. Kingma; Prof.dr. J.-P. Guyot, Université de Genève, CH.  
  
Jasper Smit. Exploring deep brain stimulation as a treatment for tinnitus. Supervisors: Prof.dr. R.J. 
Stokroos; Prof.dr. Y. Temel; Co-supervisor: dr. Jahanshahianvar.  
  
Bindu Paravil Sankaran. Brain MRI in Mitochondrial Disorders: Correlating the Phenotype with 
Genotype. Supervisor: Prof.dr. H. Smeets; Prof.dr. A. Taly, NIMHANS, Bangalore, India.  
  
Syenna Schievink. Vascular cognitive impairment; at the heart of the matter. Supervisor: Prof.dr. 
F.R.J. Verhey; Prof.dr. R.J. van Oostenbrugge; Co-supervisor: dr. S. Köhler.  
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Isabelle Bos. Biomarkers of Alzheimer’s disease; relations with vascular factors and cognition in 
the pre-dementia stages. Supervisor: Dr. P.J. Visser; Prof.dr. F.R.J. Verhey; Co-supervisor: dr. S.J.B. 
Vos.  
  
Stijn Michielse. Road work ahead; cerebral pathways mediating Psychological mechanisms 
underlying the psychosis spectrum. Supervisor: Prof.dr. J.J. van Os; Cosupervisor: dr. M.C. Marcelis.  
  
Georgios Schoretsanitis. Risperidone-based therapeutic regimens; Drug interactions and adverse 
drug reactions. Supervisor: prof.dr. K.R.J. Schruers; Co-supervisor: dr. M. Bak .  
  
Alieske Dam. INLIFE; An innovative online social support intervention for caregivers of persons 
with dementia. Supervisor: Prof.dr. M.E. de Vugt; Prof.dr. F.R.J. Verhey; Cosupervisor: Dr. M.P.J. van 
Boxtel.  
  
Roel Haeren. Vascular ventures; Analysis of vascular structures and function in epilepsy. 
Supervisor: Prof.dr. Y Temel; Co-supervisor: dr. K. Rijkers; Dr. G. Hoogland.  
  
Chiara Fabbri. Pharmacogenomics of antidepressant drugs: perspectives for the personalization 
of treatment in depression. Supervisors: Prof.dr. K. Schruers;  Prof.dr. A. Serretti, Bologna.  
  
Esther van Duin. Dancing in the (B)rain’; neurobiology of reward, stress & Information processing 
in 22q11.2 deletion syndrome. Supervisors: Prof.dr. T. van Amelsvoort;  Prof.dr. J. Booij, UvA. Co-
supervisor: dr. D. Hernaus.  
   
Rob Verdonschot. Oropharyngeal dysphagia and its psychiatric Comorbidities; The prevalence of 
affective symptoms and the unmet clinical need for integrated care in medically unexplained 
symptoms. Supervisor: Prof.dr. B. Kremer;  Co-supervisors; Dr. L. Baijens; dr. S. Vanbelle.  
  
Lisanne Breuer. Accelerated Cognitive Ageing in Epilepsy’ Does it Exists? Supervisors: Prof.dr. A. 
Aldenkamp; Prof.dr. P.  Boon, UZ Gent; Co-supervisors: dr. A. de Louw, Kempenhaeghe, Heeze; dr.ir. 
S. Zinger, TUE.  
  
Liselot Kerpershoek. Access to formal dementia care; A European perspective. Supervisors: 
Prof.dr. F. Verhey; Prof.dr. M. de Vugt; Prof. B. Woods, Bangor University, UK Co-supervisor: Dr. C. 
Wolfs.  
  
Henrietta Steinhart. Same Same but Different; Psychological Interventions and how to Mind the 
Knowledge Practice Gap. Supervisor: Prof.dr. I. Myin-Germeys. Co-supervisor: Dr. U. Reininghaus.  
  
Ulrich Mehnert. The management of urine storage dysfunction in the neurological patient. 
Supervisors: Prof.dr. G. van Koeveringe; Prof.dr. Ph.van Kerrebroeck; Prof.dr. S. Wachter, Antwerpen; 
Prof.dr E. Chartier-Kastler, Sorbonne, Paris.  
  
Giovanne B. Diniz. Weaning-induced alterations on neuropeptidergic populations of the rat 
hypothalamus. Supervisors: Prof.dr. H. Steinbusch; Prof.dr. J. Bittencourt, ICB/USP, Brasil.  
  
Rajani Ravindra Battu. Inherited Retinal Diseases: New Imaging and Molecular Genetics. 
Supervisor: Prof.dr. C.A.B. Webers. Co-supervisors:Dr. J.S.A.G. Schouten, CWZ; dr. T.T.J.M. 
Berendschot.  
  
2019 
Jans van Ool. Diagnostic and neuropsychiatric considerations in epilepsy and intellectual 
disability; Psychological perspectives. Supervisor: Prof.dr. A. Aldenkamp. Co-supervisors: Dr. J. 
Hendriksen; Dr. H. Schelhaas, Kempenhaeghe.  
  
Eveline Janssen. Depression in the elderly: focus on high risk groups. Supervisors: Prof.dr. F. 
Verhey; Prof.dr. M. de Vugt. Co-supervisor: Dr. M. Schram.   
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Cécile Kicken. Extreme blood coagulation; investigating the influence of physiological extremes 
on thrombin generation and platelet activation. Supervisor: Prof.dr. W. Buhre  Co-supervisors; Dr. 
B. de Laat; Dr. M. Lancé, Qatar.  
  
Martinus van Eerd. Diagnosis and Interventional Pain Treatment of Cervical Facet Joint Pain. 
Supervisor: Prof.dr. M. van Kleef. Co-supervisor; Dr. J. Patijn, Eindhoven; Dr. M. Sommer.  
  
Chenxing E. Zhang. Novel insights in the pathophysiology of cerebralsmall vessel disease – a 
study using advanced imaging techniques. Supervisors: Prof.dr. R.J. van Oostenbrugge; Prof.dr.ir. 
W.H. Backes; Co-supervisor: dr. J. Staals.  
  
Ivo Eijkenboom. A zebrafish model of small-fiber neuropathy. Supervisors: Prof.dr. H.J.M. Smeets; 
Prof.dr. C.G. Faber; Co-supervisor: dr. J. Vanoevelen.  
  
Bianca de Greef. Small fiber neuropathy: from underlying conditions to treatment. Supervisor: 
Prof.dr. C.A. Faber; Co-supervisor: Dr. I.S.J. Merkies; Dr. J.G.J. Hoeijmakers.  
  
Lotte Berk. MINDFULNESS AND AGING: Exploring Mechanisms and Interventions. Supervisors: 
Prof.dr. J. van Os; Prof.dr. M.W. de Vugt; Co-supervisor: dr. M.P.J. van Boxtel.  
  
Mor Dickman. Practice patterns and outcomes of corneal transplantation. Supervisor: Prof.dr. 
R.M.M.A. Nuijts; Co-supervisors: Dr. T.J.M. Berendschot; dr. F.J.H.M. van den Biggelaar.  
  
Thyagi Ponnamperuma. Mental Health Problems in Sri Lankan Adolescents Exposed to the 
Tsunami and Other Traumatic Events. Supervisor: Prof.dr. M.W. De Vries; Co-supervisor: Dr. N.A. 
Nicolson.  
  
Robbert C. Maatman. Anterior cutaneous nerve entrapment  syndrome (acnes): an analysis of 
various subtypes and alternative treatment modalities. Supervisor: Prof.dr. M. van Kleef; Co-
supervisors: Dr. R.M.H. Roumen, dr. M.R.M. Scheltinga.  
   
Mari Elshout. Neovascular Age-Related Macular Degeneration in the Era of Value-Based Health 
Care. Supervisor: Prof.dr. C.A.B. Webers; Co-supervisor: Dr. J.S.A.G. Schouten.  
   
Jeroen Deenik. Thinking inside the box; Changing lifestyle  to improve the health status of 
inpatients with severe mental illness. Supervisor: Prof.dr. P.N. Harten; Co-supervisors: Dr. D.E. 
Tenback; dr. I.J.M. Hendriksen.  
  
Thomas Draak. Peripheral Neuropathy outcome measures  Standardisation (PeriNomS) study 
part 3: Capturing the Patient’s Voice. Supervisor: Prof.dr. C.G. Faber; Co-supervisor: Dr. I.S.J. 
Merkies.   
   
Ana Luisa Gil Martínez. Neuroprotection in neurodegenerative processes associated with 
Parkinsonism and aging. Correlation  between dopaminergic neuronal death and glial activation. 
Supervisor: Prof.dr. H.W.M. Steinbusch,  Prof.dr. Maria-Trinidad Herrero Ezquerro, University of Murcia.  
   
Bernice J.A. Gulpers. Anxiety in older adults; Correlates, comorbidities  and prognosis with 
lifespan perspectives. Supervisor: Prof.dr. F.R.J. Verhey,  Prof.dr. R.C. Oude Voshaar; Co-supervisor: 
Dr. S. Köhler.  
  
Elke Devocht. Combining a cochlear implant and a hearing aid in opposite ears: The best of both 
worlds. Supervisor: prof.dr. H. Kingma; co- supervisor: dr. E.I.J. George.  
  
Gillian Townend. Rett Syndrome: Recognising the Communication Challenges, Needs and 
Potential of Individuals Living with a Rare Disease. Supervisor: Prof.dr. L.M.G. Curfs; co- supervisor: 
Dr. P.B. Marschik, Med. University of Graz, Austria.  
  
Takashi Koizumi. Genetic and neuroinflammatory components of familial and sporadic cerebral 
Small Vessel Disease. Supervisor: Prof.dr. H. Steinbusch,Prof.dr. T. Mizuno,Japan; co-supervisor: Dr. 
S. Foulquier.  
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Muhammad Ali. Integrative network-based approaches for modelling Human disease. Supervisor: 
Prof.dr. J. Kleinjans; co-supervisor: Dr. D. van den Hove; Dr. E. Pishva.  
  
Guillaume Durand. The adaptive side of psychopathy. Investigating adaptive characteristics 
associated with the psychopathic personality. Supervisor: Prof.dr. B. Rutten; co-supervisor: Dr J. 
Lobbestael.  
  
Darius C. Henatsch. Honey: A Novel Treatment in Chronic Ear Infections. Supervisor: Prof.dr. R.J. 
Stokroos; UMC Utrecht/UM; co-supervisor: Dr. J.J. Briedé.  
  
Reinhilde J. Melles. Vaginal penetration: pain or pleasure? The role of fear and sexual arousal. 
Supervisor: Prof.dr. M.L. Peters; co-supervisor: Dr. M. ter Kuile, LUMC, Dr. M. Dewitte.  
  
Raul Felipe Abella Antón. Cardiac Surgery Biochemical Monitoring in Congenital Heart Diseases 
Infants. Supervisors: Prof. dr. D. Gazzolo, Prof. dr. L.J.I. Zimmermann, Prof. dr. J.S.H. Vles, co-
supervisor; Dr. A.W.D. Gavilanes.  
  
Francesca M. Snoeijen-Schouwenaars. Diagnostic, neuropsychiatric and therapeutic 
considerations in epilepsy and intellectual disability – medical perspectives –. Supervisor: prof.dr. 
A.P. Aldenkamp, co-supervisors: Dr. H.J. Schelhaas, SEIN Zwolle; dr. J.G.M. Hendriksen, 
Kempenhaeghe, Heeze.  
  
Mariëlle H.J. Pruppers. Peripheral Neuropathies: Standardizing Functional Assessment. 
Supervisors: prof.dr. C.G. Faber; prof.dr. N.C. Notermans, UU;Dr. I.S.J. Merkies, ius promovendi.  
  
Shenghua Zong. Autoantibodies in disorders of the brain: expanding the spectrum. Supervisor: 
prof.dr. P. Marinez; co-supervisor: dr. M. Losen; dr. R. Rouhl.  
  
Jan-Willem Kallewaard. Diagnosis and minimally invasive treatment of chronic discogenic low 
back pain. Supervisor: prof.dr. M. van Kleef; co-supervisors: prof.dr. H. van Santbrink; dr. P. Willems.  
  
Simone M. Crivelli. Sphingolipid metabolism in the pathophysiology and treatment of Alzheimer’s 
disease. Supervisors: prof.dr. P. Martinez-Martinez; prof.dr. E. de Vries, VUmc. Co-supervisors: dr. M. 
Losen; dr. M. Mulder, Rotterdam.  
  
Natasha Pahuja. Etiopathogenesis, advanced imaging and treatment outcomes in Asian Indians 
with keratoconus. Supervisor: prof.dr. R. Nuijts, co-supervisor: dr. R. Shetty, Bengaluru.  
  
Pooja Khamar Mayur Raksha. Clinical, Molecular and Biomechanical outcomes of SMILE (small 
incision lenticule extraction) and other refractive surgery techniques. Supervisor: prof.dr. R. Nuijts, 
co-supervisor: dr. R. Shetty, Bengaluru.  
  
Niels Janssen. Patterns and pathways. Indicators for potential improvements of dementia care. 
Supervisors: prof.dr. F. Verhey; prof.dr.mr. S. Evers; Co-supervisor: dr. R. Handels.  
 
Giovanni Mansueto. Childhood adversities and Psychosis: investigation of the potential aetio-
pathogenetic mechanisms. Supervisor: prof.dr. K. Schruers; co-supervisors: prof.dr. F. Cosci, 
University of Florence, It; prof.dr. R. van Winkel, KU Leuven.  
  
Joke Debruyne. Cochlear implantation in adults with early-onset deafness. Supervisors: prof.dr. B. 
Kremer; prof.dr.ir. T. Francart, KU Leuven; Co-supervisor: dr.ir. J. Brokx.  
  
Koenraad Meuwissen, Burst Spinal Cord Stimulation in a Rat Model of Chronic Neuropathic Pain: 
Spinal and Supraspinal Mechanisms. Supervisors: prof. dr. E.A.J. Joosten; prof. dr. M. van Kleef.  
  
Lisa Schmiedek, Episodic memory in ageing and AD: a possible target for electrical stimulation ? 
Supervisors: prof. dr. F.R.J. Verhey; prof. dr. A.T. Sack; co-supervisor: dr. H.I.L. Jacobs  
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Paolo Maino, Implantable Intrathecal Drug Delivery in Treatment of Chronic Intractable Pain and 
Spasticity: Improvement of Safety and the Use of Imaging Techniques. Supervisors: prof. dr. E.A. 
Joosten; prof. dr. M. van Kleef.  
  
José Geurts, Chronic Pain; Impact of Chronic Pain on a Societal, Personal, and Treatment Level. 
Supervisors: prof. dr. C.D. Dirksen; prof.dr. M. van Kleef; co-supervisor: dr. P.C. Willems.  
  
Brigitte Brouwer, Painful Small Fiber Neuropathy; Symptoms, assessments and interventions. 
Supervisor: prof. dr. C.F. Faber; co-supervisors: dr. I.S.J. Merkies, Willemstad, Curaçao; dr. J.G.J. 
Hoeijmakers.  
  
Ruth Gussenhoven, Antenatal inflammatory insults and preterm brain injury: Pathophysiology 
and therapeutic strategies. Supervisors: prof. dr. B.W. Kramer; prof. dr. L.J.I. Zimmermann; Dr. 
T.G.A.M. Wolffs.  
  
Adriana (Janine) Collet, Specific Care on the Interface of Mental health and Nursing home 
“SpeCIMeN”. Supervisors: prof. dr. M.E. de Vugt; prof. dr. J.M.G.A. Schols; Prof. dr. F.R.J. Verhey.  
  
Fares Nigim, Glioblastoma and Meningioma Biology, Targeted Therapy and Oncolytic Virus 
Therapy. Supervisors: prof. dr. Y. Temel; prof. dr. S.D. Rabkin, Harvard; cosupervisors: dr. H. 
Wakimoto, Harvard; dr. L. Ackermans.  
  
Leonie Banning, Neuropsychiatric symptoms in Alzheimer’s disease; Associations with 
biomarkers. Supervisor: prof. dr. F.R.J. Verhey; co-supervisors: dr. P. Aalten; Dr. I.H.G.B. Ramakers.  
  
Johan Haumann, Prevalence and pharmacological treatment of pain in patients with cancer; The 
role of opioids with and without NMDA receptor affinity. Supervisor: prof.dr. E.A. Joosten; co-
supervisors: Prof.dr. M.H.J. van den Beuken-van Everdingen; dr. S.M.J. Van Kuijk.  
   
Joost Riphagen, Vascular matters in aging and dementia. Supervisor: prof.dr. F.R.J. Verhey; co-
supervisor: Dr. H.I.L. Jacobs.  
  
2020 
Nikos Priovoulos, Structural and functional imaging of the locus coeruleus at 7T: from 
methodological to clinical application. Supervisor: prof.dr. F.R.J. Verhey; co-supervisors: Dr. H.I.L. 
Jacobs; dr. B.A. Poser.  
  
Simone Verhagen, The power of individual landscapes; A clinical exploration of personal 
experience sampling and new horizons. Supervisors: prof.dr. P.A.E.G. Delespaul; prof.dr. J.J. van 
Os, UM/UU; co-supervisor: dr. C.J.P. Simons.  
  
Nagy Youssef, Epigenetics, resilience and brain stimulation: advances in the mechanistic and 
therapeutic utility in patients with affective (PTSD and mood) disorders. Supervisor: Prof.dr. B.P.F. 
Rutten; co-supervisor: Prof. dr. P. Sienaert, KU Leuven.  
  
Abhishek Appaji, Retinal vascular features as a biomarker for psychiatric disorders. Supervisor: 
Prof. Dr. C.A.B. Webers; co-supervisor: Dr. T.T.J.M. Berendschot, Dr. Naren P. Rao.  
  
Koos Hovinga, Angiogenesis Inhibition in Glioblastoma. Supervisor: prof. dr. Y. Temel; co-
supervisor: Prof. V. Tabar, New York, USA.  
  
Gerhard Drenthen, Myelin and networks, Magnetic Resonance Imaging in Epilepsy. Supervisors: 
prof.dr.ir. W.H. Backes; Prof.dr. A.P. Aldenkamp; co-supervisor: dr. J.F.A. Jansen.  
  
Anna Gorlova, Understanding the Molecular Mechanisms of Aggression in BALB/C and TPH2-
Deficient Mice. Supervisor: prof.dr. K. Lesch, Universitätsklinikum Würzburg, cosupervisors: dr. T. 
Strekalova; prof.dr. L. Bettendorff, University of Liège.  
  
Ekaterina Veniaminova, The impact of the ‘Western Diet’ on Emotional, Social and Cognitive 
Behaviours as revealed by a study on conventional and serotonin Transporter-Deficient Mice. 
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Supervisor: prof.dr. K. Lesch, Universitätsklinikum Würzburg, co-supervisors: dr. T. Strekalova; prof. 
D.C. Anthony, Oxford.  
  
Dmitrii Pavlov, The contribution of CNS inflammation and Glycogen Synthase Kinase-3 (GSK-3)-
cascades on adverse memory learning on mouse models of emotional stress. Supervisor: prof.dr. 
K. Lesch, Universitätsklinikum Würzburg, co-supervisors: dr. T. Strekalova; prof.dr. L. Bettendorff, 
University of Liège.  
  
Eric Fonseca Wald, Absence Epilepsy and Panayiotopoulos Synrome: Neurocognition and Brain 
Development. Supervisor: prof.dr. R.J. Vermeulen; co-supervisors: Dr. S. Klinkenberg; dr. M.J.A. 
Debeij-van Hall; Dr. J.G.M. Hendriksen, Epilepsiecentrum Kempenhaeghe.  
  
Kimberley S. Noij, Cervical vestibular evoked myogenic potentials; Toward optimizing clinical 
use. Supervisors: prof.dr. H. Kingma; prof. S.D. Rauch, MD, Massachusetts Eye and Ear, Harvard; co-
supervisor: Dr. R. van de Berg.  
  
Mark J. van Tilburg, Advancement in cVEMP’s. Supervisors: prof.dr. H. Kingma; prof.dr. S. Rauch, 
Harvard; co-supervisors: dr. R. van de Berg; dr. B. Herrmann, Boston.  
  
Nalini Atcharayam, Duchenne Muscular Dystrophy: The NIMHANS Experience. Supervisors: prof.dr. 
T. Delhaas; prof.dr. B.W. Kramer.  
  
Murat L Atagün, Cognitive neurophsysiology and neurochemistry in bipolar disorder. Supervisor: 
Prof. Dr. Therese van Amelsvoort; co-supervisors: Dr. Sinan Guloksuz; Dr. Marian Drukker.  
  
Majed Aldehri, Deep brain stimulation, memory functions and mechanisms. Supervisor: Prof. dr. Y. 
Temel; co-supervisors: dr. S. Hescham; dr. A. Jahanshahianvar.  
 
 
